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People living with HIV have up to a fourfold probability of developing type 2 diabetes (T2D), 
driven by HIV-related factors including the direct effect of certain HIV medicines, and general 
factors, notably obesity and age. This mixed-methods research, studying HIV patients in South 
London, aimed to characterise risk factors for T2D, and investigate the effectiveness and 
acceptability of a pilot lifestyle intervention. 
 
Data from a cross-sectional study (n=338) showed a T2D prevalence of 15.1%. Rather than HIV-
specific factors the greater contribution to risk of prediabetes/T2D were the conventional risk 
factors hepatic steatosis and hypertension (odds ratios 7.3 and 2.6 respectively); modifiable 
factors made a greater contribution to prediabetes/T2D than fixed or historic factors. 
 
A pilot diet and activity intervention for people with HIV and prediabetes (n=33) demonstrated 
statistically significant improvements in 6-month change in glucose and insulin for both fasting 
levels (5.5% and 23.6% reductions respectively) and postprandial 3-hour incremental area 
under the curve (17.6% and 31.4% reductions respectively), and significant reductions in mean 
values for weight (4.7%), waist (6.2%), systolic blood pressure (7.7%) and fasting triglycerides 
(36.2%). 
 
Qualitative interviews (n=23) identified key themes of confidentiality and fear of disclosure of 
HIV status. Those who declined participation or achieved fewer intervention goals exhibited an 
external health locus of control, blaming diabetes risk on HIV medicines. Those who achieved 
more goals prioritised treating prediabetes. Enablers included a desire to avoid adding to pill 
or disease burden, and a strong support network. Deliberate weight loss leading to loss of 
cultural identity and disclosure of HIV status were significant barriers. 
 
T2D is highly prevalent in HIV. The effectiveness of the pilot intervention demonstrates the 
potential to prevent or delay T2D in HIV. However, people living with HIV present with unique 
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1   INTRODUCTION 
 
1.1  Background 
 
This thesis describes a portfolio of research investigating the relationship between human 
immunodeficiency virus (HIV) and type 2 diabetes (T2D). People living with HIV (PLWH) in the 
United Kingdom (UK) form the focus of this research, investigating areas for which there is a 
paucity of published evidence: the phenotype of prediabetes and T2D in this cohort and how 
this has changed over the last 10 years; the effectiveness and acceptability of preventing T2D 
in PLWH presenting with prediabetes; and characterising enablers and barriers to diet and 
physical activity change, some of which are specific to PLWH. 
Elsewhere, investigators have conducted prospective observational and cross-sectional studies 
characterising incidence, prevalence and factors associated with T2D in HIV in cohorts outside 
of the UK. I present these in a literature review in Section 1.5.2, page 38.  
PLWH and T2D face particular challenges. T2D has been reported to be up to four times more 
prevalent among PLWH matched to HIV negative individuals for age, ethnicity and body mass 
index (BMI). The screening for, and management of, T2D in HIV present distinct challenges, as 
antiretroviral (ARV) medications can result in underestimation of glycated haemoglobin and 
can interact with hypoglycaemic agents leading to the necessity of dose adjustment. HIV 
patients with T2D may have a poorer response to diabetes treatments compared to matched 
HIV negative individuals. And, finally, to date no HIV-specific diabetes screening or treatment 
guidelines have been developed in the UK, Europe, USA and other regions. 
‘unless better prevention can be achieved, 
between 2016 and 2026 as many as 15,000 
new HIV-associated type 2 diabetes diagnoses 





Despite these challenges to date no investigators have compared how factors associated with 
T2D in HIV may have changed over time, or estimated the relative contribution of modifiable 
and fixed factors. Additionally there is no published data regarding the uniquely diverse HIV 
cohort in the UK. The few studies that have investigated the effect of lifestyle change on 
markers of insulin resistance in PLWH employed support too intensive to be applied widely in 
clinical practice, and demonstrated either an absence of or a small effect size. 
In this thesis I have presented background information on both HIV and type 2 diabetes, with 
reviews of prevention of T2D through changes in diet and physical activity. I have then 
presented a summary of issues facing people living with both conditions. The Introduction 
concludes with a discussion of my epistemological stance and how this frames my approach to 
this project, and finally I have presented an overview of design, research hypotheses, and 
aims and objectives. 
I have discussed choice of methodology, described procedures and presented results of three 
inter-related studies: 
1. In the phenotype study I have aimed to delineate how the prevalence of dysglycaemia 
(prediabetes and T2D itself) has changed over time, and to investigate which factors 
drive these changes.  Methodology and results are presented in sections 2.5 and 3.1 
2. The findings from a pilot diet and lifestyle intervention are presented in Section 3.3. I 
have described lifestyle interventions in HIV patients in the literature review, but to 
date no lifestyle intervention to specifically impact insulin resistance in this patient 
group has been published. The intention for this pilot intervention was to investigate 
the effectiveness of an individualised approach on markers of insulin resistance, based 
on proven diabetes prevention trials 
3. I have presented the methods and results of a qualitative investigation in sections 2.7 
and 3.4 respectively. Enablers and barriers to diet and activity change in PLWH, some 
of which are HIV-specific, have been characterised by other investigators in a 
peripheral manner only 
Finally, in the discussion and conclusion I have presented key findings, weighed up strengths 






1.2 Genesis of the Project: a Personal 
Perspective 
 
Shortly after I commenced work as a specialist dietitian in the HIV clinic at St. Thomas’ Hospital 
in 1998 we set up a multidisciplinary metabolic clinic for HIV outpatients. This was in response 
to the developing need to treat patients experiencing body shape changes (lipodystrophy). At 
this time there appeared to be an association between certain ARVs and metabolic 
abnormalities including dysglycaemia (Kilby and Tabereaux, 1998). The use of those ARVs was 
largely discontinued, however there remained a legacy of toxicities for some of the patients 
who had been exposed to them. Patients presenting with T2D were otherwise few, 
unsurprising given the relatively young age and modest BMI of the cohort. However, by 2010 a 
pattern emerged where patients recently diagnosed with T2D electively attended for advice 
from the HIV specialist dietitians. Patients reported GPs prescribing medication to control 
dysglycaemia, only to be told later in HIV outpatients that these medicines may negatively 
interact with their HIV treatment. Faced with suboptimal therapy for their T2D, patients were 
seeking advice to modify lifestyle factors. At this time dietitians in HIV care began discussing as 
yet unpublished observations of HIV-specific barriers to changing diet and physical activity. For 
example some overweight patients reported fear of deliberate weight loss, believing this might 
accidentally disclose HIV status to family and friends. 
 
In January 2012 an HIV article was published in the national diabetes magazine Balance (Flagg 
et al., 2012), discussing for the first time in the UK challenges facing PLWH and diabetes 
comorbidity. At a patient forum meeting shortly after, HIV patients, interested members of the 
public and HIV science advocates suggested that given potentially suboptimal treatment of 
T2D in PLWH, the focus of any future research should be diabetes prevention. They felt it was 
important that this research should reflect their diversity, and in particular recruit women, 
people from Black and Minority Ethnic groups (BME) and older people. 
 
These views informed the design of the research presented in this thesis. The project was 
funded by the National Institute for Health Research (NIHR) as part of a Clinical Doctoral 
Research Fellowship. Patient and public involvement continued to inform the ongoing 
development of the work. The research programme commenced in June 2012, with the final 





1.3   HIV 
 
1.3.1 HIV: History and Prevalence 
 
The HIV epidemic continues to develop. In 2014 2.0 million people were diagnosed with HIV 
increasing the estimated global prevalence to 36.9 million (UNAIDS, 2015). Despite the 
widespread introduction of successful antiretroviral therapy the predicted HIV-related 
mortality rate for 2015 is 1.7 million. The World Health Organisation (WHO) has a stated aim 
that by 2020 goals to treat 90% of PLWH with ARVs will significantly reduce transmission, 
morbidity and mortality (World Health Organisation, 2015). 
HIV was first identified in 1983 although more recently isolation of the virus from earlier 
preserved tissue samples has led to the theory that HIV evolved from a simian retrovirus in 
Africa sometime around the start of the 20th century (Maartens et al., 2014). In 1981 the 
United States Centre for Disease Control was made aware of a rare pneumonia caused by 
Pneumocystis jirovecii (previous nomenclature Pneumocystis carinii) in five gay men who 
presented with a concomitant suppressed CD4 T-cell count resulting in a deficit in cell-
mediated immunity (Gottlieb et al., 1981). The link between the development of profound 
immunodeficiency and the retrovirus HIV was made and the term acquired immune deficiency 
syndrome (AIDS) was used to describe this. AIDS presents with wasting: protein energy 
malnutrition. In Africa those with AIDS were referred to as having “slim disease”, and for many 
people an enduring image of a person ill with HIV is someone experiencing severe 
undernutrition (Maartens et al., 2014). In the late 1990s use of highly active antiretroviral 
therapy (HAART) became widespread, where two or more ARVs are used in combination to 
suppress viral replication allowing immune reconstitution. Its widespread use in recent years 
has led to HIV becoming, for those able to access treatment, a chronic manageable condition, 
with dramatic reductions in morbidity and mortality. Transmission of HIV continues with over 2 
million testing positive worldwide each year. Despite best efforts vaccines for both prevention 
and treatment continue to prove elusive. Although vaccine research continues, to combat 
ongoing transmission of HIV the World Health Organisation has released guidelines that all 
PLWH should be treated with HAART irrespective of degree of immunosuppression (World 
Health Organisation, 2015). Taken as a whole, the cohort of PLWH is an ageing population as 





Table 1.1: UK Regional HIV Prevalence and Ethnicity Data, 2014 




























40,947 2,624 25,679 1,742 1,423 5,902 78,317 
UK Total 46,310 2,649 27,017 1,779 1,462 6,383 85,489 
Source: Public Health England, 2015 
 
In the UK over 85,000 people are known to be living with HIV (Table 1.1). Another 25,000 are 
estimated to be HIV positive and unaware of their status (Public Health England, 2015a). Given 
the history of the epidemic, two groups make up the largest part of the cohort: gay men, the 
majority of whom are White, and Black Africans resident in the UK. Non-White ethnicities 
comprise the majority of Londoners living with HIV. HIV incidence in the UK remains stable, 
with around 6,200 new HIV positive diagnoses per year. The area in the UK with both the 
highest incidence and highest prevalence is South East London, where the majority of patients 
who participated in the current research reside. Here the incidence of HIV continues at a 
steady annual rate of approximately 600 cases, whereas the diagnosis of AIDS and HIV-related 
death rates have both declined rapidly to less than 30 cases each per year. 
HAART consists of two or more ARVs used in combination, each targeting different sites in the 
viral replication pathway. Adherence is vital to prevent viral resistance and can prove 
challenging, especially when medications must be taken with or without food and within 
certain time windows (Maartens et al., 2014). For these reasons the risks and benefits of 
switching from one ARV to another is cautiously considered, although this can remain a 
treatment option. Following the WHO guidelines, the British HIV Association (BHIVA) revised 
guidelines recommend that all HIV patients should be treated with HAART irrespective of 
disease progression or degree of immunosuppression (Churchill et al., 2015). 
Stigma associated with HIV infection remains prevalent and can lead to negative attitudes, 
prejudice, discrimination, and psychological damage. This stigma may stem from incorrect 
beliefs regarding behaviours associated with HIV transmission, onward transmission of the 
virus itself, and disease progression. People living with HIV can self-isolate as a result, and 
rates of poor mental health are high, with up to 50% reporting a current or past psychiatric 





1.3.2  The Metabolic Consequences of HIV Infection 
 
Both HIV infection and antiretroviral therapy may lead to an array of long-term metabolic 
changes (Table 1.2), of which T2D is one, and is discussed in more detail in Section 1.5. Prior to 
the development of effective ARVs metabolic changes were observed as HIV infection 
progressed, thought to be associated with inflammation and cytokine disturbance. These 
changes included futile cycling of triglycerides and hypogonadism (testosterone deficiency). 
More recently, it has become apparent that ARVs used to treat HIV can lead to a range of 
chronic metabolic complications, including redistribution of subcutaneous fat (lipodystrophy) 
and dyslipidaemia, and increased risk or accelerated development of non-communicable 
conditions associated with ageing including osteoporosis, cognitive decline, cardiovascular 
disease, stroke, chronic kidney disease, non AIDS-defining cancers and importantly for the 
research presented in this thesis, type 2 diabetes. 
Investigators leading the large international prospective multi-cohort Data Collection on 
Adverse Events of Anti-HIV Drugs (D:A:D) study (n=33,308) found a 42% prevalence of 
metabolic syndrome (Worm et al., 2010). In the UK the Cardiovascular Risk Evaluation and 
Antiretroviral Therapy Effects (CREATE) study investigators (Aboud et al., 2010, Elgalib et al., 
2011) characterised demographics, anthropometry, biochemistry, HIV and ARV history, 
medication use and cardiovascular risk factors for 1,021 patients recruited from outpatient 
clinics in South London. In this cohort, modifiable cardiometabolic risk factors, specifically 
overweight, hypertension, hyperlipidaemia and smoking, contributed to the majority of the 
risk of subsequent disease. Metabolic syndrome was present in 10-14% of participants, 
substantially lower than found in the D:A:D study. However, in the D:A:D study metabolic 






Table 1.2: Metabolic Consequences of HIV Infection and Antiretroviral Therapy 
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Introduction of ARV 
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8 
References: 1 - Christeff et al., 2002; 2 - (Christeff et al., 2002, Tripathi et al., 2013); 3 - (Weirzbicki et 
al., 2008); 4 – Stanley and Grinspoon, 2012; 5 - (Szep et al., 2011); 6- (Rochira et al., 2015); 7 - (Falco 
et al., 2002); 8 - McCutchan et al., 2012. 





1.3.3  Ageing with HIV 
 
Ageing in PLWH forms a research focus in well-resourced countries investigating whether 
conditions associated with ageing are accentuated and/or accelerated in PLWH. These 
conditions include osteoporosis, cardiovascular disease, and importantly for research 
presented in this thesis, type 2 diabetes. Current opinion and evidence is summarised in Table 
1.3 and particular issues regarding the relationship between ageing in HIV and T2D are 
discussed later in Section 1.3.4. 
Table 1.3: The Prevalence and Aetiology of Conditions Associated with Ageing in HIV 
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incidence in HIV declining, postulated as 
secondary to smoking cessation and use 
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High incidence of hypertension among 
adults and children with HIV. Controlling 
for known factors, stroke incidence is 








NADC incidence is 4.65 per 1000 PYs in 
HIV compared to 2.24 in matched HIV- 
controls. Strong association with age 
5 
References: 1-2 (Grinspoon, 2015, Klein et al., 2015); 3-4 (Brown and Qaqish, 2006, Peters et al., 
2013b); 5 - (Althoff et al., 2015); 6 - (Cohen et al., 2015); 7-9 (Chow et al., 2014, Sico et al., 2015, 
Chatterton-Kirchmeier et al., 2015). 






1.3.4 Morbidity and Mortality Associated with Metabolic 
Disease and Ageing 
 
A comparison of data collected from commercial healthcare databases in the United States 
shows that there were higher rates of comorbidities among HIV patients in 2013 compared to 
2003 (Schouten et al., 2014). Increases occurred in type 2 diabetes (12.7% vs. 8.3%), 
hypertension, hyperlipidaemia, cardiovascular disease, and renal impairment. Given these 
trends were observed among all age groups, the researchers suggested that age may not be 
the sole influence on comorbidity incidence. Older PLWH have a greater incidence of 
complications compared to HIV negative adults of similar age and are characterised by a frailty 
phenotype defined as a decrease in lean body mass, weight, physical strength, energy, and 
combined with decreased levels of physical activity (Althoff et al., 2014).  
Dyslipidaemia is the most prevalent metabolic comorbid condition in HIV, present in 47% of a 
London cohort in 2005 (Aboud et al., 2010), 36% in a North American cohort in 2010-11 (Willig 
et al., 2015) and rising to 67% in a large study conducted in East Africa in 2010 (Armstrong et 
al., 2011).  Among those without hepatitis co-infection, CVD accounts for 38% of mortality, 
measured in a large cohort in the USA (Wada et al., 2014). Although the associated risk for 
cardiovascular disease (CVD) and myocardial infarction (MI) is higher in HIV, mortality rates 
due to CVD have declined since 2001 due to improved care and lifestyle change (Hasse et al., 
2011, Grinspoon, 2015).   
Despite the increased morbidity described, there is emerging evidence that life expectancy in 
HIV may be higher than matched HIV negative controls in White males who regularly attend 
their HIV outpatient appointments. Investigators suggest this may be due to regular checks 
with HIV physicians facilitating early diagnosis and treatment of illnesses and conditions 









1.3.5 Body Composition, Weight Gain, and Obesity in HIV 
 
Malnutrition associated with HIV infection, once highly prevalent, is now rare in PLWH treated 
with HIV medicines; weight gain and obesity are now highly prevalent (Yuh et al., 2015). 
Discussed in this section are concerns regarding obesity now being a major determinant of 
poor health in HIV. 
Prior to the introduction of HAART treatment prevention of wasting of lean body mass (LBM) 
was a primary goal to reduce HIV-associated mortality. In a landmark study, investigators 
demonstrated a linear relationship between wasting of LBM and time before death (Kotler et 
al., 1989). In the modern HAART era although undernutrition is much less common (Table 1.4), 
treatment and reversal of weight loss and wasting remains a primary aim of medical nutritional 
therapy (Siddiqui et al., 2009, Mangili et al., 2006). Normalisation of BMI in those who are 
underweight is recommended in US clinical guidelines (Fields-Gardner et al., 2010) and by the 
European Society for Enteral and Parenteral Nutrition (ESPEN) (Ockenga et al., 2006).  
The incidence of undernutrition in PLWH has declined and rates of obesity have increased in 
proportion with the numbers treated with HAART (Table 1.4). Cardiovascular disease, T2D and 
other conditions associated with obesity are now the main cause of morbidity and mortality in 
HIV in well-resourced countries, with rates likely to continue increasing secondary to ageing 
(High et al., 2012). Obesity in older PLWH is associated with frailty (Shah et al., 2012).  
In a South London-based study of PLWH investigators have characterised how overweight and 
obesity has changed over time (McCormick et al., 2014). Those who were obese increased 
from 8.5% in 2001 to 28.0% in 2011-12. Female gender and Black African ethnicity were 
particularly associated with BMI. Among women of Black African origin, 81% were overweight 
or obese, compared to 49% of White men. Investigators explored possible explanations for 
such a high prevalence of overweight and obesity among Black African women. There 
appeared to be no significant correlation with ARVs or concomitant clinical factors. Black 
African women underestimated their weight, expressed less dissatisfaction with their body 
shape, and less awareness of increased cardiovascular risk. The authors acknowledged a 
limited ability to compare findings with the general population, concluding that high rates of 
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initiation of HAART is 
associated with lower 
mortality for those not 
initially overweight 
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1% in 2011-12 Obese: 8.5% in 
2001, 28.0% 
2011-12 
Highest overweight and 
obesity prevalence: 
Black African women 
9 
References: 1 - (Boodram et al., 2009); 2 - (Amorosa et al., 2005); 3 - (Tate et al., 2012); 4 - (Andrade et 
al., 2012); 5 - (Wrottesley et al., 2014) ; 6 - (Willig et al., 2015); 7 - (Shah et al., 2012); 8 - (Yuh et al., 
2015); 9 - (McCormick et al., 2014). 
Source: Review by A Duncan 
 
Weight gain following initiation of HAART is common (Lakey et al., 2013) and is known to be 
associated with subsequent development of dyslipidaemia (Grinspoon and Carr, 2005) and 
with later development of CVD and T2D. In the international Data Collection on Adverse Events 
of Anti-HIV Drugs (D:A:D) cohort study (n=9,321), investigators reported on correlations 





initiation of HAART (Achhra et al., 2015). For CVD the incidence ratio rate per unit gain in BMI 
in the first 12 months of ARV therapy categorised by pre-ART BMI was: underweight, 0.90; 
normal, 1.18; overweight, 0.87, and obese, 0.95. For T2D, the incidence ratio rate per unit gain 
in BMI was 1.11 regardless of pre-ART BMI. Investigators leading the North American Veterans 
Aging Cohort study reported findings after 5 years of following up 4,311 patients who 
experienced a modest median weight gain of 2.7kg during the first 12 months of HAART (Yuh 
et al., 2015). Both studies agree that weight gain following initiation of HAART appears to be 
strongly associated with subsequent development of T2D. 
 
 
1.4   Type 2 Diabetes 
 
1.4.1  Introduction 
 
Type 2 diabetes mellitus is a metabolic condition characterised primarily by hyperglycaemia, 
resulting from inefficient insulin function. It is associated with considerable morbidity and 
mortality, and is more than three times more prevalent than all cancers combined (Diabetes 
UK, 2015). Prediabetes, commonly referred to as borderline diabetes, is also characterised by 
hyperglycaemia, with blood glucose levels above normal but below the threshold defining T2D 
(see Table 1.6). 
Diabetes is now recognised as a global pandemic with a diabetes-related mortality rate for 
2015 of 1.6 million and a predicted 2040 prevalence of 642 million (International Diabetes 
Federation, 2015, Whiting et al., 2011). Type 2 diabetes is associated with obesity and age, and 
its increasing prevalence is reflected in 2015 data from the UK (International Diabetes 
Federation, 2015): in the UK there are an estimated 3 million people with T2D. The annual NHS 
diabetes-related expenditure is £5,808 for each person with T2D, with diabetes accounting for 






1.4.2 Prediabetes and Type 2 Diabetes: Aetiology and 
Pathophysiology 
 
Development of both prediabetes and T2D takes place over an extended period of months and 
years. Their aetiology comprises three principal components: heritability with polygenic 
components; a strong association with excess body fat; and gene-environment interactions. 
Prediabetes increases lifetime risk of T2D by 70-90% (Narayan et al., 2003) although this risk 
can be mitigated through diabetes prevention measures discussed in section 1.4.3. 
Prediabetes and T2D are similar in aetiology and pathophysiology. They are characterised by 
chronic surplus energy balance, resulting in fat deposition both within adipocytes and 
ectopically, typically within and between hepatocytes, pericardially, and in muscle tissue 
(American Diabetes Association, 2014). This excess fat deposition is associated with increasing 
levels of inflammatory cytokines and the development of insulin resistance. Development of 
prediabetes and T2D can also occur in leaner individuals, here clearly associated with factors 
other than obesity such as genetic polymorphisms, medication or hepatic disease (Hu, 2011). 
Progression from prediabetes to T2D is not inevitable; treatment of obesity can reduce risk. 
For those with isolated IGT or combined IFG and IGT the lifetime risk of developing T2D 
approaches 90% (Narayan et al., 2003). Annual conversion rates from prediabetes to T2D vary 
from 4% to 19% depending on combination of IFG and IGT (de Vegt et al., 2001, Li et al., 2003). 
Resistance to the actions of insulin and resulting post-prandial hyperglycaemia initially leads to 
increased insulin release. This hyperinsulinaemic response can continue asymptomatically until 
impaired pancreatic β–cell function and eventually β–cell failure leads to insufficient insulin 
release and chronic hyperglycaemia, necessitating injected insulin therapy (Gerich, 2002).  
A normal metabolic response to food consumption, digestion and increasing blood glucose 
levels is characterised by a rapid first-phase insulin secretion, usually within 10 minutes, 
followed by a more durable second phase, characterised by a peak or plateau of insulin 
between 90 and 120 minutes (Del Prato et al., 2002). Two intestinal insulin-stimulating 
hormones, the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP), are important (Vilsboll and Holst, 2004). As plasma glucose increases, 
glucose transporters on the surface of pancreatic β-cells allow a greater influx of glucose. This 
results in an increased adenosine triphosphate to adenosine diphosphate ratio, closing 
channels allowing potassium to leave the β-cell. Membrane depolarisation then occurs 





of awaiting insulin granules. The incretin hormones are thought to amplify the insulin secretion 
pathway leading to an increase in the number of granules. The incretin effect can become 
diminished or absent in prediabetes and T2D. As well as stimulating insulin release, GLP-1 
suppresses glucagon production, limiting gluconeogenesis in the liver (Cefalu, 2010). 
Insufficient GLP-1 can explain impaired fasting glucose prevalent in T2D.  
Epidemiological studies suggest that IFG and IGT only partially overlap (Abdul-Ghani et al., 
2006), with IGT characterised primarily by muscle and not hepatic insulin resistance, whereas 
in IFG hepatic insulin resistance with relatively normal muscle insulin sensitivity occur. Both IFG 
and IGT can be characterized by a reduction in first-phase insulin release although mechanisms 
appear to vary by ethnicity (Aoyama-Sasabe et al., 2016). Individuals with IGT also have 
impaired second-phase insulin secretion (Abdul-Ghani et al., 2006). 
The development of prediabetes and T2D is associated with a range of modifiable and fixed 
factors as listed in Table 1.5. Investigators have demonstrated that despite the diversity of 
factors T2D is largely driven by obesity, potentially explaining the synchronicity between the 
increasing global prevalence of both diabetes and obesity (Hu, 2011). 
Table 1.5: Factors Associated with Risk of Development of Prediabetes and Type 2 Diabetes 
Fixed Modifiable 
Age Obesity: body mass index and waist 
Non-White Ethnicity Sedentary Lifestyle 
First degree relative with diabetes Use of medications associated with 
dysglycaemia 
Gestational diabetes Raised LDL-cholesterol 
Polycystic Ovary Syndrome Raised triglycerides 
Pro-inflammatory conditions Chronic dietary energy excess 
Menopause High sugar intake 
Socioeconomic status Low fibre intake 
Historic use of medications associated with 
dysglycaemia 
Source: (Muhlenbruch et al., 2013) 
 
Diabetes is diagnosed using WHO criteria (Table 1.6). Prediabetes encompasses both impaired 
fasting glucose (IFG) and impaired glucose tolerance (IGT) as outlined in Table 1.6. The clinical 
blood test definition of diabetes is universal, whereas the threshold for diagnosis of 





T2D increases the risk of CVD and stroke, as well as increasing the risk of admission to hospital 
(American Diabetes Association, 2014). In the UK T2D is a leading cause of blindness, kidney 
failure and amputation, resulting from chronic hyperglycaemia (Diabetes UK, 2015). 
 










Normal Glycaemia 20-41 (4.0-5.9%) ≤5.9 mmol/l ≤7.7 mmol/l ≤7.7 mmol/l 
Prediabetes 
(WHO definition) 














Type 2 Diabetes ≥49 (≥6.6%) ≥7.0 mmol/l ≥11.1 mmol/l ≥11.1 mmol/l 
NOTES:  
WHO clinical definitions are used globally apart from the USA where ADA definitions are used. 
HbA1C – glycosylated haemoglobin 
OGTT – Oral Glucose Tolerance Test 
Source: (International Diabetes Federation, 2015) 
 
 
1.4.3  Lifestyle Prevention of Type 2 Diabetes 
 
Risk of type 2 diabetes can be mitigated by treatment with medications such as metformin and 
by reduction in insulin resistance secondary to dietary change, exercise or weight loss achieved 
through lifestyle modification (Muhlenbruch et al., 2013). A series of cross-sectional studies 
have suggested there may be an association between certain components of the diet and risk 
for development of T2D. My review of these studies is summarised in Table 1.7. 
 
There is strong evidence from major randomised controlled trials (RCTs) that diet and physical 
activity interventions can prevent or delay progression to T2D in those at high risk across 
different ethnic backgrounds (Knowler et al., 2002, Pan et al., 1997, Ramachandran et al., 
2006, Tuomilehto et al., 2001) (see Table 1.8). The risk of diabetes is reduced by between 28% 
and 59% after implementation of lifestyle change (Walker et al., 2010) There is also evidence 
of prolonged benefit, with investigators leading three of the major trials reporting a lower 





(Diabetes Prevention Program Research et al., 2009, Li et al., 2008, Lindstrom et al., 2006). 
Common to the lifestyle prevention trials listed in 1.8 are goals to achieve moderate weight 
loss, change in dietary intake and increased physical activity. However, apart from reducing fat 
intake dietary goals were not identical across all four trials.  
The most significant factor for diabetes prevention is weight loss. Each 1.0 kg reduction is 
associated with a 16% risk reduction (Hamman et al., 2006). How to achieve this weight loss 
varies across trials although the four diabetes prevention RCTs used broadly similar healthy 
eating goals as promoted by global diabetes organisations (American Diabetes et al., 2008), 
(Ha and Lean, 1998), (Connor et al., 2003). Alternative dietary methods can also be effective. 
The Mediterranean Diet (Martinez-Gonzalez et al., 2008), carbohydrate restriction (Hession et 
al., 2009), the Dietary Approaches to Stop Hypertension (DASH) diet (Liese et al., 2009) and 
meal replacement (Noakes et al., 2004) approaches have all shown benefit in reducing T2D 
risk. This flexibility in dietary approaches is of great clinical utility (Walker et al., 2010). 
The Predimed trial (Salas-Salvadó et al., 2011) demonstrated that the Mediterranean diet 
reduced progression to T2D by 50% compared to a low-fat diet. Investigators randomised 
participants to a non-calorie restricted diet (Mediterranean plus either olive oil or mixed nuts, 
or a low fat diet). Over 4 years, participants lost a mean 0.6 kg. This trial demonstrated that it 
is possible to prevent or delay T2D through dietary change without significant weight loss. 
Both the Predimed trial and the Finnish DPP demonstrated that number of diet and exercise 
goals achieved is associated with reducing risk of development of T2D (Schwarz et al., 2012). In 
Predimed, for example, 6.3% of participants achieving at least half of the number of goals set 
progressed to T2D, compared to 15.0% of those achieving fewer than half. 
In terms of the individual contribution of components of lifestyle interventions for diabetes 
prevention, findings from the DaQing trial suggest that there was no significant difference in 
progression to diabetes in those allocated either diet or exercise alone, or both together (Pan 
et al., 1997). Meta analyses have attempted to look at this issue, drawing together results from 
the four major RCTs combined with smaller trials, and a review supports the DaQing trial 
findings that there is no significant difference between isolated diet or physical activity 
approaches, or both together (Gillies et al., 2007), although there is evidence that in the 
absence of weight loss, increased levels of physical activity can reduce T2D incidence by 44% 





Table 1.7: Dietary Factors Associated with Type 2 Diabetes Risk 
Dietary 
Factor 
Description Effect on 










of 16 studies 
Dietary 
Fibre 





of 8 studies 
Glycaemic 
Index 





of 21 studies 
Fruit and 
Vegetables 
High intakes of dark yellow and 
leafy green vegetables; higher total 
vegetable intake; greater variety of 




of 10 studies 
Dairy 
foods 







of 14 studies 
Coffee High intake – dose reponse up to 6 









of 28 studies 
Alcohol Moderate intake – peak risk 
reduction 10-14 g alcohol /day, but 





of 17 studies 





women only  
Fats High intake of total and saturated 
fat, although full-fat dairy may 






Sugar High intake of sugar-sweetened 




of 17 studies 
Meat Higher red meat intake. RR = 1.19 
and 1.51 for 100g unprocessed and 




of 3 studies 
References: 1 - (Fung et al., 2002); 2 - (Murtaugh et al., 2003); 3 - (Aune et al., 2013); 4 - (Barclay et 
al., 2008); 5 - (InterAct, 2015); 6 - (Schulze et al., 2004); 7 - (Greenwood et al., 2013); 8 - (Liu et al., 
2004); 9 - (Li et al., 2014); 10 - (Choi et al., 2005); 11 - (Gao et al., 2013); 12 - (van Dam et al., 2006); 
13 - (Ding et al., 2014); 14 - (Wannamethee et al., 2003); 15 - (Knott et al., 2015); 16 - (Halton et al., 
2006); 17 - (Riserus et al., 2009); 18 - (Ericson et al., 2015); 19 - (Imamura et al., 2015); 20 - (Fung et 
al., 2004); 21 - (van Dam et al., 2002); 22 - (Pan et al., 2011); 23 - (Kurotani et al., 2013); 24 – (Muraki 
et al., 2013). 






Table 1.8: Diabetes Prevention Lifestyle Intervention Randomised Controlled Trials. 
Trial and Cohort Design Outcomes Reference 
The DaQing IGT and 
Diabetes Study, 
China. n=577 with 
IGT, variable BMI, 6-
year follow up 
4 arms: (1) dietary change 
(increase fruit, vegetables 
and fibre, reduce alcohol, 
energy restriction) 
(2) increased PA (brisk 
walking 20 minutes per day) 
(3) both 
(4) standard care 
Conversion to T2D in 
control arm: 68%. 
Risk reduction (RR) 
for intervention 
arms: 
Diet – 48% 
Exercise – 41% 
Both – 46% 





n=3234 with IGT, 
mean 2.8 year 
follow up 
4 arms: (1) Intervention - 
energy deficit of >500 
kcal/day to achieve 7% 
weight reduction in 6 
months, fat <25% total 
energy intake, 150 mins 
PA/week 
(2) Metformin 
(3) Troglitazone (withdrawn 




rate: 11.0% per 
year. Lifestyle 
intervention arm RR 
58%; metformin arm 
RR 31% 





n=522 with IGT and 
mean BMI 31, mean 
3.2 year follow up 
2 arms: (1) intervention - at 
least 5% weight loss, fat 
<30% total energy intake, 
fibre >15g/1000 kcal, 4 
hours PA/week. 
(2) standard care 
≥5% weight loss – 
RR 74%; ≥4 hours 
PA/week – RR 80%. 







n=531, with IGT, 
mean BMI 25.8, 
mean 2.5 year 
follow up 
4 arms: (1) Intervention -  
Avoid sugars, fat intake <20 
g/day, increase fibre, 
vegetables and fruits, 30 
min brisk walking/day 








et al., 2006) 
Notes: IGT: Impaired Glucose Tolerance; PA: Physical Activity; RR: Risk Reduction 
Source: Review by A Duncan 
 
Work is ongoing to translate diabetes prevention RCTs into routine clinical practice. A 
systematic review and meta-analysis found a greater pooled weight loss observed for those 
studies including a larger number of evidence-based goals (Dunkley et al., 2014, Public Health 
England, 2015c, NICE, 2012). Studies restricting recruitment to participants with an initial BMI 
≥25kgm2 lost significantly more pooled weight than studies with open recruitment. A greater 
intervention effect was observed with contacts that were more frequent, of longer duration 





1.5 HIV and Type 2 Diabetes Comorbidity 
 
This section presents a review of the aetiology and prevalence of type 2 diabetes in HIV. Non-
lifestyle change interventions are reviewed. The clinical implications and current care 
guidelines for people living with both conditions are discussed. 
 
1.5.1  Dysglycaemia Prior to Treatment with HAART 
 
Prior to the development of HAART, hypoglycaemia was observed in patients experiencing 
AIDS-related weight loss and this was thought to be associated with poor nutritional status, 
wasting of LBM, and raised resting energy expenditure (Stein et al., 1990). In a study 
performed in the earlier years of the HIV epidemic, investigators using the hyperinsulinaemic-
euglycaemic clamp method measured glucose and insulin dynamics in healthy, stable HIV 
positive people and compared them to HIV negative controls (Hommes et al., 1991). They 
found that, unlike with other infectious disease, in HIV insulin sensitivity and glucose clearance 
were both increased. However, in those unwell with HIV, insulin resistance characterised by 
hyperinsulinaemia was reported to be characteristic of the host cell response to infection by 
HIV (Hadigan et al., 1999). Researchers postulated that this was due to release of pro-
inflammatory cytokines, particularly TNF-α, by peripheral leucocytes (Limone, 2003). Prior to 
the use of HAART, recombinant human growth hormone and the appetite stimulant megestrol 
acetate were used to treat AIDS-related wasting, and pentamidine was used to treat and 
prevent Pneumocystis pneumonia, all of which have a strong potential to disturb glucose 
homoeostasis (Hadigan et al., 1999). Most iatrogenic hyperglycaemia occurs due to drug-
induced insulin resistance and is potentially reversible although certain medications including 
pentamidine cause more permanent β-cell dysfunction or cytosis. Researchers demonstrated 
that in those patients with serum glucose >6.9 mmol/l, half of cases could be attributed to 







Figure 1: Mechanisms Associated with the Pre-HAART Aetiology of Dysglycaemia in HIV 
 




1.5.2 Prevalence and Phenotype of Type 2 Diabetes in HIV 
in the HAART Era 
 
In a review of 6 studies, Hadigan and Kattakuzhy suggest that PLWH treated with ARVs are up 
to four times more likely to have T2D compared to negative controls matched for age, 
ethnicity and BMI although prevalence depends on the cohort studied (Hadigan and 
Kattakuzhy, 2014). They describe prospective observational and cross-sectional studies 
investigating incidence, prevalence and factors associated with T2D in HIV in cohorts including 
participants based in the United States, Brazil, Denmark and France. However, there has been 
no published research regarding the phenotype of T2D in HIV in the UK, and no work in 
progress from searches of clinical trials registers. Investigators suggest that in PLWH, T2D may 


























central obesity. These and other studies are included in my review of published literature 
regarding T2D in HIV presented in Table 1.9.   
 
The reported prevalence of T2D varies from 2.6% to 14% according to the HIV cohort studied. 
The lowest prevalence was observed in an ARV-naïve population (El-Sadr et al., 2005) and the 
highest in a treatment-experienced cohort (Brown et al., 2005). Investigators in these studies 
compared their HIV T2D prevalence rates to T2D in the local general population and found 
prevalence ratio rates range from 0.6 to 5.0 times respectively. Incidence of T2D also varies 
according to cohort studied. Three studies suggest that whereas in the early years of HAART 
treatment (1996-98) there was a higher risk of developing T2D, more recently (1999-2010) 
there is no significant difference in T2D incidence between HIV negative and positive 
individuals (Rasmussen et al., 2012, Tien et al., 2007, Polsky et al., 2011). The highest relative 
rate of 4.1 was observed in a treatment-experienced cohort from the USA (Brown et al., 2005). 
 
Among treated HIV positive adults, the risk for T2D appears to vary according to several 
factors. These have been partially characterised in several cohorts but not in the UK, and 
include female gender, BMI, age, Black (African American) ethnicity, CD4 nadir, and a history of 
treatment with certain ARVs (Samaras, 2012). Other factors significantly associated with 
dysglycaemia in HIV include lipodystrophy where patients are more than twice as likely to 
develop T2D (Capeau et al., 2012). 
 
An increased risk for T2D has been demonstrated across a range of HIV cohorts including 
vertically transmitted children and young adults where exposure to ARVs associated with 
dysglycaemia may have been widespread (Aldrovandi et al., 2009), and in pregnancy 
(Gonzalez-Tome et al., 2008). However, among newly HIV-diagnosed individuals there appears 







Table 1.9: Review of Cohort Studies of Dysglycaemia in HIV 
Citation Data 
Collection 







Cross-sectional study, pre HAART era. 
Prevalence of T2D and drug-induced 
hyperglycaemia  
n=1392, mean age 42, 
80% male 
Prevalence of glycaemia >6.9 mmol/l was 1.8%. 







Prospective observational cohort study 
investigating incidence of T2D in HIV+ 
patients compared to matched HIV- 
n=6816, mean age 39, 
57% male, 71% Black, 
80% on HAART, 10% 
BMI ≥30 
Lower prevalence and incidence of T2D in HIV vs. 
controls (mean follow-up 5.8 years): 7% and 9% 
respectively initial prevalence, incidence 1.14 and 






Prospective observational study 
investigating incidence of T2D in a cohort 
of HIV+ women compared to matched HIV- 
n=1435 HIV+, 385 HIV-; 
mean age 37, 100% 
female, 55% Black, 
26% Hispanic, mean BMI 
25.5 HIV+, 26.4 HIV- 
Incidence of T2D in HIV+ was 2.8 per 100 patient 
years for those on PIs, and 1.2 for both ARV naïve 
and those prescribed non-PI HAART. Incidence of 
T2D for HIV- was 1.4 per 100 patient years. Note 






Prospective observational study 
investigating incidence of T2D in a national 
cohort of HIV+ patients compared to 
matched HIV- 
n=3540, mean age 38.7, 
84% male, 2.5% non-
White 18% overweight 
or obese 
Initial prevalence of T2D 3%. Mean follow-up 8 
years: incidence 0.37 per 100 patient years for 
HIV+, 0.39 for HIV-. RR in HIV was 2.83 prior to 
HAART years (1996-1999), and 0.90 since 1999 
2b 




Prospective observational study 
investigating incidence of T2D in a national 
cohort of HIV+ patients. Mean follow-up 
9.6 years 
n=1046, mean age 37, 
79% male, 10% Black, 
mean BMI 22.1, 100% 
on HAART 
Prevalence 10.6%, incidence 1.41 per 100 patient 
years. Incidence peaked in 1999, declined after. 
Hazard ratios: >50 years 3.6; BMI>30 2.9; waist: 
hip ratio >0.97 males >0.92 females 3.9; 
lipoatrophy 2.1 
2b 




Cross-sectional study: T2D prevalence in 
ARV-naïve patients 
n=419, 79% male, mean 
age 48, mean BMI 24.2 







Description of Study Cohort Principal Findings Research 
Quality 




Multicentre prospective cohort study 
investigating prevalence and incidence of 
T2D in HIV+ compared to HIV- 
n=568, 100% male, 
mean age 46 
Prevalence of T2D 7% in naïve to ARVs, 14% on 
treatment. Incident T2D 4.7 per 100 person-years 
in HIV+ compared to 1.4 in HIV- (relative rate 4.1). 
Highly correlated with lipodystrophy 
2b 
(Saves et al., 
2002) 
1999, France Cross-sectional study: phenotype of 
lipodystrophy and other metabolic 
complications 
n=614, 80% male, mean 
age not stated but 63% 
>34 years 
5.7% had T2D, all of whom were prescribed PIs, 
and the majority also prescribed AZT, ddI or d4T 
3 






Incidence of new-onset diabetes in large 
international D:A:D prospective 
observational study 
n=33,389, mean age 38, 
male 74%, mean BMI 
23.0 
2.8% had T2D at entry; incidence rate 0.57 per 
100 patient years and associated with cumulative 
ARV exposure, d4T, AZT and ddI, lipids, and 
lipodystrophy 
2b 






Mortality data from the very large 
international D:A:D prospective 
observational study. Data analysed in 2013 
N=49,731, mean age 46, 
mean BMI 23.8 
2.8% had T2D at entry; 2006 – 3.1%; 2011 – 4.6%. 
Note: Relatively low BMI cohort. Mortality for 
those with T2D was 19.6% - mean overall 
mortality of 7.9% 
2b 
(Gonzalez-




Prospective cohort study investigating 
gestational diabetes in HIV+ women 
without T2D 
N=669, mean age 31. 7% had gestational diabetes, independently 
associated with age and exposure to PIs. 
Compares with 4.5% rate in general population 
2b 




Prospective cohort study investigating 
incidence of T2D in HIV+ women (n=1524) 
compared to matched HIV- (n=564) 
Mean age 39, 100% 
female, 56% Black, 28% 
Hispanic, mean BMI 26.8 
T2D incidence per 100 patient years: HIV- 2.0, 
HIV+ naïve to ARVs 1.5, protease inhibitor-
containing HAART 2.5, non-PI HAART 2.9 
2b 
(Ledergerber 
et al., 2007) 
2000-2006, 
Switzerland 
Retrospective cohort study investigating 
incidence of T2D 
n=6513, mean age 38, 
69% male, 84.5% White, 
73% on HAART, mean 
BMI 22.5 
Mean follow-up 6 years. Initial prevalence 1.9%, 
incidence 0.44 per 100 patient years. RR for: 
males 2.5, >60 years 4.3, Black participants 2.1, 








Description of Study Cohort Principal Findings Research 
Quality 




Prospective cohort study investigating 
incident dysglycaemia in older adults with 
or at risk of HIV 
n=222 (HIV+), 47% male, 
mean age 50, mean 
follow-up 18.6 months 
Overweight 37%, obese 24%. Initial prevalence – 
prediabetes 29%, T2D 5%. Incident prediabetes 






Cross-sectional study comparing lipids and 
glycaemia in HIV+ and HIV- young people 
aged 7-24 
n=240 HIV+, 146 HIV-. 
HIV+: mean age 12.6 
HOMA significantly higher in HIV+: 2.3 vs 1.5; all 
lipid fractions significantly different in HIV+ 
3 
(Galli et al., 
2012) 
2008, Italy Cross-sectional study comparing T2D risk 
in HIV+ and HIV- 
n=4249 HIV+, 9148 HIV-. 
HIV+: mean age 46, 76% 
male, mean BMI 23.2 
Prevalence of T2D in HIV+ 4.1%, 2.5% in HIV-, 
associated with age, BMI, hypertension, CD4 
nadir, triglycerides, duration of HIV infection 
3 
(Calza et al., 
2011) 
2009, Italy Cross-sectional study comparing lipids and 
glycaemia in HIV+, no HIV- comparison 
n=755. Mean age with 
T2D 48, without T2D 37. 
66% male 
Prevalence of T2D 4.5%. Associated with age, 







Cross-sectional study comparing risk for 
prediabetes in HIV+, no HIV- comparison 
n=148, mean age 42, 
65% male, 92% on 
HAART 
Prediabetes prevalence was 27.5% associated 
with BMI (OR per 5kg weight gain 1.24), 
compared to general Thai population 5% 
3 




Cross-sectional study comparing risk for 
prediabetes and T2D in newly diagnosed 
HIV+ not yet on HAART, no HIV- 
comparison 
n=2006, mean age 40, 
76% male 
9.5% had IFG, 10.5% had T2D. Age and lower CD4 
were associated with T2D. Prediabetes and T2D in 
China have been reported as 9.7% and 11.6% 
respectively in the general population 
3 
Research Quality:      1 – Randomised Controlled Trial; 2a – Intervention without randomisation; 2b – Prospective Cohort Study; 3 – Cross-sectional study. 
Abbreviations: AZT – zidovudine; ARV – antiretroviral; BMI – Body Mass Index; D:A:D - Data Collection on Adverse Events of Anti-HIV Drugs Study; d4T – 
stavudine; ddI – didanosine; HOMA – Homoeostatic Model of Assessment; HAART – Highly Active Antiretroviral Therapy;  IFG - Impaired 
Fasting Glucose; OR – Odds Ratio; PI – Protease Inhibitor; RR – Relative Risk; T2D – Type 2 Diabetes. 





1.5.3  The Aetiology of Dysglycaemia in HIV 
 
The aetiology of dysglycaemia in HIV is complex, multifactorial, and not fully understood. 
Altered glucose homoeostasis in PLWH appears to be mediated by changes in adipocyte 
function, peripheral glucose disposal, hepatic insulin resistance and impaired β-cell insulin 
secretion (Hruz, 2011). In this section I have presented a summary of factors thought to 
contribute to dysglycaemia in HIV, including the direct effect of ARVs, gene-environment 
interactions, inflammation, leptin, vitamin D deficiency, and hepatic impairment. 
 
The protease inhibitor (PI) class of ARVs, and in particular Indinavir and Ritonavir, may have a 
number of detrimental effects on metabolic health. Both have been shown to both increase 
insulin resistance through interference with glucose transport type 4 (GLUT-4)-mediated 
transport (Walli et al., 1998, Hadigan and Kattakuzhy, 2014, Loonam et al., 2016). Most 
protease inhibitors developed more recently are believed not to have this effect (Hruz, 2011). 
Ritonavir in particular has been shown to interfere with potassium signalling within β-cells 
impairing insulin release (Neye et al., 2006). Ritonavir in its most commonly-used lower 
boosting dose is not associated with insulin resistance (Taylor et al., 2010). Indinavir and to a 
lesser extent ritonavir impair the ability of insulin to suppress endogenous hepatic 
gluconeogenesis (Lee et al., 2009). PIs may also induce β-cell apoptosis (Zhang et al., 2009). 
 
Those nucleoside reverse transcriptase inhibitors (NRTIs) associated with the development of 
lipodystrophy most likely induce insulin resistance through mitochondrial toxicity and are now 
rarely used (Samaras, 2012). In the Women’s Interagency HIV Study, duration of exposure to 
the NRTI class drugs, especially stavudine, was found to be most closely related to insulin 
resistance (Tien et al., 2008). In the large international D:A:D cohort (De Wit et al., 2008), 
treatment with stavudine, zidovudine or didanosine all independently contributed risk to the 
development of T2D. In two other large prospective studies (Capeau et al., 2012, Brown et al., 
2005), stavudine and indinavir were associated with insulin resistance and hyperinsulinaemia.  
 
Insulin resistance in HIV appears to be associated with a combination of reduced peripheral 
uptake of glucose and impaired hepatic clearance of glucose (Haugaard et al., 2005). This 
effect has been observed in children vertically infected with HIV and on HAART, where only 1 





As in the general population genetic factors appear to contribute in the development of 
diabetes in HIV. In a Swiss study comparing HIV positive and HIV negative participants, four 
polymorphisms were associated with T2D in HIV positive participants, estimated to contribute 
14% of the variability in T2D risk (Rotger et al., 2010). 
 
HIV-associated inflammation is thought to upregulate chemokines involved in insulin 
regulation (Hruz, 2011). In a US-based study higher levels of markers of TNF-α activation were 
significantly associated with the development of T2D after the first year of HAART (Brown et 
al., 2010). Increased levels of reactive oxygen species associated with HIV-related 
inflammation are thought to interrupt early insulin signalling pathways (Hruz, 2011). Increased 
microbial translocation across the gut which has been found to be higher in HIV patients 
compared to HIV negative controls can exacerbate inflammation and has been correlated with 
insulin resistance (Pedersen et al., 2013). 
Reduced leptin levels have been associated with both insulin resistance and lipodystrophy in 
HIV patients (Deloumeaux et al., 2011, Veloso et al., 2012). 
Vitamin D insufficiency, highly prevalent in HIV infection, was associated with both impaired β-
cell response and insulin resistance in HIV positive participants without diabetes (Moreno-
Perez et al., 2013). Supplementation with vitamin D increased insulin resistance at 24 weeks, 
although levels returned to baseline after 48 weeks (van den Bout-van den Beukel et al., 2008).  
In a recent pilot study, correction of glutathione deficiency using cysteine and glycine 
supplementation demonstrated improved insulin sensitivity in older HIV positive patients 
(Nguyen et al., 2014). 
Finally, investigators leading six studies have reported a strong signal for higher prevalence of 
T2D among hepatitis C (HCV) co-infected individuals (Howard et al., 2010, Calza et al., 2011, 
Berenguer et al., 2012, Bhagani, 2009, Butt et al., 2004, Capeau et al., 2012, Jain et al., 2007) 
compared to those with HIV or HCV alone. This added risk appears be mediated by non-
alcoholic hepatic steatosis and liver fibrosis, both exacerbating insulin resistance. Hepatic lipid 
content in HIV positive participants irrespective of hepatitis status is correlated with degree of 







Figure 2: Factors Involved in the Aetiology of Dysglycaemia in Treated HIV Infection. 
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1.5.4 Non-lifestyle Interventions for Insulin Resistance in 
HIV 
 
There have been few medical or nutraceutical interventions for insulin resistance (IR) in HIV. In 
a pilot (n=9) trial of methionyl human leptin (metreleptin) in combination with pioglitazone in 
HIV patients with lipoatrophy, investigators demonstrated improved postprandial glycaemia 
and insulin sensitivity and a 15% reduction in central fat mass, but no effect on lipids or 
triglycerides (Magkos et al., 2011).  
 
Two nutritional approaches to treating IR in PLWH have been investigated. Chromium 
supplements have been piloted (Feiner et al., 2008) and subsequently used in two randomised 
placebo-controlled trials at 400µg/day for 16 weeks (Aghdassi et al., 2010) and 1000µg/day for 


































Spirulina and soya bean supplements have been piloted in a small study that recruited 
participants in the Cameroons (Marcel et al., 2011). Drop-out rates were significantly different 
between the two arms, weakening claims that spirulina confers a greater chance of improving 
insulin sensitivity compared to soy. 
 
 




HbA1C in HIV Patients: 
The screening and management of prediabetes and T2D in HIV present distinct challenges. 
Among HIV positive patients HbA1c is insensitive, although highly speciﬁc, for diagnosing 
diabetes. However, specific ARVs have a variable inﬂuence on the relationship between HbA1c 
and fasting glucose (Eckhardt et al., 2012). Treatment with ARVs can result in underestimation 
of glycated haemoglobin by up to 0.5 percentage units (4.5 mmol/mol) (Slama et al., 2014, Kim 
et al., 2009). The use of HbA1c in conjunction with a fasting glucose measurement or 
preferably an oral glucose tolerance test has been proposed to be the most reliable method 
for diabetes screening in HIV (Hadigan and Kattakuzhy, 2014). 
 
Clinical Challenges: 
PLWH with T2D may have a poorer response to diabetes treatments compared to HIV negative 
individuals (Han et al., 2012). The recently-developed ARV dolutegravir interacts with 
metformin requiring dose adjustment (Zong et al., 2014), and the use of metformin in patients 
with lipoatrophy can lead to worsening of facial wasting (Kohli et al., 2007). Hyperglycaemia in 
HIV increases the risk of developing tuberculosis infection (Achhra et al., 2014). HIV patients 
with IR are less likely to respond to hepatitis C treatments (Vachon et al., 2011) and IR 
increases hepatocellular carcinoma risk in those with HIV / Hepatitis C coinfection (Salmon et 
al., 2012). Finally, IR in HIV patients is associated with poorer neuropsychological performance 
(Valcour et al., 2012). 
 
 







To date no clinical guidelines have been published or developed specifically for those with 
both HIV and either prediabetes or T2D. The British HIV Association (BHIVA) produces 
guidelines and standards of care for PLWH in the UK and has published guidelines on screening 
for metabolic conditions (Asboe et al., 2012); those pertinent to screening for disturbances in 
glucose homoeostasis are summarised in Figure 3. The European AIDS Clinical Society (EACS) 
has used guidelines for clinical care of T2D in the general population for HIV patients living 
with T2D (Lundgren et al., 2008, Ryom et al., 2016). EACS acknowledges the lack of published 
HIV-specific research in this field. These guidelines are summarised in Figure 4. I performed a 
search of other national and international HIV treatment or management guidelines, and this 
revealed no specific mention of diabetes. These guidelines included the WHO (World Health 
Organisation, 2015), the International Antiviral Society (Gunthard et al., 2014), the National 
Institute of Health in the USA, the Thai National HIV Guidelines (Manosuthi et al., 2015) and 
the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. The Southern 
African HIV Guidelines also do not mention specific care guidelines, but do recommend routine 
screening of blood glucose given that the pro-glycaemic NRTIs zidovudine and stavudine 







Figure 3: UK Guidelines for Screening for Dysglycaemia in HIV. 
 
 





Figure 4: European Guidelines for Clinical Care for Dysglycaemia in HIV. 
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1.6 Diet and Exercise in HIV 
 
Cohort Studies: 
There have been a number of prospective cohort studies that have recognised distinct dietary 
patterns in PLWH. Researchers aimed to correlate aspects of dietary intake with obesity in an 
American HIV cohort (Hendricks et al., 2006). Total and saturated fat intakes were significantly 
higher than recommended levels, with fibre intake reducing incrementally as BMI increased. In 
another study from the same cohort, researchers reported that patients without lipodystrophy 
had a significantly higher fibre intake compared to those with lipodystrophy (Hendricks et al., 
2003). In the only study published to date to report dietary intakes in a UK HIV cohort, the 
majority of participants consumed higher than recommended levels of total and saturated 
fats, and those with lipodystrophy had lower fibre intakes (Klassen and Goff, 2013). In a 
Croatian study, adherence to the Mediterranean diet was positively correlated with reduced 
atherosclerotic plaque formation in both HIV positive and HIV negative participants (Višković 
et al., 2013). Finally an investigation of diet and insulin resistance recruited HIV positive 
women from San Francisco and Chicago. Using HOMA-IR to assess insulin resistance, 
statistically significant correlations were observed between both high intensity exercise and 
higher incomes in those with lower levels of insulin resistance, and between higher 
consumption of sweets and higher levels of insulin resistance (Hessol et al., 2013). 
 
Interventions: 
A literature search retrieved a small number of diet and physical activity intervention studies 
for PLWH published since the introduction of HAART in 1998, presented in Table 1.10. The 
majority of interventions were designed to prevent or treat dyslipidaemia although six of the 
twelve did additionally measure markers of glucose homoeostasis. In a meta-analysis with a 
CVD focus, investigators found evidence of a weak non-significant pooled effect of dietary 
interventions on cholesterol fractions but a significant effect on reducing triglyceride levels, 
with a greater effect when omega-3 supplements were added (Stradling et al., 2012).  
 
In a small study based in Boston, researchers recruited HIV positive adults with metabolic 
syndrome between 2003 and 2005 (Fitch et al., 2006). The study aimed to investigate the 
effect of diet and exercise on the components of the metabolic syndrome and their combined 





intervention (n=12) or usual care (n=16). The intervention was highly intensive: weekly 
individual sessions with a dietitian plus 3 hours supervised exercise per week over a 6 month 
period. At baseline, dyslipidaemia and hypertension were the principal contributors to 
metabolic syndrome. Participants’ baseline mean fasting glucose of 5.05 mmol/l increased to 
5.22 mmol/l after 6 months. Compared to usual care, the intervention achieved small but 
significant changes in HbA1c, with a 0.2% unit rise observed in the control group. Significant 
reductions were also observed in waist measurement and systolic blood pressure, but not 
weight, glucose, triglycerides or an increase in HDL. All participants remained classified as 
having metabolic syndrome. The same researchers later published results from a more 
developed intervention study based on the same cohort (Fitch et al., 2012). This study aimed 
to investigate the effect of diet, exercise and metformin on markers of cardiovascular disease. 
Participants were randomised to: metformin alone, metformin plus lifestyle, lifestyle plus 
placebo or placebo alone. The lifestyle intervention was highly intensive, mirroring the 
previous study. Compared to baseline, there was no significant change in HbA1c observed 
between the 4 arms. There was a significant reduction in insulin resistance measured by 
HOMA-IR in the metformin plus intervention arm only. Other significant findings included 
metformin reducing progression of coronary artery calcification whereas lifestyle did not. 
 
A Danish study aimed to investigate the effects of a 16-week supervised endurance or strength 
training intervention on insulin sensitivity specifically in HIV positive men with lipodystrophy. 
Investigators found both modalities significantly improved peripheral insulin sensitivity 
(Lindegaard et al., 2008). 
 
In summary, of the twelve studies presented here, five recruited sufficient numbers of 
participants to draw statistically and clinically significant conclusions. None of these studies 
were designed with a primary outcome to measure the effect of diet and exercise on markers 
of insulin resistance. Of the seven studies measuring markers of glucose homoeostasis as 
secondary outcomes, two demonstrated a beneficial effect. Interventions were typically 
intensively delivered over extended periods ranging from daily to monthly visits for up to one 





Table 1.10: Diet and Physical Activity Interventions in HIV in the HAART Era. 
Cohort Intervention Results Ins. Res. Ref. 
Spain, n=230, HAART, 
dyslipidaemia 
Low fat diet for 6 months Reduced total cholesterol, TGs and weight, strongest effect in 
those on protease inhibitors 
No 1 
Brazil, n=30, HAART, 
lipodystrophy 
Low fat diet plus aerobic exercise versus low fat diet 
alone, 12 weeks 
Reduced body weight, and waist to hip ratio in both groups, no 
change in lipids 
No 2 
Brazil, n=83, naïve  NCEP diet, 4 sessions over 12 months post HAART Diet prevented weight gain & dyslipidaemia seen in control arm No 3 
USA, n=191, raised 
triglycerides 
NCEP diet, 4 visits, 6 months, supervised exercise 
3/week, plus niacin and fenofibrate 
Diet and exercise plus niacin and fenofibrate conferred strongest 
effect on lipids 
No 4 
Hong Kong, n=48, 
HAART 
Mediterranean versus low fat, low cholesterol diet, 4 
sessions over 12 months 
Mediterranean diet – total cholesterol  from 4.6 to 5.1 mmol/l; 
Low fat diet – triglycerides  from 1.90 to 3.22 mmol/l 
No 5 
USA, n=18, women, 
BMI>30 
Weekly group diet sessions, and 90mins supervised 
exercise 3/week, 12 weeks 
Mean 6.7kg weight loss, but no improvements in fasting glucose, 
insulin sensitivity or lipids 
Yes 6 
USA, n=28, HAART 6 months weekly diet advice, 3 hours exercise/week Intervention reduced waist, BP and HbA1c but not lipids Yes 7 
Denmark, n=20, men 
with lipodystrophy 
Sedentary men, 2 arms: strength or endurance 
training, supervised 3/week for 16 weeks 
Both arms improved insulin sensitivity and  HDL. Endurance 
training  LDL, Strength training  LBM,  triglycerides 
Yes 8 
USA, n=54, HAART, 
BMI 19-30 
Usual care or omega-3 supplements plus lipid-
lowering diet plus meals for first 3/16 weeks 
Intervention significantly reduced triglycerides, but not other 
lipid fractions or any markers of insulin resistance 
Yes 9 
Rwanda, n=187 Supervised exercise 3/week for 6 months Intervention reduced waist and weight but not HOMA-IR Yes 10 
USA, n=50, HAART, 
metabolic syndrome 
4 arms, 12 months: Metformin/placebo with 
diet/exercise or nil. Weekly diet, exercise 3/week 
Lifestyle plus metformin had greatest effect on artery 
calcification and reducing HOMA-IR, mostly driven by metformin 
Yes 11 
Thai, n=59, ↑LDL Individualised dietary, 7 sessions over 6 months Reduced LDL and triglycerides in intervention arm vs usual care No 12 
Notes: Ins. Res. = Insulin resistance measured in this study, yes/no; NCEP = National Cholesterol Education Programme; BP = blood pressure; LBM = lean body mass. 
References: 1 - (Barrios et al., 2002); 2 - (Terry et al., 2006); 3 - (Lazzaretti et al., 2012); 4 - (Balasubramanyam et al., 2011); 5 - (Ng et al., 2011); 6 - (Engelson et al., 2006); 7 - (Fitch 
et al., 2006); 8 - (Lindegaard et al., 2008); 9 - (Woods et al., 2009); 10 - (Mutimura et al., 2008); 11 - (Fitch et al., 2012); 12 - (Chotivichien et al., 2016) 





1.7  Behaviour Change 
 
The effectiveness of diet and exercise interventions can be measured by the degree of 
behaviour change achieved by participants. In this section I have presented a brief overview of 
behaviour change theory and a review of enablers and barriers to lifestyle change as 
background to help explain methodologies chosen for the pilot intervention. 
1.7.1 Behaviour Change Theories and Practice 
 
Changing human behaviours is fundamental to achieving optimal health (Fisher et al., 2011). 
Behaviour can moderate external or genetic influences and impact on health. Interventions to 
change behaviour have the potential to prevent or manage disease, to impact on quality of life 
and to improve health at the individual and population levels. However, it is recognised that 
sustaining positive behaviour change can be highly challenging. Investigators studying a range 
of lifestyle behaviours found the most successful behaviour change was smoking cessation 
following diagnosis of heart disease, where 40% quit. This contrasted with those recently 
diagnosed with T2D where regular exercise rates increased among 7% of those with higher 
education, and declined among those with lower education levels (Newsom et al., 2012).  
There is a wealth of literature describing theories of health behaviours. A recent review listed 
83 different theories and models, including social cognitive theory, theories of reasoned action 
and planned behaviour, and the health action process model (Michie et al., 2011a). For 
practical reasons I have chosen to work with the COM-B (Capability, Opportunity, Motivation – 
Behaviour) behaviour change model (Michie et al., 2011b). This was developed to assist health 
researchers identify relevant techniques to support delivery of interventions. 
The COM-B wheel has three layers: sources of behaviour, intervention functions and policy 
categories. Capability to change behaviour encompasses both psychological and physical 
capacity to engage in an activity, including the necessary knowledge, skills and tools. 
Opportunity includes physical and social aspects enabling, prompting or facilitating a 
behaviour. As well as conscious thoughts and goals Motivation also encompasses unconscious 
habits.  The author identifies nine intervention functions: education, persuasion, 
incentivisation, coercion, training, restriction, environmental restructuring, modelling, and 
enablement. Finally the policy functions describe the processes involved in implementing an 





1.7.2 Enablers and Barriers to Diet and Exercise Change 
 
Successful behaviour change is dependent on utilisation of enablers or motivations and 
overcoming barriers to change, some of which may be specific to the disease, illness or health 
condition experienced by the individual (Murray et al., 2013). I conducted a review of 
qualitative research studies investigating enablers and barriers to adopting diet and physical 
activity change and have presented this in Table 1.11. The search was limited to reports 
published between January 2010 and December 2015 characterising enablers and barriers to 
diet or physical activity change from participants in intervention studies. The search identified 
12 publications, two of which were systematic reviews. All research papers cited collected data 
from participants through in-depth interviews. 
For analysis and comparison, enablers and barriers can be categorised using the Theoretical 
Domains Framework (TDF) (Cane et al., 2012), as can techniques used to change them. There 
are 14 domains, and these have been matched against behaviours listed in Table 1.11: 
1. Knowledge 
2. Skills 
3. Social role and identity 
4. Beliefs, capabilities and self-confidence 
5. Optimism 
6. Beliefs about consequences and outcomes 
7. Reinforcement, incentives and punishment 
8. Interactions 
9. Goals 
10. Memory, attention and decision processes 
11. Environmental context and resources 
12. Social influences and group norms 
13. Emotions, anxieties and fears 
14. Behavioural regulation and self-monitoring 
The majority of enablers and barriers to diet and exercise change elicited from the literature 






Table 1.11: Review of Enablers and Barriers to Diet and Exercise Change 
Enablers 
Factor (TDF Domain) Description Refs 
Knowledge/education (1) New understanding, for example calories in food, 
benefits of exercise 
6 
Planning (2) Planning ahead facilitates both dietary change and 
exercise opportunities 
1 
Value of change (3) Admiration of active people, or desire to serve as an 
example to others 
4 
Coping positively with 
setbacks (4) 
Experience of setbacks acknowledged as disappointing 
but used to spur on to renew efforts to achieve goals 
2 
Knowledge of illness (6) Better understanding of the consequences of illness 
(CVD) drives behaviour change 
7 
Family history (6) Family history of illness (Diabetes) 3 
Desire to improve health 
(6) 
Diet and exercise used as a means to improve overall 
health 
1 
Drawing on success (7) Previous experience of success (weight loss, smoking) as 
a driver to change behaviours 
2 
Future focus (9) Motivation driven by future goals, for example 
protecting family time 
1 
Goal setting (9) Goal setting acts as a motivator 5 
Motivation/willpower 
(10) 
Determination and discipline to succeed drive 
behaviour change and achievement of goals 
1 
Mindfulness (10) Mindfulness approaches facilitate change, for example 
attention to healthy food choices 
6 
Cultural sensitivity (11) Education materials in participant’s own first language; 
culturally appropriate diet and physical activity advice 
3 
Local facilities access (11) Exercise facilities accessible in own local environment 8 
Tools, technical 
equipment and aids (11) 
Food scales, pedometers, exercise aids, technologies, 
apps, self-completed records or diaries, all reported to 
promote successful behaviour change 
1 





Exercising together with someone, support from family 
or employer, making common decisions 
1 
Pleasure (13) Fun, wellbeing, and social interaction experienced from 
exercising 
8 
Flexibility (14) Allow flexibility in approach, for example treats in 
moderation 
2 
Portion control (14) Active regulation of portion size, particularly outside of 
usual routines 
6 
Daily exercise (14) Incorporating physical activity into own routine of daily 
life 
4 
Lifestyle adaptation (14) Successfully incorporate change into usual routines of 
daily living 
2 







Factor (TDF Domain) Description Ref 
Isolation – personal (3) Lack of support from others in immediate relationships, 
socially, societally or professionally  
7 
Body image (3)  Concerns about physical appearance limit exercise 
(cancer) 
9 
Not interested (4) No interest in adopting physical activity at all, or 
achieving physical activity goals 
4 
Poor physical health (4) Pre-existing health challenges, such as fatigue, stroke, 
musculoskeletal injury or disease, pain, incontinence 
1 
Lack of future focus (6) Unfavourable future perspective (cancer survivors) 
limits motivation to change behaviour and achieve goals 
9 
Fear - current illness (6) Fear of exacerbating current illness through physical 
activity (cancer) and increasing healthier food intake 
(kidney disease) 
 
Denial of ill-health (6) Denial of severity of illness (CVD) limits motivation to 
change 
7 
Fear of injury (6) Fear of injury resulting from exercise (not related to 
specific illness or condition) 
8 
Negative reactions (8) Intentional or unintentional comments or actions from 
others 
6 
Lack of guidance (8)  Lack of guidance from health professionals or 
insufficient guidance provided in study design 
7 
Difficulty changing (10) Difficulty in doing without usual foods, changing to 
healthier alternatives 
5 
Lack of willpower or self-
control (10) 
Although initial motivation may have been high, relapse 
of previous behaviours occurs 
5 
Bad weather (11) Seasonal or unexpected bad weather inhibits outdoor 
physical activity 
1 
Isolation – distance (11) Geographically distant from healthcare centre or site of 
intervention 
7 
Cost (11)  Healthier foods perceived as being more expensive than 
usual foods 
1 
Lack of time (11) No time for exercise - family, social or occupational 
constraints 
4 
Cultural barriers (12) Fasting (Ramadan, Lent, routine fasting), sharing of 
traditional sweets (South Asian communities), under-
estimating BMI among Blacks (USA), social valorisation 
of obesity as markers of wealth and success in males 
and fertility and attractiveness in females (Africa) 
10, 
11 
Poor Mental Health (13) Anxiety, depression and other mental health challenges 
diminish ability to change behaviour and achieve goals 
9 
Not coping, setbacks (13) Demoralised by poor progress or relapses 2 
TDF: Theoretical Domains Framework. References: 1 - (Murray et al., 2013); 2 - (Stead et al., 2015); 3 
- (Morrison et al., 2014); 4 - (Korkiakangas et al., 2011); 5 - (Hammarstrom et al., 2014); 6 - (Metzgar 
et al., 2015); 7 - (Murray et al., 2012); 8 - (Clarke et al., 2015); 9 - (van Putten et al., 2016); 10 - (Cohen 
et al., 2013); 11 - (Hendley et al., 2011); 12 - (Oyekanmi and Paxton, 2014). 





1.7.3 Diet and Exercise Behaviour Change in People Living 
with HIV 
 
Few studies have been published reporting issues regarding enablers and barriers to diet and 
exercise behaviour change in PLWH. Researchers conducting a questionnaire-based study in 
the UK reported that among 92 HIV positive Black African and Black Caribbean origin patients, 
being overweight was not considered to be a health concern (Bradbeer and Bakar, 2008).  In a 
study based in New York a purposive sample of 123 HIV positive people was invited to take 
part in focus groups, exploring expectations, perceptions and beliefs related to a healthy 
lifestyle (Capili et al., 2014). Barriers to healthy behaviours included financial barriers to 
making healthier food choices, using obesity to mask HIV infection and isolation. Facilitators 
included good patient-provider communication, peer support and maintaining a positive 
attitude. The authors suggest that financial barriers are the primary barrier and social support 
the primary facilitator. In South Africa, participants in an intervention to increase physical 
activity were interviewed regarding enablers and barriers to change (Roos et al., 2015). 
Barriers identified included low energy levels, stress, family responsibilities, poor weather, 
domestic abuse and crime. Facilitators included support from friends and family, religious 
practices, and access to parks.  From the COM-B model, these three studies highlight a lack of 
motivation and capability to change as barriers, and opportunity as well as motivation from 
self and others as enablers. 
 
There is a series of reports regarding body image in people living with HIV. People experiencing 
lipodystrophy report psychological distress associated with their appearance (Huang et al., 
2006, Blashill and Vander Wal, 2010). In a questionnaire-based study of 103 HIV positive 
women in New Orleans investigators suggest that African-American women prefer a large 
body size and believe they will not be perceived as sick if they gain weight (Clark et al., 1999). 
Increased BMI is associated with negative body image in older HIV positive men and White HIV 
positive women (Sharma et al., 2007).  
 
Enablers and barriers to lifestyle change in people living with HIV partly correspond with those 
characterised in Table 1.11. There additionally appear to be HIV-specific factors, and these 





1.8   Estimating Disease Risk 
 
Disease risk prediction tools and calculators use individual data entered into an algorithm to 
estimate disease risk. There are a number of tools developed for use in diverse or particular 
cohorts. Given the increased risk of T2D and CVD in PLWH (see section 1.3.4) predicting 
disease presents an opportunity to reduce potential morbidity. CVD prediction tools may 
underestimate risk in PLWH (NICE, 2014b).  
The Framingham Risk Score published in 1998 may inaccurately estimate CVD risk in people 
living in the UK (Brindle et al., 2003, Mahmood et al., 2014). Two CVD risk tools developed and 
validated in UK populations are the JBS3 score developed by the UK’s joint societies (Joint 
British Societies Board, 2014), and the QRISK2 calculator derived from UK primary care 
patients (Hippisley-Cox et al., 2008). QRisk2 is the tool endorsed and currently recommended 
by NICE to predict CVD risk in the UK (NICE, 2014b). 
The HIV-specific D:A:D CVD risk score was developed from the prospective observational D:A:D 
study, a collaboration of 11 cohorts observing HIV patients from 212 clinics in Europe, Australia 
and the United States (Friis-Moller et al., 2010). Investigators have compared the efficacy of 
traditional CVD risk tools such as Framingham and the European Systematic Coronary Risk 
Evaluation Score (SCORE) with the D:A:D CVD risk score in a European cohort of HIV patients 
and observed only a moderate level of agreement (Begovac et al., 2015). Observed agreement 
was better in a Brazilian cohort (Nery et al., 2013). However, in a Thai cohort Framingham 
predicted high risk in 10% compared to 1% using D:A:D (Edwards-Jackson et al., 2011). 
A range of tools have been developed to predict risk of developing T2D including the Finnish 
FINDRISC tool (Saaristo et al., 2005), the Framingham Diabetes Risk tool (Wilson et al., 2007), 
the Cambridge Diabetes Score (Griffin et al., 2000), the QDScore based on data from GP 
practices in the UK (Hippisley-Cox et al., 2009) and the Leicester Risk Assessment tool (Gray et 
al., 2010). Additionally an HIV-specific diabetes risk prediction equation has been developed 
from the D:A:D study (Petoumenos et al., 2012). The investigators compared the D:A:D and 







1.9  Epistemology 
 
In this section I aim to interpret how my beliefs and experience have influenced my approach 
to conducting this research project. The key philosophical issues of ontology and epistemology 
underpin the individual’s approach to research. Ontology, the nature of the world and what 
there is to know about it, can be divided into two broad positions: realism and idealism. For 
realists external reality exists independently of beliefs or understandings and can be observed 
and known directly, approximately, or in the case of materialism in relation to economic or 
physical features. For idealists no external reality exists independently of beliefs or 
understandings (Rachael Ormston, 2014). In terms of research I place myself towards the 
realist end of the spectrum. Although I generally believe that phenomena identified by 
research reflect reality, I am open to the possibility that alternative explanations may exist, 
and in this regard I would feel comfortable being labelled a “critical realist” (Bhaskar, 2013) or 
a “cautious realist” (Blaikie, 2007). 
Epistemology concerns the basis of knowledge and how the individual learns about reality. An 
inductive approach builds knowledge through observation, allowing development of theories 
or laws. Deductive logic uses theory as a starting point, developing a hypothesis for testing. 
Previous authors have argued that either a purely inductive or purely deductive approach is 
practically unachievable (Blaikie, 2007). I would agree with this as in modern society there are 
few avenues for research to proceed without prior exposure to ideas or information. I place 
myself towards the inductive end of the spectrum as, for me, observations in clinical practice 
have generally led to development of hypotheses. 
A key epistemological issue in research is the relationship between the investigator and the 
participant, and the degree to which this relationship may affect observation and results. This 
concept is separate to the Hawthorne effect where research participation itself can affect 
outcomes or data produced (McCambridge et al., 2014). Where the phenomena under 
investigation are entirely unaffected by the investigator the results are free of value on their 
part and the report can be objective. Where the participants are affected by the investigator or 
the research process, an objective account cannot be produced and results are value-mediated 
through the researcher. Between these polarities lies the position of empathic neutrality. 
Researchers are encouraged to be transparent about their assumptions, values and bias at all 





My research practice is undoubtedly influenced by clinical practice and observations of 
patients, as mentioned already. Additionally, I practice with a patient-centred approach. 
Although beneficial for the patient and research participant, this approach has potential to be 
detrimental to the research process. For example, when weighing up the benefits and 
challenges of a technique to measure an outcome, I might be persuaded to choose the 
technique with the least burden for participants even if this results in a lower quality of 
research output. With my prior experience in healthcare management I am acutely aware of 
key financial and quality challenges facing the NHS and this has potential to lead to 
prioritisation of interventions or approaches with a lower financial burden. I am aware that I 
place importance on health research being clinically relevant. Finally, in terms of qualitative 
and quantitative research, my background in quantitative research is counterbalanced by 
immersion in behaviour change in clinical practice. 
 
1.10 Design, Hypothesis, Aims and    
Objectives 
 
With the risk of developing T2D in a treatment-experienced cohort reported as up to four 
times higher than matched HIV negative controls (Brown et al., 2005), it was calculated that 
unless prevention could be achieved, between 2016 and 2026 as many as 15,000 new HIV-
associated T2D diagnoses may present in the UK (Health Protection Agency, 2012, Dyson et al., 
2011). Lifestyle interventions are highly effective at preventing the progression from 
prediabetes to T2D reducing incidence by up to 59% (Walker et al., 2010, Goff and Duncan, 
2010). Therefore, the potential that despite the actions of HIV infection and antiretroviral 
medicines a lifestyle intervention in patients with HIV-associated prediabetes would improve 
insulin sensitivity and other metabolic parameters proved a distinct and clinically important 
avenue for investigation and provided the underpinning theory for this research project. 
 
Given the growing impetus to develop a pragmatic and affordable T2D prevention intervention 
and the complexity of the cohort to be investigated, the study design was developed using the 
Medical Research Council (MRC) guidance on development, evaluation and implementation of 
complex interventions to improve health (Craig et al., 2008), and the work presented in this 






  Initial Work  → Evidence Review →    Development   → Pilot & Evaluate →    Implement 
 
 
1.10.1 Project Design 
 
The portfolio of research presented in this thesis aimed to investigate the following: 
 
 Factors associated with prediabetes and T2D in an HIV cohort in the UK 
 Changes over time, through comparing new data with that collected from the same 
cohort 10 years previously 
 The effectiveness and acceptability of an individualised 6-month diet and exercise 
intervention designed to reduce markers of insulin resistance in those stable on 
antiretroviral therapy and with prediabetes 
 Enablers and barriers to lifestyle change in PLWH and prediabetes 
 
I designed the portfolio of research in three distinct but interrelated parts, with the potential 
for participants recruited progressing from one part to another, as outlined in Figure 6. 
 
 Part 1: The Phenotype of Dysglycaemia in HIV 
A cross-sectional study designed to describe the phenotype of T2D in HIV. Compare 
findings with data collected 10 years earlier 
 Part 2: Diet and Physical Activity Intervention 
A pilot intervention to investigate the effectiveness of individualised advice to change 
diet and exercise on markers of insulin resistance in those with prediabetes 
 Part 3: Qualitative Research Study 
A qualitative investigation of the acceptability of the interventional study, enablers and 






















































Part 1: Study to Describe  
the Phenotype of T2D in HIV 
 n=338 
 Purposive sampling to represent wider cohort 
 60 minute visit 
 Clinical assessment of factors associated with 
T2D, including anthropometry 
 Review of medical notes 
 Review of clinical biochemistry 
Part 3: Acceptability of the Intervention,  
and Characterisation of  
Enablers and Barriers to Change 
 
 Up to 25 participants purposively sampled 
 In-depth semi-structured interviews 
 Thematic analysis 
 
Part 2: Effectiveness of 6-month  
Individualised Diet and Exercise Intervention  
on Markers of Insulin Resistance 
 n=30 to completion of 6-months 
 Goal setting based on major diabetes 
prevention studies 
 Individualised diet and physical activity advice 
from a specialist dietitian 
 6 monthly visits, telephone follow-up, coaching 




were ineligible for, 
or declined to take 
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Figure 6: Summary Flowchart of Study Design. 
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1.10.2 Underpinning Theory 
 
People living with HIV and treated with ARV medicines are at a higher risk of developing T2D. 
The aetiology of insulin resistance in PLWH is complex and multifactorial, including a range of 
fixed and modifiable contributory factors. The small number of prior lifestyle interventions in 
PLWH have had either no effect or a small effect on insulin resistance, even with intensively 
delivered support. Despite this, there is potential for diet and exercise change to reduce insulin 




For each of the three parts of the study presented in this thesis, research questions were 
designed to test the following hypotheses: 
1. In HIV patients, BMI, diet, physical activity and a range of other factors are 
independently associated with impaired fasting glucose and type 2 diabetes when 
compared to patients with normal fasting glucose 
2. A 6-month intervention of diet and physical activity advice, individualised to address 
ethnic and socioeconomic differences, will result in a clinically significant reduction in 
glucose incremental area under the curve over a three-hour meal tolerance test, in 
PLWH with impaired fasting glucose 
3. PLWH at risk of type 2 diabetes experience both HIV-specific and general enablers and 
barriers to behaviour change 
 
1.10.4 Aims and Objectives 
 
1. The Phenotype of Dysglycaemia in HIV 
 
Aims:  
To phenotype dysglycaemia in this cohort, and describe how this has changed over time. 
 
Primary objective:  
To compare a range of demographic, anthropometric, medical, diet, activity and 







Secondary objectives:  
 To compare data collected in this study with historic data collected 10 years 
previously principally from our cohort in the CREATE study (Aboud et al., 2010) and 
with data from the general population in London and the UK 
 Given the piloting of a diet and physical activity intervention, to assess in particular 
the relationship between dietary intake and physical activity and dysglycaemia 
 To assess associations between BMI, gender and ethnicity 
 To assess which tools are most accurate for predicting CVD and T2D risk in this 
cohort using data from the phenotype study 
 
 
2. Diet and Physical Activity Intervention 
 
Aims:  
To assess the effectiveness of individualised diet and physical activity advice on markers of 
insulin resistance in people living with both HIV and prediabetes. 
 
Primary objective:   
To measure the change from baseline at 6 months for glucose incremental area under the 
curve, measured in a 3-hour meal tolerance test. 
 
Secondary objectives:  
 To measure the change from baseline at 6 months for insulin incremental area 
under the curve measured in a 3-hour meal tolerance test, indices of insulin 
resistance/sensitivity, dietary change, physical activity, lipids, anthropometry and 
body composition, frailty, blood pressure, CD4 count and HIV viral load, and 
cardiovascular and diabetes risk 
 To measure the effect of the intervention on quality of life 
 To measure the effect of the intervention on bowel habits and gut symptoms 
 
 
3. Qualitative Research Study 
 
Aims:  
(1) Investigate the acceptability of the diet and physical activity intervention 
(2) Characterise enablers and barriers to behaviour change 
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2.1   Introduction 
 
This chapter details the rationale for design and choice of methodology as well as procedures 
used in the three studies presented in this thesis, procedures used, and the management 
approach employed to oversee the conduct of the research (Figure 7). 
 
2.2 Ethical Practice and Approval 
 
The research presented in this thesis was conducted in compliance with the principles of the 
Declaration of Helsinki 2008, the Human Tissue Act 2004, and Good Clinical Practice. The 
protocol was approved by the London-Bromley NHS Research Ethics Committee (REC) on 
12/11/2013, ID number 13 LO 1543, and subsequently by the King’s Health Partners (KHP) 
Research and Development. Regular progress reports were submitted to the REC and to KHP. 
 
2.3 Recruitment and Screening 
 
Participants were recruited from HIV outpatient clinics within KHP through self-referral in 
response to advertising in clinic waiting areas or by referral by members of the clinic 
healthcare team. The primary site for recruiting participants was the HIV outpatient clinic at St. 
Thomas’ Hospital in central London. Secondary sites, both within the KHP organisation, were 
‘the research presented in this thesis was conducted in compliance with 
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the smaller HIV outpatient clinics at King’s College Hospital and the Beckenham Beacon Health 
Centre in South East London. The poster used to advertise the study is presented in Appendix 
1.  All potential participants were provided with both a participant information sheet and a 
consent form (Appendix 2), describing the study and providing sufficient information for 









Diet and Physical Activity 
Intervention 
A: Deliver a 6-month individualised 
diet and physical activity 
intervention 
B: Use a frequently-sampled liquid 
meal tolerance test to measure 
markers of insulin resistance 
C: Measure secondary outcomes 
(e.g. anthropometry, quality of life, 
lipids, dietary intake, activity) 
Phenotype of Dysglycaemia in HIV 
A: Cross-sectional study to collect 
demographic, anthropometric, 
medical, dietary and 
socioeconomic data from a sample 
purposively recruited to represent 
the clinic demographic  
B: Compare this with data 
previously collected in 2005C: 
Analyse by glycaemic status 
Qualitative Research Study 
A: Consider theoretical perspective, 
researcher viewpoint and 
reflexivity 
B: Conduct semi-structured in-
depth interviews with a purposive 
sample 
C: Thematic analysis of interview 





64 METHODOLOGY AND PROCEDURES 
In line with NHS guidance (Health Research Authority, 2016) the participant information sheet 
and consent form were piloted with the expert patient and HIV positive scientist working 
group convened for this study to ensure readability, as participant information produced for 
HIV research studies has been criticised for being at an advanced literacy level inaccessible to 
many (Collins et al., 2015).  
A screening form was used to assess eligibility prior to arranging a meeting to discuss 
participation and consent. The formal signed consent of participants was obtained before 
initiating any study procedures. All potential participants had at least 24 hours to read the 
participant information sheet, understand the protocol, the risks and benefits, and were 
encouraged to ask questions. However, if the participant expressed a preference to consent at 
the time of obtaining the information sheet and consent form, they were able to provide 
consent at that time (Health Research Authority, 2016). In these cases, the researcher 
contacted the participant 24 hours later to confirm their decision to be involved.  
Potential participants were assessed for capacity to consent for themselves (Health Research 
Authority, 2013). Potential participants without a good understanding of verbal or written 
English were not invited to take part in any of the three study parts as there was no provision 
for translation or interpreters within the research budget. Finally, following NRES guidelines, 




2.4  Research Management 
 
2.4.1 Research Supervision 
 
The research was overseen by a PhD Supervision Committee, with regular meetings scheduled 
according to KCL policy. More frequent supervision was provided by supervisors and email 
contact with collaborators. Research quality was also overseen by the sponsor, the Research 
and Development department at Guy’s and St. Thomas’ Hospital. The trial was open for audit 
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2.4.2 Participant Welfare 
 
Prior to commencement of the research, an adverse event (AE) was defined as any symptom, 
illness or experience that develops or worsens in severity during the course of the study. 
Intercurrent illnesses or injuries were regarded as AEs. Abnormal results of laboratory or 
diagnostic procedures were also considered to be AEs if a) they were associated with a serious 
adverse event, clinical signs or symptoms, b) led to additional treatment, or c) were considered 
to be of clinical significance. A serious adverse event (SAE) was defined as: fatal; life-
threatening; required or prolonged a hospital stay; or resulted in significant disability. As lead 
investigator I oversaw the safety of the study, including assessment and appropriate reporting 
of AEs. Medical monitoring included a regular assessment of the number and type of SAEs, 
overseen by physicians. All AEs were recorded in the participants’ case histories. Risk 
assessment was performed prior to commencing the study (Table 2.1). 
 
Table 2.1: Assessment and Mitigation of Risk in Intervention Procedures 
Issue Potential Risk Mitigation 
Phlebotomy Venous cannulation can present 
a small risk to the participant, 
e.g. pain, haematoma formation, 
and to the individual 
undertaking the procedure 
(principally needle stick injuries) 
An experienced and competent 
research nurse inserted the 
cannula. In the event of a failure 
an experienced alternative 
research nurse or doctor was 
asked to assist 
Fasting Certain ARVs must be 
administered with food to 
ensure adequate absorption 
Those who normally took 
morning ARVs were asked to 
take them with the test meal 
Physical Activity Participants were encouraged to 
increase physical activity levels 
as part of the intervention, 
potentially leading to discomfort 
on over-exertion 
Advice given mirrored that 
delivered as part of everyday 
clinical practice. Participants 
were advised to be mindful of 
safety and tolerance 
Mental Health Some participants may fear that 
losing weight might lead to 
disclosure of their HIV status 
On-call access to a psychologist 
and counsellors was available 
Participants were asked to 
complete an HIV-specific quality 
of life questionnaire with 
potentially upsetting questions 
On-call access to a psychologist 
and counsellors was available 
During the interviews 
participants may say something 
that they regret 
Participants were reminded they 
could ask for any section of the 
recording to be deleted 
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2.4.3 Participant Remuneration 
 
As directed by the NHS Research Ethics Committee the following remuneration was provided 
to participants: 
 Reimbursement in full of all travel expenses  
 Breakfast (£3) for any fasting visits 
 £25 for attending for the FSLMTT on days 1 and 180 
 £20 for attending for interview 
 
 
2.4.4 Data Management 
 
Source data was defined as the clinical findings, observations, laboratory and test data, and 
other information contained in source documents. Source documents were the original 
records including medical records, pharmacy dispensing records and recorded data from 
automated laboratory systems. Participant data was anonymised and coded. Data was stored 
on a password-protected laptop and on password-protected memory keys. All records were 
stored in compliance with the Data Protection Act (Information Commissioner's Office, 2015). 
It was attempted to minimise missing data throughout the design of the research protocol. 
Spurious data deemed to be as a result of a defective piece of equipment was excluded if that 
test could not be repeated. 
 
2.5 Phenotype of Dysglycaemia in HIV 
 
2.5.1 Rationale for Design 
 
The aim of this cross-sectional study was to phenotype dysglycaemia (prediabetes and T2D) in 
this HIV cohort and how this has changed over time. Data from a comparable cohort had been 
collected 10 years previously in the CREATE study (Aboud et al., 2010) and for this project was 
reanalysed by me. With this in mind 2015 data collection methods were designed to allow 
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Consideration was given regarding the method of selecting participants in order that the 
sample represent the population, and selection bias minimised. In HIV medical research it has 
proved challenging to recruit women and people from Black and Minority Ethnic groups 
(Loutfy et al., 2014, Bass et al., 2016, Wolak et al., 2012, Castillo-Mancilla et al., 2014). 
Additionally, the phenomenon of research fatigue has been described (Pagano-Therrien, 
2013). Taken together these two factors could potentially lead to particular sub-groups being 
underrepresented. To overcome these issues, it was decided to recruit participants using a 
proportionately stratified random sampling methodology. Ideally, recruiting a sample stratified 
by factors of interest would result in a cohort being representative of the population. 
The principal factor correlated with dysglycaemia is obesity (Hu, 2011). Stratification of the 
sample by BMI category was considered. However, prior to analysis of data collected in this 
study the population distribution of obesity in this HIV cohort was unknown. Patients 
attending HIV outpatients are coded by gender, ethnicity (9 categories) and age, therefore the 
population distribution of these factors in known. Given their association with dysglycaemia 
these factors were chosen to construct a purposive, proportionately stratified random 
sampling methodology.  
 
2.5.2 Power Calculation and Sampling 
 
The hypothesis for this cross-sectional study was that BMI and other factors are independently 
associated with dysglycaemia. Sample size was calculated using assumptions from a 
preliminary analysis of the 2005 data (the CREATE study) indicating a prevalence of 
dysglycaemia of 28% with a mean BMI of 24.9 kg/m2. With absolute and type 1 errors both set 
at 5% using the formula n = 
Z2 x p(1-p)
d2   where Z = type 1 error, p = expected proportion in the 
population, and d = precision or absolute error (Charan and Biswas, 2013), the sample size was 
calculated to be 339, approximately 10% of those regularly attending outpatients.   
 
To facilitate stratified sampling, anonymised clinical coding data was used to obtain 
demographic information regarding adult HIV patients who had attended outpatients twice or 
more within the 12 months prior to commencing the study. This data was subdivided by 
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into 4 reflecting the distribution of the population. “Other” ethnicities in the sampling 
structure included South and East Asians, Latin Americans, and Others, together comprising 
approximately 10% of the population. The study recruitment target of 339 participants was 
proportionately entered into a purposive stratified sampling grid (Table 2.2), using 
methodology from purposive sampling in diabetes surveys (Dowse and Zimmet, 1992). Where 
the sample in any cell was less than 1% this was rounded up, resulting in a total recruitment 
target of 340 participants. Selection bias was minimised by screening every third patient on 
outpatient lists (Levy and Lemeshow, 2008). 
Table 2.2: Phenotype Study Stratified Sampling Grid 
Age Band (years) 18-29 30-39 40-49 50-59 60-69 70+ 
Male White 7 17 48 44 33 7 
Black African 1 6 13 11 2 1 
Black Caribbean 1 1 8 8 1 1 
Other 1 9 8 6 3 1 
Female White 2 2 2 2 1 1 
Black African 2 12 28 23 5 1 
Black Caribbean 1 1 4 4 1 1 
Other 1 2 2 2 1 1 
Source: A Duncan 
 
2.5.3 Inclusion and Exclusion Criteria, Cross-sectional 
Study 
 
Participants were eligible for participation in the phenotype study as follows: 
 HIV positive adults (aged ≥18 years old) 
Participants were ineligible as follows: 
 If no fasting glucose within the last three months and unable to fast for a single blood 
glucose test 
 Unable to provide informed consent to participate 
 Unable to attend for a 30-minute research assessment and data collection visit 
 Unable to communicate in English 
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2.5.4 Methods of Data Collection, Cross-sectional Study 
 
Data collection in 2014 and 2015 was designed as far as possible to be comparable to that 
collected 10 years earlier. Methods of data collection in 2004-2005 for the CREATE study have 
been described previously (Elgalib et al., 2011). In summary, potential participants were 
referred by the healthcare team, screened and consented. A range of demographic, medical, 
biochemical and anthropometric data outlined in Table 2.3 was collected during a short clinical 
assessment conducted by healthcare researchers, anonymised and entered into a password-
protected Microsoft Excel spreadsheet. As shown in Table 2.3 a wider range of data was 
collected in 2014-2015 reflecting knowledge of metabolic risk factors which had emerged over 
the intervening time. All participants attended fasting, and were stratified by glucose 
measurements or a recorded diagnosis of type 2 diabetes. Those with a prior diagnosis of T2D 
and those newly diagnosed on this fasting test were combined into a single group “type 2 
diabetes”. Data was collected through a direct interview corroborated from medical notes and 
e-records, anonymised and entered into a password-protected Microsoft Excel spreadsheet. 
 
Demographic Data: 
Age was recorded on the day of the data collection interview. Self-identified categorisation of 
ethnicity, country of birth and parental ethnicity were recorded, and together constructed 
seven groups: White, Black African, Black Caribbean, South Asian, East Asian, Latino and Other. 
Participants defining themselves as Black British were categorised as African or Caribbean 
according to parental ethnicity. Gender was self-identified as male or female, with no 
participants self-identifying as transgender. First and second degree relatives with T2D were 
recorded, and separately relatives with type 1 diabetes.  
 
Anthropometry: 
Height and weight were measured using standardised calibrated electronic equipment, and 
BMI was calculated and categorised as: underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), 
overweight (25.0-29.9 kg/m2) and obese (≥30.0 kg/m2). Waist, defined as the midpoint 
between the lowest rib and the supra-iliac crest, was measured using a non-stretch tape 
measure and categorised using ethnic and gender-specific International Diabetes Federation 
(IDF) criteria (Alberti et al., 2006); these criteria were also used to define metabolic syndrome 
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Table 2.3: Data Collected From Cross-sectional Studies in 2005 and 2015 





Type 2 Diabetes 
Age   
Gender   
Ethnicity   
Relative with Type 2 Diabetes   
BMI    
Waist   
Gestational Diabetes   
Polycystic Ovary Syndrome   
Socioeconomic Status   
Employment Status   
Higher Education   
Dietary Intake    
Physical Activity   
Hypertension   
Smoking   
Cardiovascular Disease   
Stroke   
Renal Impairment   





Type 2 Diabetes 
Duration of HIV infection   
Duration of ARV therapy   
Exposure to ARVs associated with diabetes   
Weight change following initiation of ARVs   
CD4 nadir   
HIV suppression (viral load)   
Lipodystrophy syndrome   
Hepatitis B Co-infection   
Hepatitis C Co-infection   
Vitamin D   
Dyslipidaemia   
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Table 2.4: Definitions of Central Obesity and Metabolic Syndrome 





≥94 cm ≥80 cm 
South and East 
Asian, Latino 
≥90 cm ≥80 cm 
Metabolic 
Syndrome: Central 
obesity plus two or 




≥1.7 mmol/l or 
specific treatment 




<1.03 mmol/l or 
specific treatment 
<1.29 mmol/l or 
specific treatment  
Blood Pressure Systolic ≥130 or 
diastolic ≥85 mm Hg 
or specific treatment 
Systolic ≥130 or 
diastolic ≥85 mm Hg 
or specific treatment 
Glucose 
(Fasting) 
≥5.6 mmol.l or 
diagnosis of T2D 
≥5.6 mmol.l or 
diagnosis of T2D 




Socioeconomic status was calculated using two methods. The UK National Statistics 
Socioeconomic Classification (NS-SEC) is the tool currently used by the UK government and 
most widely in studies of health inequalities; it categorises according to type and status of 
employment using an online tool (Office of National Statistics, 2010). Categories 1 to 6 
comprise higher managers / professionals, lower managers / professionals, intermediate 
occupations, small employers, technical occupations, semi-routine occupations, and routine 
occupations respectively. Category 7 combines students, the retired or unemployed. For this 
study, category 7 was subdivided to record these separately, as PLWH are disproportionately 
unemployed secondary to chronic illness, with only 47% of Londoners living with HIV employed 
(Ibrahim et al., 2008). The data collection form is shown in Appendix 7.3. 
 
The MacArthur Socioeconomic Scale uses a Likert scale in order that participants can define 
themselves in terms of subjective socioeconomic status, firstly within their own self-defined 
community and secondly more widely (Adler et al., 2000). This scale was chosen as it has the 
ability to identify people of a lower socioeconomic status who might be well-supported or of a 
high status within their own community. This has been correlated with better health and 
reduced mortality (Singh-Manoux et al., 2003). The data collection form is shown in Appendix 
7.4. I selected this methodology as many PLWH have been unemployed for extended periods, 
often since their HIV diagnosis potentially over 30 years previously. However, they may be 
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In addition to the two socioeconomic status measures participants were asked if they 
considered themselves to be in a situation of financial struggle. This was self-categorised using 
three options developed to assess this factor in chronic illness (Surtees and Wainwright, 2007): 
(a) Quite comfortably off (b) Able to manage or (c) I struggle to get by from week to week. 
Only those who answered (c) were defined as in financial struggle. Finally, attainment of higher 
education was also ascertained. 
 
Lifestyle Behaviours: 
A range of lifestyle factors was recorded in order to characterise the variables needed for CVD 
and diabetes risk calculations (Hippisley-Cox et al., 2009, Hippisley-Cox et al., 2008, Gray et al., 
2010). The number of portions of fruits and vegetables usually consumed per day was 
recorded as well as hours per week of physical activity defined as exertion greater than usual 
walking speed. Smoking status was categorised as current, never, or ex-smoker, with number 
of cigarettes recorded.  
 
Participants were asked to record a 5-day diet diary and were issued a stamped return 
envelope to increase compliance. The MRC Human Nutrition Unit 5-day diary with 
photographs to aid recording of portion size was used. Rationale for method of assessing 
dietary intake is discussed fully in Section 2.6.9. Those participants who did not return 
completed diaries within 2 weeks were reminded to do so by telephone or email according to 
their chosen method of communication. A final third reminder was issued one month later to 
non-responders. Estimated energy expenditure was calculated using Oxford (Henry) equations 
to compute basal metabolic rate, with a physical activity factor of 1.3 for this relatively 
sedentary cohort (mean 2.3 hours of activity per week, see Table 3.3) applied to calculate total 
energy expenditure (Henry, 2005).  
 
Medical Information: 
Blood pressure was measured three times by a Vital Signs 300 Series 53000-E4™ electronic 
sphygmomanometer after at least five minutes of relaxed sitting, and a mean calculated for 
both systolic and diastolic measures. Hypertension was defined as a mean greater than 140 
systolic or greater than 85 diastolic mm Hg of blood, or current use of hypertension 
medication i.e. those with treated hypertension included within the “hypertension” group 
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checked at interview were: cardiovascular disease including myocardial infarction, stroke or 
transient ischaemic attack, chronic kidney disease, polycystic ovary syndrome, and hepatitis B 
or C. A history of gestational diabetes was also recorded. These were corroborated from 
medical notes with those successfully cleared of hepatitis C categorised as negative. Use of 
statins and corticosteroid medications was recorded. Hepatic steatosis was recorded from 
medical notes. Hepatic steatosis was assessed using standard clinical definitions by biopsy, MRI 
scan, or assessed by Fibroscan with an attenuation greater than 250 (Sasso et al., 2016). 
 
HIV Parameters: 
Known duration of HIV infection was measured from the date of the first positive HIV antibody 
test, and duration of ARV therapy from the date of first use of any ARV. Exposure to ARVs 
associated with insulin resistance was defined as current or historic treatment with AZT 
(zidovudine), ddI (didanosine), ddC (zalcitabine), d4T (stavudine), Indinavir, or high-dose 
Ritonavir (De Wit et al., 2008) (Rasmussen et al., 2012) (Hadigan and Kattakuzhy, 2014). 
Weight change following initiation of ARVs and CD4 nadir were corroborated where possible 
from medical notes; those predating 1996 were frequently unobtainable. HIV suppression was 
defined as current HIV viral load being undetectable (<50 copies per ml). Lipodystrophy 
syndrome was defined as current or historic by participant recall or physician diagnosis from 
the medical notes, and date of onset was recorded.  
 
Biochemical Data: 
Fasting lipids (total cholesterol, LDL, HDL and triglycerides), and vitamin D were recorded. For 
this study dyslipidaemia was defined as: total cholesterol, LDL cholesterol or triglycerides 
above the reference range, or HDL cholesterol below the reference range. The common use of 
the term dyslipidaemia differs between clinical practice among specialists working in HIV care 
and diabetes care. LDL and triglycerides are frequently raised in PLWH. HDL can be suppressed 
or apparently induced by certain ARVs, whereas in diabetes care, triglycerides are often raised 
and HDL can be low; the HDL to triglyceride ratio is often used as an indicator of metabolic 
health.  
 
Vitamin D is not regularly measured in this cohort. I anticipated there would be a large 
proportion of missing data and chose to define this variable as most recent measurement 
within 3 years of data collection. Additionally Vitamin D measures are subject to seasonal 
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2.5.5 Disease Risk Modelling 
 
Data was applied to a range of risk prediction tools described previously (Section 1.8). Clinically 
significant risk thresholds were used as benchmarks for assessing each equation’s ability to 
predict risk and degree of correlation. For CVD risk, the threshold used was 10% or greater 10-
year risk, and for T2D, moderate or high risk was used, as moderate risk predicts prediabetes 
(NICE, 2014b). For estimating CVD risk the Framingham, QRisk2, JBS and D:A:D equations were 
used. I chose these tools as, despite reports of underestimating CVD risk in HIV patients, 
Framingham remains the best known estimation tool. QRisk2 is recommended by the British 
HIV Association. JBS remains in use in the primary care setting, and although based on QRisk2 
data this tool was designed to estimate lifetime risk as opposed to shorter-term 10-year risk in 
the other tools, and may be useful in a younger cohort such as those living with HIV. The D:A:D 
equation is the only HIV-specific prediction equation developed to date. 
For estimating T2D risk, the QDRisk, Cambridge, Leicester, FINDRISK, and D:A:D equations were 
used and compared. Diabetes risk tools are used less frequently in clinical practice compared 
to CVD risk tools. However, this study offered an important opportunity to test the sensitivity 
and specificity of each tool and consider implications for clinical practice (Peters et al., 2013a). 
 
2.5.6 Statistical Analysis, Cross-sectional Study 
  
Data for both time points 2005 and 2015 was imported from Microsoft Excel and analysed 
using IBM SPSS. Distribution of the data was tested. For variables with a normal distribution 
arithmetic means and standard deviations were calculated. Variables without a normal 
distribution were considered for log or square root transformation. Medians and interquartile 
ranges were calculated. Characteristics of the two time points were compared and, where 
appropriate, differences between the two studies were calculated and assessed for statistical 
significance using Chi-squared (categorical variables) and ANOVA (continuous variables) tests. 
Pearson’s Chi-square and Phi coefficient and Pearson’s product-moment correlation coefficient 
were calculated for categorical and continuous variables respectively.  
Regarding ethnicity, small numbers of participants were of South Asian, East Asian, Latin 
American or Other descent. For statistical analysis these categories were combined into a 
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Black Caribbean and Other, allowing a closer examination of relationship between ethnicity 
and factors associated with dysglycaemia. 
To assess risk factors associated with prediabetes and T2D, these two categories were 
combined into a single dependent variable labelled dysglycaemia, given evidence from the 
general population (Narayan et al., 2003) and in other HIV cohorts (Polsky et al., 2011, Capeau 
et al., 2012) that those with prediabetes are likely to progress to type 2 diabetes. For dietary 
analysis prediabetes and T2D were analysed separately as participants with T2D were more 
likely to have changed their dietary intake as a result of diagnosis, whereas those with 
prediabetes were largely diagnosed with this condition on entry to this study. For both 2005 
and 2015 data univariate analysis of associations with dysglycaemia was performed using Chi-
squared and ANOVA tests. Collinearity was tested between variables. For analysis of dietary 
intake, comparison between normoglycaemia, prediabetes and T2D was performed using 
ANOVA with Tukey’s Honestly Significantly Different (HSD) test used to identify differences 
between groups. Additionally a Bonferroni adjustment was made to the alpha significance 
level. As there were three comparisons made, the alpha significance level used for comparison 
of dietary intake between groups was 0.017. 
Binary logistic regression models were constructed for data from 2005 and 2015 to distinguish 
the independent contribution of factors to dysglycaemia. All variables demonstrated through 
univariate analysis to be significantly associated with dysglycaemia were considered for 
inclusion in the model. However, any pairs of variables with significant Pearson correlation 
were examined and only one variable of the pair was included in the model, chosen by clinical 
significance (Cohen, 1992). The backwards stepwise removal method was used, where 
variables lacking a statistically significant relationship were systematically removed (Menard, 
2002). Odds ratios with confidence intervals were calculated.  
Two logistic regression model options were considered. The first option pooled all HIV-related 
variables and compared these with general (non HIV-related) variables. The second option 
pooled all fixed variables and compared these with modifiable variables. The second option 
was chosen as information regarding modifiable factors was considered clinically relevant. 
Modifiable variables were defined as those amenable to lifestyle change, with or without 
added effect from medication, for example hepatic steatosis and triglycerides. Fixed variables 
were defined as historic or those that would not respond to lifestyle change, for example 
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modifiable variables alone, and all variables together. The ability of each of the three models 
to predict dysglycaemia was measured using the area under receiver operator characteristic 
(ROC) curves (Alemayehu and Zou, 2012). ROC curves are most often used to calculate clinical 
thresholds when developing tests or markers for a disease. In this instance, the difference in 
proportions of the area under the curve (AUC) was used to determine which model best 
predicts dysglycaemia. 
Receiver Operator Characteristic (ROC) curves were also used to investigate sensitivity and 
specificity for the various tools used to estimate disease risk, comparing how each disease risk 
equation correctly or incorrectly classified those at high risk of CVD or dysglycaemia. The 
overall strength of prediction of each equation was estimated using the AUC and its statistical 
significance. The number of cases of comorbid disease correctly identified by each prediction 
tool was also compared using Pearson’s correlation. 
 
2.6 Diet and Physical Activity Intervention 
 
2.6.1 Rationale for Pilot Intervention Design 
 
The aim the intervention presented in this thesis was to investigate the effect of individualised 
diet and exercise advice on markers of insulin resistance in PLWH at risk of developing T2D. 
Evidence that in PLWH diet or exercise change even when delivered with intensive support 
impacts weakly on insulin resistance, coupled with the uniquely diverse aetiology of 
dysglycaemia in PLWH, led to the decision that effectiveness must be explored prior to 
conducting a randomised controlled trial. This follows the guidelines recommended by the 
MRC for development of complex interventions (Craig et al., 2008). As previously described 
(Table 1.10) there have been six interventions in PLWH reporting the effects of diet or exercise 
on markers of insulin resistance. All six interventions were designed with highly intensive 
support, with daily or weekly sessions with dietitians or exercise instructors over three to 12 
months. One trial provided all meals for the day. In two of the six studies markers of insulin 
resistance or HbA1c were reduced following the intervention whereas the other four studies 
showed no effect. Given the increasing prevalence of overweight and obesity in PLWH, the 
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2.6.2 Choice of Intervention Structure 
 
I based the intervention design on four large diabetes prevention trials (Table 1.8), with goals 
set for diet and physical activity change, and a target of 7% weight loss over six months 
(Knowler et al., 2002, Walker et al., 2010) (Figure 8). People living with HIV experience specific 
issues regarding diet, exercise and weight loss. These include the need to maintain lean body 
mass to support immune function (Wheeler et al., 1998), the pharmacokinetic importance of 
observing food-ARV interactions (Tseng et al., 2015) and consideration of metabolic issues 
(Table 1.2). Given these issues and the diversity of the cohort, an individualised advice 
approach was chosen. This was to be delivered by me, a dietitian specialising in HIV care, over 
a 6-month period with monthly review appointments. Markers of insulin resistance were 
measured at the start and end of the intervention together with a range of secondary outcome 
measures. 
 
2.6.3 Diet, Physical Activity and Behaviour Change 
 
For this study, in addition to the primary goal of reducing insulin resistance, I gave 
consideration to the prevalent metabolic health issues faced by PLWH including hypertension, 
dyslipidaemia and the risk of developing osteoporosis. The Mediterranean diet has a positive 
effect on dyslipidaemia and other health outcomes (Sofi et al., 2008). The DASH diet reduced 
hypertension (Appel et al., 1997). Both have been used to good effect in diabetes prevention 
trials (Martinez-Gonzalez et al., 2008, Liese et al., 2009). The two dietary approaches are 
described in Table 2.5 (Bach-Faig et al., 2011). For this intervention with the specific needs of 
PLWH in mind I chose to use a pragmatic combination of Mediterranean and DASH dietary 
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Table 2.5: A Comparison of the Mediterranean and DASH Diets 
 
Mediterranean DASH 
Carbohydrates >50% carbohydrates from 
wholegrains 
7-8 portions / day 
Sweets 2/week 
Fats Olive oil daily Low fat overall 
3 tablespoons oil/fat per day 
Protein foods ↓ meats and poultry 
↑ fish, pulses, nuts, seeds 
↓ meat and poultry 
↑ fish 
Nuts/seeds/pulses 5/week 
Fruits and vegetables 
 
Fruit 1-2, vegetables 3+ per day 8+ portions / day 
Salt No specific limit No added salt 
Dairy 2 portions low fat dairy / day 2 portions low fat dairy / day 
Other Red wine in moderation  
Source: A Duncan 
 
Behaviour Change: 
NICE guidelines recommend that when developing interventions specific behaviour change 
techniques should be used to support adherence and these must meet individual needs (NICE, 
2014a). In complex interventions the function and process of the intervention should be 
standardised, not the components themselves in order to maximise effectiveness (Hawe et al., 
2004). To date there is no published research regarding behaviour change in diet and physical 
activity interventions in PLWH. I therefore chose behaviour change techniques and supporting 
strategies listed in Tables 2.6-2.8 based on prevalent themes from the literature review 
presented in Table 1.11 on page 52. 
Using the Theoretical Domain Framework to categorise these (Cane et al., 2012), I concluded 
that the principal areas requiring behaviour change support in lifestyle interventions are: 
goals; beliefs about consequences and outcomes; reinforcement and incentives; 
environmental context and resources; social influences and group norms; behavioural 
regulation and self-monitoring. Techniques to support change within these domains required a 
standardised delivery and support framework; I chose motivational interviewing and cognitive 
behavioural therapy, widely used in diabetes prevention and also in HIV transmission risk 
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7% weight loss 
in 6 months 






goals Energy deficit 
















fats >15% total 
daily energy
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Table 2.6: Diet and Exercise – Individualisation of Intervention Components 
 Standardised Process Individualised Component Refs 
ENERGY Daily deficit of 600 kcal / 
day based on estimated 
total energy expenditure 
Estimate energy expenditure based 
on weight, age, gender and activity 
using modified Oxford equations 
1 
WEIGHT Goal to achieve 7% weight 
loss in 6 months, or until 
BMI of 22.5 kg/m2 achieved 
If 7% weight loss would result in a 
BMI <22.5 kg/m2, then target 
weight = BMI 22.5 kg/m2 
2 
WAIST Aim to  waist size until IDF 
risk targets achieved: less 
than 94cm (♂), 90cm 
(Asian ♂), 80cm (♀)  
Where achievement of waist target 
is unlikely in 6 months, negotiate 
achievable target, with a guideline 
of 7% reduction 
3 
FAT Saturated fat to comprise 
<10%, and 
monounsaturates >15 % of 
total daily energy intake 
Advice should reflect ethnicity, 
food habits, socioeconomic status, 
lifestyle patterns, access to food, 
cooking ability. Tailor advice to 
medical issues, e.g. raised LDL 
4 
CARBOHYDRATE >50% of carbohydrate 
intake from wholegrains 
As for fat. Individualise advice for 
any gastrointestinal symptoms 
5 
ADDED SUGARS Restrict added sugar, 
sugar-sweetened drinks, 
biscuits, cakes, sweets  
Discuss use of artificial sweeteners, 
diet drinks and alternatives to 
sweet foods  
6 
SODIUM <6g salt daily 
(<2.5g sodium / day) 
As for fat. Sodium restriction may 





≥7 portions fruit and 
vegetables daily 
As for fat. Cognisance of fruit and 
vegetables perceived as most 
expensive part of dietary change 
7 
FISH 2 portions fish/week, one 
of which should be oily 
As for fat. May be a priority for 
those a higher CVD risk 
8 
STEPS PER DAY 10,000 steps/day, building 
gradually by 1,000 
steps/day until goal 
achieved or exceeded 
Methods of achieving 10,000 
steps/day based on individual’s 
current lifestyle, ability, 




30 minutes moderate 
physical activity 3/week, 
building incrementally 
Consider accumulating 30 minutes 
in shorter blocks across the day. 
Type of activity to suit individual 
11 
ALCOHOL No standard goal for 
alcohol 
Reduce alcohol to effect overall 





Eat three times per day, 
spread across the day. 
Encourage healthy snacks 
Advice should reflect food habits, 
lifestyle, access to food, medical 
issues, food-drug interactions 
13 
References: 1 - (Henry, 2005); 2 - (Tuomilehto et al., 2001); 3- (Alberti et al., 2006); 4 - (Ericson et al., 
2015); 5- (Aune et al., 2013); 6- (Gardner et al., 2012); 7- (Liese et al., 2009); 8 - (Stradling et al., 
2012); 9 - (Yates et al., 2009); 10 - (Tudor-Locke et al., 2011); 11 - (Knowler et al., 2002); 12 - (Knott et 
al., 2015); 13 - (Tseng et al., 2015) 
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Table 2.7: Behaviour Change Techniques – Individualisation of Intervention Components 
 Standardised Process Individualised Component Refs 
REINFORCEMENT Reminder & motivational 
text messages 
The content of the text message 
will be individualised, or 
alternatives used where participant 






behaviours or unhelpful 
thinking, evaluate 
frequency and intensity, 
reconceptualise to aid 
understanding, facilitate 
skills to replace 
behaviour, set goals, 
assess progress 
Need for CBT will be identified on 
an individualised basis. 
Reconceptualisation, facilitation of 





Elicit change talk, evoke 
motivation from 
participant, agree goals, 
positive encouragement, 
foster autonomy 
Use at every contact but 
individualise to reflect participant’s 





Day 1: health implications 
of developing T2D will be 
discussed 
Revisit across the 6 months as 
appropriate, including health 






of an experience as a 
failure acknowledged by 
dietitian, then position 
this as a learning 
experience 
Technique used where 






Support from others will 
be discussed with all 
participants 
Support may be from family, 
friends, peers, or colleagues, 
individualised to participant’s 
situation. In cases of isolation, 
greater support from study 
dietitian or from charities or 




Reward for achievement 
encouraged, with the 
caveat that food or 
alcohol should not be 
used as a reward 
Individual to identify own reward 5 
References: 1 - (NICE, 2014a); 2 - (Baker et al., 2011); 3 - (Tuah et al., 2011); 4 - (Martins and McNeil, 
2009); 5 - (Paulweber et al., 2010) 
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Table 2.8: Participant Information and Resources – Individualisation of Intervention 
Components 
 Standardised Process Individualised Component Refs 
PEDOMETER CW-600 digi-walker given to all 
participants at first visit, with 
instructions for use and how to 
record daily number of steps in 
diary 
Smart phone can be used 
as an alternative, with 
discussion that when 
phone not in pocket steps 




National Dietary Resources (NDR-
UK) “Weight Loss You Can See” 
booklet given to all participants 
at first visit 
African and Caribbean 
inserts 
3 
DAILY DIARY Participants encouraged to 
record food and mood, daily 
record of number of steps 
achieved, challenges, successes, 
and any questions or issues to 
raise at next visit. Given at first 
visit 
To be completed by all 
participants at a level 




Summary of standardised dietary 
goals for the interventions with 
suggestions how to achieve 
these, given at first visit 
Delete any inappropriate 






British Heart Foundation (BHF) 
Get Active Stay Active booklet, 
given to all participants at second 
visit 
Additional resources on an 
individual basis, e.g. African 
and Caribbean Diabetes UK 
booklet 
3 
FOOD SAMPLES At second visit discuss food 
samples: low salt, wholegrains, 
low fat, and encourage to take 
samples away to try 
The participant to choose 
which items preferred 
4 
FOOD LABELS Resource sheet explaining how to 
understand food labels given at 
second visit 
For all participants. Extra 
resources available for 
individuals who require 
further explanation 
3 
MRC FOOD DIARY 5 day diary using photographs to 
aid estimation of portion size. 
Given prior to first and last visits 
For all participants 5 
References: 1 - (Yates et al., 2009); 2 - (Tudor-Locke et al., 2011); 3 - (Baker et al., 2011);  4 - (Moore 
et al., 2009); 5 - (Medical Research Council, 2016) 
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2.6.4 Methodology for Measuring Primary Outcome 
 
The primary outcome for the intervention was the change from baseline at 6 months for 
markers of insulin resistance, specifically glucose incremental area under the curve. A range of 
methods are used in clinical research for measuring glycaemic status, insulin sensitivity / 
resistance, and glucose disposal; this is summarised in Table 2.9. Of these methods, the three I 
considered for measuring the primary outcome in this study were the hyperinsulinaemic-
euglycaemic clamp (HIEC), the oral glucose tolerance test (OGTT), and the frequently sampled 
liquid meal tolerance test (FSLMTT). My rationale for selecting the FSLMTT is outlined below. 
 
The HIEC is considered to be the gold standard for measuring insulin sensitivity/resistance. It 
has been used extensively in research with HIV-positive participants (Neye et al., 2006, Taylor 
et al., 2010, Nguyen et al., 2014, Moreno-Perez et al., 2013). However the HIEC is time-
consuming, labour-intensive and expensive to implement, requiring a trained and experienced 
operator. Additionally, due to the HIEC being based on intravenous stimuli it may not reflect 
insulin and glucose dynamics under normal physiological conditions, for example those 
occurring after normal meals (Roden, 2007). 
 
The OGTT is a well-established test requiring considerably less training, experience and 
resources than the HIEC. It has been used extensively in HIV patients (Gianotti et al., 2011). 
The use of frequent sampling points over a 120 or 180 minute time course allows for more 
sophisticated modelling of insulin and glucose dynamics and estimation of insulin sensitivity 
(Roden, 2007). 
 
More recently meal tolerance tests have been favoured over the OGTT because mixed nutrient 
stimuli more closely mimic usual physiological eating. I selected the FSLMTT as the method for 
measuring the primary outcome as it would provide the most detailed level of data with a 
reasonable use of resources and with only a modest burden for participants (Roden, 2007). 
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Table 2.9: Methods for Measuring Insulin and Glucose Dynamics 
Method Description Notes Ref 
Fasting glucose 
and insulin 
Single phlebotomy after an 
overnight fast 
Least participant burden. 
Simple indices e.g. HOMA 
(Matthews 
et al., 1985) 
HbA1c Surrogate for medium-term 
glycaemic control that does 
not require fasting 
More expensive than 
glucose. May be less 






75g glucose (fasting), up to 4 
samples over 120 mins, 
Clinically glucose only but 
adding insulin allows 
modelling 
Simple physiological test 








Measured meal eaten in 
fasting state, glucose and 
insulin at several time points 
120-180 minutes afterwards 
Demanding for 
investigators to ensure 
consistency, most 
physiologically relevant, 








Extended version of the OGTT 
with insulin and glucose 
measured at up to 11 time 
points over 120-180 minutes 
Moderately intensive. 
More physiologically 










Insulin and glucose are 
sampled frequently over 120-
180 mins following a mixed-
nutrient liquid meal (fasting) 
Moderately intensive. 
Readily reproducible for 
investigators. Evaluates 
incretins 








Over 180 minutes following 
an IV bolus of glucose in the 
fasting state frequent insulin 
and glucose samples are 
modelled to produce an 
insulin sensitivity index 
Moderately intensive. 
Tends to be inaccurate in 
those with diabetes who 
secrete little insulin and 






Fasting, IV octreotide 
suppresses endogenous 
insulin secretion, IV insulin & 
glucose given, samples at 
150-180 mins determine 
muscle insulin sensitivity 
Slightly less intensive than 
the HIEC. Does not reflect 
hepatic insulin sensitivity 
or action of incretins 





A standard bolus of insulin is 
given IV in the fasting state. 
Drop in glucose at 8 time 
points over 30 minutes gives 
measure of insulin sensitivity 
Hypoglycaemia can occur 
requiring monitoring / IV 
glucose. Does not 
differentiate peripheral vs 
hepatic insulin sensitivity 






Fasting, insulin infused IV to 
suppress gluconeogenesis. 
Glucose IV to achieve steady 
state at normal blood glucose 
Considered gold standard. 
Expensive and labour 
intensive. Potential 
burden on participant 
(DeFronzo 
et al., 1979) 




85 METHODOLOGY AND PROCEDURES 
Various models of FSLMTT have been used (Table 2.10), for example using carbohydrate doses 
ranging from 33-80g, 15-18g protein, and 6-12g fat in a 150-500ml dose. I developed a 
protocol for the FSLMTT using a readily-available mixed nutrient drink, Fortisip Compact™. This 
product is produced under strict conditions resulting in a reliably consistent delivery of 
nutrients. A dose of 200g weighed using electronic scales provided 60g carbohydrate, 19g 
protein and 18g fat. Other studies used time points ranging from 0-120 to 0-240 minutes. For 
this study 0-180 minutes was chosen in order to characterise any delayed response to a meal 
challenge in HIV patients. Consultation with a patient-public involvement group had led to the 
decision to limit research visits to a maximum of 4 hours, therefore extending the test to 4 
hours post meal would breach this timescale, and potentially add limited extra data. I 
developed a standard operating procedure for the FSLMTT (Appendix 5).  
 
2.6.5 Frequently Sampled Liquid Meal Tolerance Test 
Procedure 
 
In the 24 hours prior to the FSLMTT participants were instructed to refrain from vigorous 
exercise, smoking and alcohol, and to eat three standard meals containing carbohydrates. 
Fasting was defined as nothing to eat and only water to drink from 10 hours prior to attending. 
In practice all FSLMTTs commenced between 8 and 10am to suit the participant and fasting 
commenced between 10pm and midnight accordingly. In order to prevent risk of dehydration 
and aid ease of phlebotomy participants were encouraged to drink 500-1000ml water prior to 
leaving home to attend the FSLMTT appointment. On the morning of the FSLMTT a qualified 
research nurse inserted a BD Nexiva™ Dual Port 20 Gauge 25mm cannula into the participant’s 
antecubital fossa on the non-dominant arm using intradermal lignocaine (1%) to anaesthetise 
the skin, employing standard aseptic techniques. After a period of 10 minutes allowing the 
participant to relax, fasting samples for glucose, insulin, lipids and HbA1c were taken from the 
cannula, as outlined in Table 2.11. A zero sample was taken 10 minutes later followed 
immediately by the participant being asked to consume the liquid meal. Participants chose to 
consume the liquid meal either at room temperature or chilled from the refrigerator. The 
choice was noted and repeated at the post-intervention visit as temperature can affect rate of 
gastric emptying (Mishima et al., 2009). Participants were informed that they should consume 
the entire 200g dose in steady sips and were timed using an electronic stopwatch to ensure a 
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Table 2.10: Frequently Sampled Liquid Meal Tests – Models Used 
Study and 
Reference 
Preparation Liquid Meal Used Phlebotomy Notes 








6 hours before 
test 
237ml dose of 
Boost-HP™ 
(Nestle): 33g CHO, 
15g protein, 6g fat 
0, 15, 30, 60, 
90, 120 
minutes 














Sustacal™ (Nestle) - 
1kcal/ml drink, 
6ml/kg, max dose 
of 360ml. 360ml 
provides 52g CHO, 
15g protein, 10g fat 










USA & Canada, 
relatives of T1D 







HP™, for either max 
dose of 360ml 
0, 15, 30, 60, 
90, 120 
One of several 
methods used 
in this trial 
(Maki et al., 
2009) 
USA, adults with 
T2D 




Confirm these 2 
before fasting 
for 10 hours 
500g chocolate 
Ensure™ (1kcal/ml), 
consume within 10 
minutes. Provides 
80g CHO, 18g 
protein, 12g fat 









(Maki et al., 
2010) 
USA, adults with 
normal glucose 
IFG and T2D 
 




fast for 10 hours 
500g chocolate 
Ensure™ (1kcal/ml), 
consume within 10 
minutes. Provides 
80g CHO, 18g 
protein, 12g fat 










(Maki et al., 
2011) 
USA, adults with 
increased waist 






consume within 10 
minutes. Provides 
80g CHO, 18g 
protein, 12g fat 
0, 30, 60, 90, 
120 




Note: CHO - carbohydrate 
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Over the next three hours blood was taken at 5, 10, 15, 30, 60, 90, 120, 150 and 180 minutes. 
A total of 86ml of blood was taken during the test. Saline (0.9%) was flushed before and after 
each blood draw to maintain patency of the cannula and lines. In order to prevent dilution of 
samples with saline, 2ml blood was discarded prior to obtaining each sample. An additional 
blood sample was drawn and together with a urine sample transferred for processing and 
long-term storage at -80⁰C in the KCL Infectious Diseases BioBank at Guy’s Hospital. The 
intention for these samples is to investigate gene expression and metabolomics. This proposed 
study is not part of the research presented in this thesis. 
 
Table 2.11: Sampling Schedule for the Pre and Post Intervention Visits 
 Time in Minutes 
-10 0 5 10 15 30 60 90 120 150 180 
Glucose  
(2ml fluoride oxalate) 
x x x x x x x x x x x 
Insulin 
(2ml clotted serum) 
x x x x x x x x x x x 
Lipids  
(2ml clotted serum) 
x           
HbA1c  
(2ml EDTA) 
x           
Incretins  
(2ml EDTA + DPPIV 
inhibitor) 
 x    x x  x   
Sample for future DNA 
analysis (EDTA) 
x           
 Urine sample for 
future metabolomics 
analysis 
x           
Source: A Duncan 
All specimens were labelled using a unique study identification code with no identifiable 
information recorded on samples. The code used was in the format: STOP123AB1. This 
referred to: STOP – The STOP Diabetes in HIV study; 123 – Participant study number; AB – 
Participant initials; 1 – Visit number. In addition specimens were labelled with the analyte and 
time point of collection in minutes, for example GLU 0, INS 90. Vacutainer tubes for all samples 
other than insulin were chilled on ice prior to drawing samples. Samples were processed (Table 
2.12) prior to placing in 2 cryotubes (primary and duplicate sample) and were racked in 10 x 10 
cryogenic storage boxes in a -80oC freezer. Finally, once all participants completed the 
intervention primary samples were couriered to the King’s Lab for analysis, remaining frozen 
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Table 2.12: Processing Schedule for Intervention Blood Samples 
Analyte Sampling Tube Preparation Volume 
Glucose  Fluoride oxalate 
(grey) 
Stored on ice and 
centrifuged within 15 
minutes at 2500 rpm at 4⁰C 
2ml blood, aliquot 
serum into 2 
cryovials for freezing 
Insulin Plain clotted (gold) Room temperature for 30 
minutes. Centrifuged at 
2500 rpm at 4⁰C 
2ml blood, aliquot 
serum into 2 
cryovials for freezing 
Incretins EDTA (purple) with 
100µl DPPIV 
inhibitor added 
Stored on ice and 
centrifuged within 2 
minutes at 2500 rpm at 4⁰C 
2ml blood, aliquot 
serum into 2 
cryovials for freezing 
Lipids Plain clotted (gold) No preparation: sent 
directly to Guys lab 
2ml blood 
HbA1c EDTA (purple) 
 
No preparation: sent 





EDTA (purple) Courier transferred at 
room temperature to the 
BioBank for processing 
2 x7ml vacutainers  
Notes: 
2500 rpm in the centrifuge used is equivalent to 559 times gravity  
EDTA: Ethylene Diamine Tetra-acetic Acid 
Source: A Duncan 
 
2.6.6 Modelling Glucose and Insulin Dynamics 
 
Glucose and insulin results from the tests described in Table 2.9 can be modelled to estimate 
insulin sensitivity, insulin resistance, β-cell function and glucose clearance rates. Several 
models have been developed and tested in various patient groups and those commonly used 
are described in Table 2.13. For this study, I chose a range of indices of insulin sensitivity, 
resistance and glucose clearance rates. 
HOMA and QUICKI have been used extensively in studies of HIV patients and have been 
validated for use within people of Black African origin (Ntyintyane et al., 2010). However, both 
use simple formulae based on fasting insulin and glucose only. The McAuley Index formula 
uses fasting triglycerides in addition to insulin; I selected this index as triglyceride levels can be 
high in PLWH (Alencastro et al., 2011). Finally, the oral glucose insulin sensitivity index (OGIS) 
was chosen to estimate glucose clearance as all variables required for the complex equation 
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Table 2.13: Glucose and Insulin Modelling Indices  













Fasting glucose and 
insulin 
0.56 Widespread and 
validated 
QUICKI 




Fasting glucose and 
insulin 









Insulin and glucose at 
0 and 120 minutes 





sensitivity index  
Insulin and glucose at 
0 and 120 minutes, 
and body mass 
0.83 Not reported in 
research 







Fasting insulin and 
triglycerides 
0.63 Not reported in 
research 







Fasting insulin and 120 
minute insulin and 
gluose, plus age, 
gender and BMI 
0.62 Not reported in 
research 









Fasting glucose and 
insulin over time 
following a glucose 
dose plus body mass 
0.63 Not reported in 
research 
published to date 
OGIS 







insulin and glucose at 
0,60,120 plus body 
surface area 
0.65 Not reported in 
research 
published to date 
- Abbreviations: HIEC – Hyperinsulinaemic-euglycaemic clamp; IFG – Impaired fasting glucose; 
HOMA – Homoeostatic model of assessment; QUICKI – Quantitative insulin sensitivity index; 
OGIS – Oral glucose insulin sensitivity. 
- Source of HIEC correlations: (Gutch et al., 2015) 
- Date of search for use of indices in HIV cohorts: 4/4/16 
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2.6.7 Power Calculation, Intervention 
 
Powering a Hypothetical Randomised Controlled Trial: 
In the PREPARE study, an RCT carried out in an HIV negative UK population (Yates et al., 2009), 
investigators measured the effect on insulin resistance of a 6 month course of advice to 
increase physical activity. Measured by an OGTT, they observed a 0.8 mmol/l drop in 2-hour 
post-load glucose when comparing the intervention and control arms. Assuming this same 
effect size of a difference of 0.8 mmol/l post-load plasma glucose between an intervention and 
control arm in a hypothetical RCT investigating HIV patients at risk of developing diabetes, 25 
participants would need to complete the study per group in order to detect this difference 
with a power of 80% using a significance level of 0.05.  
 
Powering The Intervention Presented in this Thesis: 
As previously described, a single intervention arm was chosen for this pilot study investigating 
effectiveness rather than an RCT. Planning to follow up at least 30 participants to completion 
of the 6 month intervention, it was estimated as many as 46 would need to be recruited to 
achieve this. The drop-out rates for lifestyle intervention studies in HIV patients are potentially 
as high as one in three (Fitch et al., 2012) as lifestyle change may be more difficult to maintain 
in this cohort (Petroczi et al., 2010). It was estimated that recruiting 46 patients with a 33% 
drop-out rate would result in 30 participants completing.  
 
It was calculated that with 30 participants followed up it would be possible to obtain an 
informative estimate of the primary outcome: standard deviation (SD) of the change in 
markers of insulin resistance, specifically incremental area under the curve for glucose over 
the three-hour FSLMTT. A 95% confidence interval for the SD would range from 0.775 to 1.32 
times higher than the obtained estimate of the SD (Vickers, 2003). As it was estimated that 30 
participants followed up to completion would be a sufficient number to estimate the SD for 
other continuous outcomes collected (Browne, 1995), any subsequent sample size calculations 
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2.6.8 Inclusion and Exclusion Criteria, Intervention 
 
Participants were eligible for participation in the intervention study as follows: 
 HIV positive adults (aged ≥18 years old) 
 Stable on their current HAART regimen for at least the last 6 months (stable is defined 
as: tolerating their therapy well without a wish or need for change) 
 Unlikely to need to change their ARVs within the next 6 months 
 Have impaired fasting glucose (5.6 – 6.9 mmol/l inclusive) 
 Able to give informed consent 
 Willing and able to participate in a diet and exercise programme 
 Able to attend monthly appointments for 6 months  
 In the opinion of the investigator unlikely to have any planned events within the 
scheduled 6 months that would prevent adherence to a lifestyle change programme 
 Competent in English language 
Participants were ineligible as follows: 
 Have a clinical diagnosis of type 1 or type 2 diabetes 
 Have a fasting glucose indicative of diabetes (≥7.0 mmol /l) 
 Have a random glucose indicative of diabetes (≥11.1 mmol/l) 
 Pregnant, planning for a pregnancy, or lactating 
 Naive to antiretroviral therapy 
 Have medical problems that may interfere with patient safety 
 Have a current medical condition that makes dietary change or exercise inadvisable 
 Are fitted with an artificial cardiac pacemaker device 
 Have liver impairment suggested by liver function tests (ALT) within the last year 
elevated ≥2.5 times above the upper level of the laboratory reference range 
 Have hepatitis B or C co-infection 
 Use medicines that might interfere with glucose homeostasis measures, e.g. 
corticosteroids, anabolic steroids, testosterone or diabetes medications 
 Currently serving a custodial sentence 
Only those participants stable on ARVs and unlikely to change regimens during the 6-month 
intervention period were eligible, as metabolic changes as a direct result of initiating or 
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2.6.9 Data Collection Methods, Intervention 
 
The following data collection methods were used in the pilot intervention study: 
 
Demographic, Social and Socioeconomic Data: 
Ethnicity and gender data were recorded as described for the phenotype study. Age was 
recorded at baseline of the intervention.  
 
Anthropometry: 
At every visit height and weight were measured using standardised calibrated electronic 
equipment, and BMI was calculated and categorised as: underweight (<18.5 kg/m2), normal 
(18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2) and obese (≥30.0 kg/m2). Waist and hip 
circumferences were measured using a non-stretch tape measure and categorised using ethnic 
and gender-specific International Diabetes Federation (IDF) criteria (Alberti et al., 2006); these 
criteria were also used to define metabolic syndrome as described in Table 2.4. Waist was 
defined as the midpoint between the lowest and rib and the supra-iliac crest. The hip 
measurement was taken at the largest circumference around the buttocks with the tape 
measure held horizontal above the supra-pubic bone. Clothing that might obstruct the 
measurements were moved from the waist and hip area. The participant was then asked to 
stand upright with arms relaxed at the side, feet evenly spread apart at approximately 
shoulder width, and body weight evenly distributed. 
 
Body Composition: 
Bioelectrical impedance analysis (BIA) was performed at baseline and post-intervention using a 
Quadscan 4000 multifrequency bioelectrical impedance analyser in order to estimate fat and 
lean body mass. The device has been validated in PLWH of different ethnicities and in those 
with or without lipodystrophy (Forrester et al., 2008). Use of this device is contraindicated if 
the participant has an indwelling pacemaker device or knows or suspects pregnancy. 
Participants were invited to lie on an examination couch for 5 minutes while data was inputted 
into the device. Four single-use self-adhesive electrode pads were attached, 2 each to the right 
wrist and ankle, and then connected to the Quadscan by attaching 4 leads. Dry lean weight, 
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Socioeconomic Status: 
Socioeconomic status was calculated at baseline using the same methods described in the 
phenotype study in Section 2.5.4, namely NS-SEC, the MacArthur scale, an assessment of 
financial struggle and Attainment of higher education was also ascertained. 
 
Social and Lifestyle Factors: 
A range of lifestyle factors was recorded in order to characterise the variables needed for CVD 
and diabetes risk calculations at baseline and post-intervention (Hippisley-Cox et al., 2009, 
Hippisley-Cox et al., 2008, Gray et al., 2010). Usual consumption of portions of fruits and 
vegetables per day was recorded as well as hours per week of physical activity defined as 
exertion greater than usual walking speed. Smoking status was categorised as current, never, 
or ex-smoker, with number of cigarettes recorded. Social isolation was defined as a state in 
which the individual lacks a sense of belonging socially, lacks engagement with others, has a 
minimal number of social contacts and they are deficient in fulfilling and quality relationships 
(Nicholson, 2009). Presence of social isolation was recorded as specific expression by the 
participant of one or more of these factors at baseline, midpoint and post-intervention.  
 
Quality of Life: 
A range of HIV-specific quality of life assessment tools and questionnaires has been produced. 
The HIV Medical Outcomes Study (MOS-HIV) 35-item instrument questionnaire (Wu et al., 
1997) and the HIV/AIDS Targeted Quality of Life (HAT-QoL) questionnaire have been used most 
extensively in clinical trials with PLWH (Clayson et al., 2006). The HAT-QoL questionnaire was 
chosen to assess the impact of the 6-month intervention on the participant's quality of life as it 
has been demonstrated to reflect a wide range of aspects of physical and mental health in 
those on HAART (Holmes and Shea, 1999). The questionnaire was completed by participants at 
baseline and post-intervention. It has nine sections with between 2 and 5 questions in each 
section. Analysis provides a percentage score in the following categories: satisfaction with life, 
health worries, financial security, issues around HIV medications, mastery of living with HIV, 
HIV disclosure issues, relationship with healthcare providers and sexual function, as well as a 
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Dietary Intake, Food Habits and Access to Food: 
Within research studies dietary intake is a challenging variable to measure, with a high 
potential for error when analysed (MacIntyre, 2009). Irrespective of method used to record 
and analyse dietary intake, underreporting occurs resulting in systematic bias (Freedman et al., 
2006). A number of dietary assessment tools were considered for evaluation of intake. Dietary 
recall is not routinely used in research studies as resulting macro and micronutrient analysis is 
inaccurate (Bingham et al., 1994). Diet diaries completed prospectively by participants over a 
varying number of days reflect complete dietary intake as opposed to usual intake, producing a 
more accurate analysis as the number of days increases (Nelson et al., 1989). Participant 
enthusiasm and accuracy of recording decreases as number of days of recording increases. 
Accuracy is increased by use of weighing scales for diaries of a limited number of days 
(Livingstone et al., 1992). Additionally, in HIV positive participants, food frequency 
questionnaires validated in the general population were found to underestimate micronutrient 
intake compared to diet diaries (Hendricks et al., 2005).  
 
Metabolic biomarkers can be used to assess dietary compliance with specific guidelines, for 
example serum linoleate, oleate and palmitate to correlate olive oil intake and urine sodium 
and potassium from 24-hour collections to correlate salt and fruit and vegetable intake 
respectively (Ismail et al., 2013).  
 
For this study I considered the accuracy of calculating macronutrient intake a priority. Dietary 
intake was measured using the MRC Human Nutrition Unit 5-day diary at baseline and post-
intervention. Participants were instructed to include at least one weekend day within their 5-
day diary as variation between weekdays and weekend days can be significant (Thane, 2006). 
Twenty-four hour recall using the triple-pass method (MacIntyre, 2009) was used at monthly 
review meetings on days 30, 60, 90, 120 and 150 to monitor achievement of dietary goals but 
not for full analysis of intake. The MRC diary contains colour photographs and household 
measures of a wide variety of foods to aid recording of portion size (Medical Research Council, 
2015). To improve accuracy diaries were reviewed with participants to clarify brands, portion 
sizes, food preparation methods and condiment use (Cantwell et al., 2006). Nutritional analysis 
of 5-day diaries was conducted using Nutritics™ dietary analysis software.  
 
Wholegrains include whole wheat, wholemeal ﬂour, wheat ﬂakes, bulgar wheat, whole and 
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ﬂour, whole barley and popcorn. Dietary analysis of wholegrain intake can be challenging, 
secondary to coding of foods contained in analysis software and databases (Thane et al., 
2007). For this study any foods containing ≥10% whole-grain content were defined as 
wholegrain in order not to exclude the contribution to whole-grain intake from porridge. 
Unlike other breakfast cereals consumed whole, porridge is coded as being made up with milk 
or water, and is estimated to have an 11% wholegrain content (Thane et al., 2007). Cornmeals 
consumed as staple foods in African diets were included as wholegrains only if product 
labelling indicated they had not been de-hulled, de-branned and de-germed. Foods containing 




Physical activity was recorded at baseline and post-intervention using the International 
Physical Activity Questionnaire (IPAQ) widely used in clinical trials and validated in many 
populations (Craig et al., 2003). Activity was calculated as mean minutes per day sedentary 
time, walking, moderate metabolic equivalent of task (METs), intense METs and total mean 
MET minutes per day. At baseline participants were issued with a Yamax CW-600 digi-walker™ 
pedometer and instructed to record the number of steps walked each day on monthly record 
sheets for the entire intervention (Corder et al., 2007). Other physical activity was recalled at 
monthly visits on days 30, 60, 90, 120 and 150. 
 
Gastrointestinal Habits and Symptoms: 
Participants completed a functional bowel habits and symptoms questionnaire (Appendix 7.6) 
at baseline and post-intervention. Participants were asked to describe the severity of a range 
of gastrointestinal symptoms and complete the Bristol Stool Form chart. This questionnaire 
was developed by the gastroenterology group of the British Dietetic Association and is 
currently being validated. Each question is scored from 0-3, with no symptoms scoring 0, and 
severe symptoms scoring 3. 
 
Medical Information: 
All relevant current and historic medical information was recorded, including an exhaustive 
medication and supplement history. Relevant medical information included any condition that 
might affect diet or physical activity, comorbid conditions, and mental health issues. Blood 
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et al., 1994). Co-morbidities checked were: cardiovascular disease including myocardial 
infarction, stroke or transient ischaemic attack, chronic kidney disease, polycystic ovary 
syndrome, osteopaenia or osteoporosis and hepatitis B or C. Although infectious hepatitis was 
an exclusion criteria for this study those successfully cleared of hepatitis C were categorised as 
negative. A history of gestational diabetes was also recorded.  
 
HIV Parameters: 
A full history of HIV-related factors was recorded, including known duration of HIV infection 
measured from the date of the first positive HIV antibody test, and duration of ARV therapy 
from the date of first use of any ARV. Exposure to ARVs associated with insulin resistance was 
defined as current or historic treatment with AZT (zidovudine), ddI (didanosine), ddC 
(zalcitabine), d4T (stavudine), Indinavir, or high-dose Ritonavir (De Wit et al., 2008), 
(Rasmussen et al., 2012) (Hadigan and Kattakuzhy, 2014). Weight change following initiation of 
ARVs and CD4 nadir were corroborated where possible from medical notes. CD4 count and HIV 
viral load were measured at baseline and post-intervention using routine clinical measures. 
HIV suppression was defined as current HIV viral load being undetectable (<50 copies per ml). 
Lipodystrophy syndrome was defined as current or historic by participant recall or physician 
diagnosis from the medical notes, and date of onset was recorded.  
 
Marker of Frailty: 
Handgrip strength (Norman et al., 2011) and the five-times sit-to-stand test (Richert et al., 
2014) have both been validated as markers of frailty in PLWH (Kooij et al., 2016). Handgrip 
strength was chosen for this study as the sit-to-stand test is not validated in longitudinal 
investigations. At baseline and post-intervention participants were asked to perform handgrip 
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2.6.10 Laboratory Analysis 
 
Lipids and HbA1c 
Dyslipidaemia was defined as in the phenotype study. Lipid fractions and additionally HbA1c 
were measured in the fasting state at baseline and post-intervention. Venous blood samples 
(2ml) were taken into EDTA tubes and immediately transferred for processing and analysis to 
the clinical laboratory at St. Thomas’ Hospital. 
Insulin, Glucose and Incretin Hormones 
Sample analysis was performed at King’s Lab in Denmark Hill, London: 
Insulin: 
The Siemens Advia Centaur assay was used to assess insulin levels (El Kenz and Bergmann, 
2004). This is a two-site sandwich immunoassay using direct chemiluminometric technology.  
Samples were incubated with two monoclonal mouse anti-insulin antibodies. Insulin forms a 
sandwich between these two antibodies. Following incubation a magnetic field was applied 
holding the solid phase at the site of the reaction cuvette. After washing the cuvette was then 
moved to the luminometer and base reagent added to enhance the light reaction. Light 
intensity was measured immediately and converted to relative light units. Light units are 
directly proportional to insulin concentration. 
Glucose: 
Glucose was analysed using the Plasma Glucose Advia 2400 assay utilising the glucose oxidase 
method (Westwood et al., 1986). 
Incretins: 
GLP-1 is comprised of 37 amino acid residues and is mainly secreted in the form of GLP-1(7-36) 
amide in response to food intake. GIP circulates as a biologically active 42-amino acid peptide. 
Samples were degraded into their inactive form after cleavage by dipeptidyl peptidase-4 
inhibitor added to the EDTA vacutainers. This assay is a Sandwich ELISA based on the total 
number of molecules from samples adhering to the wells of a microtiter plate coated by a pre-
titred amount of anti- GLP-1 and anti- GIP polyclonal antibodies. Enzyme activity was 
measured spectrophotometrically, directly proportional to the amount of captured incretin. 
Incretin calibration curves were calculated and active incretin concentrations in the samples 
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2.6.11 Scheduling 
 
The schedule for the 6-month intervention is described in Table 2.14. There were three 
principal visits scheduled. Day 1 and Day 180 marked baseline and post-intervention 
respectively, when the participant attended fasting and full data collection occurred including 
the FSLMTT to measure the primary endpoint. These visits were estimated to need 
approximately 4 hours to complete data collection.  
 
An intervention mid-point visit was scheduled on Day 90. At this visit estimated to be of 1-hour 
duration, the participant attended fasting for a single phlebotomy and routine data collection. 
The rationale for collecting fasting insulin, glucose, lipids and HbA1c at this mid-point was to 
yield data for any participants who dropped out between months 3 and 6. 
 
It was not possible within the protocol to have others collect or analyse data. In order to 
minimise bias, as far as possible I delayed analysis of results until the final participant exited, 
whilst at the same time being able to provide motivational feedback to individual participants 
on their progress over the intervention. I was aware of, and participants were informed about 
and motivated by their anthropometry, BIA results, fasting glucose and lipids at baseline and 
midpoint, handgrip strength and blood pressure. Analysis of the remainder of results was 
delayed until the final participant exited the intervention. This included analysis of blood 
glucose and insulin samples collected from the FSLMTT, analysis of all questionnaires, 
calculation of CVD and T2D risk and statistical analyses. 
 
2.6.12 Outcome Measures 
 
Recruitment rate was defined as the proportion of eligible patients who consented to 
participate at intervention baseline. The attrition rate was defined as discontinuation or loss to 
follow-up of participants over the 6 months. Attendance at the monthly appointments and 
completion of food diaries will be used as indicators of participation and study compliance. 
Achievement of each of the 10 goals for the intervention described in Figure 8 was recorded 
and aggregated into a score. Achievement of 6-10 goals was considered high, 3-5 goals 
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Table 2.14: Intervention Schedule – Procedures and Data Collection 
















Duration (minutes) 30 240 15 30 30 60 30 30 240 
Clinical Research 
Facility 
 X    X   X 
Venue of participant’s 
own choice 
X   X X  X X  
Telephone Call   X       
Information & consent X         
Demographics X         
HIV parameters X     X   X 
Diet diary issued X    X   X  
Diet diary collected  X    X   X 
Remind to attend 
fasting next visit 
X    X   X  
24-hour dietary recall   X X X  X X  
FSLMTT  X       X 
Fasting glucose, insulin      X    
Lipids, HbA1c  X    X   X 
BioBank samples  X       X 
Manual 
anthropometry  
 X  X X X X X X 
BIA  X       X 
Hand grip strength  X       X 
HAT-QoL 
questionnaire 
 X       X 
IPAQ questionnaire  X       X 
Issue with Pedometer  X        
Review pedometer 
data 
  X X X X X X X 
Smoking history  X       X 
Blood pressure  X       X 
10 year CVD/T2D risk  X       X 
Agreed goal setting  X X X X X X X  
Lifestyle advice given  X X X X X X X  
Adherence to lifestyle   X X X X X X X 
Motivational 
interviewing 
  X X X X X X  
Support discussion   X       
Adverse event 
monitoring 
 X X X X X X X X 
Trial exit advice         X 
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2.6.13 Statistical Analysis, Intervention 
 
Data was collected and entered into a secure Microsoft Excel spreadsheet, then transferred for 
statistical analysis to SPSS version 22. Distribution of the data was tested. For variables with a 
normal distribution arithmetic means and standard deviations were calculated. Variables 
without a normal distribution were considered for log or square root transformation. Medians 
and interquartile ranges were calculated.  
 
As this was a pilot study, statistical analysis was descriptive with a focus primarily on 
confidence intervals (CIs) as opposed to statistical significance of rejection of the null 
hypothesis (Lancaster et al., 2004). Descriptive statistics were used to explore a range of 
findings including recruitment and completion rates and demographics. Confidence interval 
estimation at the 95% level were used. Paired t-tests were used to compare the effect of the 
intervention. Significance levels were set at <0.05 with two-tailed tests. 
 
The relationship between outcomes and adherence to the intervention was explored by 
classifying participants by number of goals achieved: 6-10 goals - high achievers, 3-5 - 
moderate and 2 or fewer - poor achievers (Oakley et al., 2006). Future risk of developing CVD 
and T2D was estimated using the QRisk2 and QDiabetes equations respectively. It was 
anticipated that there would be insufficient power to assess differences between subgroups of 
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2.7 Qualitative Study 
 
In these sections I briefly introduce concepts underpinning qualitative research in healthcare, 
my philosophical position and how this might bias conduct of this study, and background to 
selection of methodology. Sampling, data collection and data analysis procedures are outlined. 
 
2.7.1 Introduction to Qualitative Research  
 
Historically, health researchers utilised objective natural science methodologies. Over time 
phenomena were measured at increasingly minute levels in the pursuit of perceived accuracy. 
This philosophy, reductionist and positivist in nature, facilitated advances in quantitative 
research methodologies somewhat at the expense of qualitative approaches (Rachael 
Ormston, 2014).  More recently, healthcare researchers in addition to asking “how many” have 
been asking “why” and “how”, and indeed the MRC now advocates for inclusion of qualitative 
research methodology at all stages of development of complex interventions (Craig et al., 
2008). Qualitative methods are increasingly used alongside quantitative methods in RCTs 
(Lewin et al., 2009). Qualitative methods can help develop an understanding of how to 
implement research findings into routine clinical practice (Kennedy et al., 2014) and have been 
used to identify modifiable factors for improving health care (Wright et al., 2004). However, as 
the training of health care professionals remains rooted in laboratory and basic sciences 
governed by natural laws, it is not surprising that investigators conducting a broad review of 
health-related studies concluded that taken as a whole research methodology remains 
overwhelmingly quantitative (Crawford et al., 2003).  
The underlying theories methods or practice of qualitative research can be difficult to clearly 
define due to the heterogeneity of its nature (NK and YS, 2011). However, qualitative research 
can be very broadly defined as the collection, analysis and interpretation of non-numerical 
data, referring to research methods focussing on the importance of context for the data being 
examined and a deeper understanding of any phenomenon. Qualitative research generates 
new knowledge, understanding and perspectives, and is being used increasingly in health care 
investigations, including both HIV (Power, 1998) and diabetes related research (Seale et al., 
2013). Diet and physical activity can have a significant impact on the health of people living in 
the UK and qualitative research methods are well-suited to investigating behaviours influenced 
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standardised and adaptable investigative methods can be utilised. However, in health care 
most qualitative research investigators have used interviews and focus groups (Sofaer, 2002). 
Data generated is rich and complex. Analysis of this data retains its complexity whilst at the 
same time respecting the uniqueness of the individual participant. Qualitative researchers are 
open to emerging theories. They acknowledge their role and personal perspectives within the 
research process, maintaining a reflexive approach (Rachael Ormston, 2014). 
A wide range of techniques and approaches is used in qualitative healthcare studies. 
Ethnography, where the researchers immerse themselves within and directly observe the 
behaviour of the cohort, was used to investigate decision making by GPs (Gabbay and le May, 
2004). This was voted as one of the most influential British Medical Journal papers published in 
the last 20 years (Payne, 2015). The meaning people attach to a phenomenon or how they 
make sense of their social world is explored using phenomenology, and this approach has been 
used to study body image in gay men (Kelly et al., 2009). Grounded theory employs systematic 
collection and analysis of data from participants in order to generate emergent theory 
regarding social processes or actions (Glaser, 1967). During the initial outbreak of severe acute 
respiratory syndrome (SARS) in 2003, researchers used grounded theory to investigate the 
impact of the outbreak on physicians’ behaviour and professionalism (Straus et al., 2004). 
Thematic analysis of data involves systematic examination to identify topics, gradually and 
progressively integrated into higher order themes. Analysis aims to answer research 
question(s). This technique is widely used in healthcare research and can be applied to data 
generated by several of the approaches listed in this section (Chapman et al., 2015). 
 
2.7.2 Positionality, Methodological Position and Bias 
 
The theoretical perspectives discussed in the previous section underpin my choice of 
methodology for data collection, analysis, and interpretation. The majority of qualitative 
research studies employ an interpretivist approach in which the focus is on how participants 
make sense of their experiences through studying social or behavioural phenomena. However, 
there is a perceived risk that qualitative research can be subjective, with the researcher’s 
background affecting aims and objectives, planning, design, analysis and interpretation 
(Guillemin and Gillam, 2004). Acknowledging bias can help the researcher and reader 
appreciate any contributions this might have made to the work. In order to understand a 
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been able to compartmentalise biases or personal beliefs in a process referred to as bracketing 
(Sorsa et al., 2015). Others have highlighted the value of intimacy and familiarity between 
researcher and participant (Charmaz, 2004). The degree of success of bracketing to set aside 
prior understanding and act without judgement cannot be measured. Irrespective of the 
avoidance or success of bracketing it is important to consider researcher reflexivity and how 
personal experience and knowledge may have influenced the research study.  
Given my background in nutritional science, clinical dietetics and quantitative research I 
acknowledge the duality of my positivist and interpretivist approaches to this study. My 
extensive experience of one-to-one clinical interviews lent itself to choosing in-depth 
interviews to collect data from participants.  I am aware that clinical interviewing is distinct 
from in-depth interviews for research. Both aim to elicit information and experiences. 
However, in the clinical situation the interviewer clearly directs the process in order to identify 
information important to their work, whereas in research practice any direction by the 
interviewer aims to allow expression of feelings or description of phenomena important to the 
interviewee (Hunt et al., 2011). I took note of the potential for power dynamics, different use 
of language and cues, and of mixed messages, for example by wearing a clinical identification 
badge during the interview. I positioned the interviewee as the expert and explained my role 
was now different before commencing each interview.  
My positivist approach from experience in science and quantitative research led to the 
development of semi-structured interviewing and the use of Framework for analysis of data. I 
felt it would be more productive to use a topic guide as I was concerned that use of open 
interviews might result in the generation of a narrow focus of data. The use of the structured 
Framework approach was a pragmatic choice given the limited time available for analysis. 
In terms of potential for bias, I developed this qualitative study with prior clinical experience of 
HIV patients’ enablers and barriers to lifestyle change. Although this prior knowledge was 
useful to inform design of the interview topic guide, I aimed to remain open to the possibility 
that interviewees would describe different enablers or barriers, and attribute them varying 
degrees of importance. There was the potential to have had a high degree of personal 
involvement in the participant’s routine health care. Participants recruited from St. Thomas’ 
hospital may have received clinical care from me prior to taking part in the research study, as 
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2.7.3 Rationale for Design of the Qualitative Study 
 
This qualitative study was designed to answer the following research questions: 
 What was the acceptability of the intervention? 
 What enablers, barriers and other factors influenced lifestyle change? 
 In this cohort, what influences participation in medical research? 
To answer the first and third of these questions, either interviews or focus groups could both 
yield rich data.  
Focus groups are semi-structured discussions with groups of typically between four and twelve 
participants. In qualitative health care research they are used to explore issues in a similar way 
to interviews (Rachael Ormston, 2014). Investigators moderating focus groups follow a typical 
structure of introducing the topic in a broad sense in order to develop group dynamics before 
focussing on key questions specific to the research question(s). Through the group structure 
investigators are able to explore individual and shared perspectives (Sofaer, 2002). 
Disadvantages of focus groups include logistics of organisation, potential for breach of 
confidentiality or the presence of a dominant person who may disrupt the group dynamic. 
Where subject matter is particularly sensitive individual participants may be unwilling to 
discuss experiences in a group setting, although conversely shared experience from focus 
groups can be positively empowering (Rachael Ormston, 2014). 
The effectiveness of complex interventions varies between individuals and I anticipated that 
there would be variations in the individual effectiveness of this intervention dependent on, for 
example, sociocultural settings (Pope and Mays, 1995). Given the potential for sensitive issues 
to be raised regarding enablers and barriers and my extensive experience of clinical interviews 
with patients, I chose one-to-one in-depth interview methodology. 
Thematic analysis was used to seek support for predefined and also emerging hypotheses. In-
depth interviews aim to explore the experiences and social behaviour of participants and the 
meanings they attribute to these experiences. Investigators encourage participants to discuss 
topics relevant to the research question(s) using open questioning, usually in one-to-one 
interviews although other structures have been used including dyads and family units. 
Interviewers in semi-structured approaches use a topic guide and will probe topics relevant to 
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the experiences and personal meaning of illness or disease. Personal issues can be openly and 
sensitively explored (Sofaer, 2002).  
Open or unstructured interviews set a single question with the participant subsequently 
speaking freely without interruption. Structured interviews employ a predefined series of 
questions (Sofaer, 2002). Semi-structured interviews were used for this study in order to 
provide structure with flexibility, where predefined themes for questioning were used as the 
starting point with the interviewer probing further or clarifying answers with the participant. 
The choice of semi-structured in-depth interviews to generate data had practical advantages 
over other methods. The use of ethnography would be logistically impractical and a case study 
approach would not foster iterative development of thematic analysis. Grounded theory could 
not apply to this study as I had explored predefined themes, and employed patient public 
involvement. Finally, in terms of logistics, one-to-one interviews could be arranged to take 
place shortly after a decision not to participate in the intervention, or after dropping out or 
completing the intervention. 
Framework was selected to analyse qualitative data. This matrix-based summary of data 
organised by theme and sub-theme in columns and participants in rows allows the researcher 
to conduct cross-case and cross-theme analysis, and aids construction of typologies (Smith and 
Firth, 2011). I selected this approach for practical reasons. Time constraints within the project 
demanded a systematic approach to thematic analysis. Framework confers the ability to 
rapidly apply themes from each interview to the construct, allowing immediate analysis.  
Following receipt of each interview transcript, initial familiarisation involved rereading and re-
listening. This was followed by identification of possible themes and sub-themes. These were 
coded using short statements to capture the meaning of the phrase. Data was imported into 
NVivo11™ software (QSR International). Initial thematic analysis resulted in completion of the 
framework matrix for that participant.  
Thematic analysis has been criticised for the potential to isolate fragments of data from the 
whole, leading to a possible misinterpretation of the data (Smith and Firth, 2011). To reduce 
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2.7.4 Sampling Structure for the Qualitative Study 
 
Whereas quantitative research aims to identify typical or mean data, qualitative research aims 
to both explore and present the breadth of data from an investigation. This may include 
extreme, atypical or outlying views and also an absence of views or experiences. In qualitative 
research rather than sampling to statistically represent the population a generalisable sample 
is sought where participants express the diversity of views and experiences. 
Participants were invited to interview if: 
 They were eligible but declined to take part in the intervention 
 They wished to take part in the intervention but on screening were found to be 
ineligible 
 They dropped out, withdrew, or were withdrawn during the intervention 
 They completed the intervention 
Participants were purposively selected to include representatives of each of these 4 categories. 
Additionally, to include maximum diversity participants were purposively sampled from the 
following groups:  
 Gay men who exercise 
 Gay men with a higher BMI 
 Black African-origin men 
 Black African-origin women  
For budgetary and logistical reasons the sample size was set at a maximum of 40 participants. 
The actual number invited to interview was determined at the point at which I was satisfied 
that a good understanding of the acceptability of the intervention and also of enablers and 
barriers to change had been achieved. Within the purposive sampling methodology 
recruitment from a particular group ceased when no new data was emerging from that group. 
In a review of analysis of qualitative data, investigators found that on average 10 interviews 
were required to reach data saturation (Francis et al., 2010) and given four groups sampled for 
diversity this married well with the maximum sample size of 40. The use of Framework to 
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2.7.5 The Interview 
 
Informed consent to take part in the interview was taken or revisited according to the 
participant’s journey through the three studies presented in this thesis. All participants were 
offered a choice of interviewer: myself or a health adviser (trained counsellor) from the HIV 
clinic. I am a White male. Given the potential for a number of African-origin participants to be 
invited to interview I engaged a Black-African female health adviser to be an alternative 
interviewer. Interviews were conducted at a place and time to suit the participant. Venues 
offered were: 
 The participant’s own home or workplace 
 A meeting room in a non-clinical area of St. Thomas’ Hospital 
 An interview room in the Clinical Research Facility at St. Thomas’ Hospital 
 A consultation room at the premises of the charity Terence Higgins Trust near King’s Cross 
 
Prior to conducting the interviews I completed a qualitative research training programme at 
the Institute of Psychiatry and at NATCEN in London, both of which included components of 
interviewing structure and techniques.  
The review I conducted presented in Section 1.7 identified little published research regarding 
enablers and barriers to diet and exercise change in PLWH. Research papers describe attitudes 
towards body image in PLWH, particularly in relation to those experiencing lipodystrophy.  
Together with findings from my review of non-HIV specific literature regarding enablers and 
barriers to diet and exercise change presented in Table 1.11 and suggestions from clinical 
practice that there may be potential for patients to experience HIV-specific barriers to lifestyle 
change, questions regarding these were developed and included in topic guides. 
Three topic guides were developed (Appendix 7). The topic guides were for: (1) those who 
declined to take part in the 6-month intervention, (2) those who dropped out of the 
intervention and (3) those who completed the intervention. Topic Guide 3 evolved over the 
course of the study reflecting the iterative nature of the work, and the final version used is 
presented in Appendix 7. As the interviews and Framework analysis progressed iterative 
themes were incorporated into the design of topic guides to minimise confirmatory bias, 
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Open questions, active listening and asking relevant follow-up questions were used to probe, 
amplify or expand themes. Mapping questions were used to contextualise experiences. Styles 
of questioning developed following participant response as interviews progressed. 
Interviews were digitally recorded. Recordings were transcribed verbatim, with notes of 
pauses, mannerisms and audible behaviour included. Prior to analysis I replaced any 
identifiable information with contextual description, for example removing the actual name of 
a partner mentioned and inserting “partner’s name”. I transcribed the first six interviews, with 
subsequent recordings transcribed commercially. Participants were offered a copy of the 




Data analysis was an iterative process where data collection and analysis occurred 
concurrently using the Framework approach. Codes were combined and contrasted, 
developing themes and categories of themes that grouped similar codes together. This 
enabled a synthesis generating a network of associations. Themes emerging from the analysis 
were checked against new data as transcripts were added using NVIVO, and influenced 
ongoing data collection. Analysis of enablers and barriers to behaviour change was aided by 
using the COM-B and Theoretical Domain Framework models (Cane et al., 2012, Michie et al., 
2011b). 
In the later stages of analysis themes emerging from the coded data were used to construct 
typologies. Collaborator Dr Carol Rivas and supervisor Dr Louise Goff jointly checked and 
discussed thematic analysis to improve rigour of findings. 
Continuous analysis of data allowed assessment of thematic saturation, where no new 
significant data was emerging from the analysis grouped according to purposive sampling. 












Three hundred and thirty-nine participants took part across the portfolio of research: 338 in 
the phenotype of type 2 diabetes in HIV study, 33 in the 6-month intervention, and 23 were 
interviewed. All 33 intervention participants and 22 of the 23 interview participants consented 
to contribute data to the phenotype study, and these 55 are included in the total of 338. 
 
Figures 9 and 10 describe the Consort Flow Diagrams for screening, phenotype, intervention 
and qualitative studies. Patients were largely identified by me, with 4% referred by others and 
1% self-referring in response to advertising. Thirteen percent did not respond to an invitation 
to be screened to take part and 33% declined to be screened. Following good practice 
guidelines (Health Research Authority, 2016), patients were not asked directly why they 
declined, but of the 104 who mentioned reasons the commonest were: research fatigue (38%), 
problematic logistics (34%) and a lack of interest in research (14%). Of the 1572 patients 
screened 2% had never had blood glucose measured and 6% had raised random blood glucose 
measured in routine clinical blood screening but were unwilling or unable to attend fasting. A 
‘Interviewer: “You said that you were happy that you reduced your waist, 
is that right?” 
Interviewee: “Right, but I wasn’t happy with the 
effect on my face. I’d rather have diabetes and a 
full face. So I’d rather be a diabetic injecting 





total of 1447 patients had fasting blood glucose results, with 69% having normal blood glucose, 
24% prediabetes defined by IFG, and 14% had type 2 diabetes. Of the 1447 patients stratified 
by glycaemia, 821 (57%) declined to take part, 167 (12%) did not meet inclusion criteria, 339 
(25%) took part in one or more of the three research studies and 120 (8%) did meet inclusion 
criteria but were surplus to sample. Reasons for exclusion from the phenotype study were: 
unable to provide informed consent (31%), unable to communicate in English (31%), unable to 
attend for data collection (19%), too unwell to take part (13%), currently serving a custodial 
sentence (4%) and type 1 diabetes (2%). Reasons for exclusion from the intervention were: 
unable to commit to a 6-month programme (33%), infectious hepatitis (28%), use of 
medications associated with dysglycaemia (17%), naïve to ARVs (17%) and pregnancy (5%). 
Stratified sampling targets for the phenotype study (Table 2.2 on page 68) were achieved. 
 
3.1.2 Participant Welfare 
 
During the 6-month intervention study, four participants experienced adverse events (AEs) 
thought to be unrelated. Participant 1 experienced a severely sprained ankle caused by losing 
balance when getting out of bed during the night. This occurred during month 2 of the 
intervention and limited physical activity for 2 weeks but was insufficient to consider 
withdrawal from the study. This participant consented to take part in an in-depth interview 
where their deep unease with facial weight loss was discussed for the first time, and 
subsequent referral for counselling was made.  
Participant 2 experienced an episode of fainting mid-way through the FSLMTT at baseline. This 
required medical attention at Accident and Emergency secondary to extremely low blood 
pressure. It was subsequently discovered that the participant’s GP had prescribed an incorrect 
dose of antihypertensives resulting in hypotension. The participant requested to re-start the 
intervention once this was remedied. Participants 3 and 4 were diagnosed with T2D at 
baseline, withdrawn from the intervention and given advice as per protocol. GPs and HIV 
physicians were informed. Both participants subsequently consented for interview. 
A participant withdrew from the intervention at month 2 on becoming acutely unwell at home. 
On admission to hospital they were diagnosed with bacterial septicaemia. This participant later 






3.1.3 Recruitment: Consort Flow Diagrams 
 
 
























 Reasons for exclusion of 167 participants: unable to provide informed consent (52), insufficient 
English language skills (52), unable to attend (32), unwell (22), other (9)  
 120 participants were surplus to the stratified random sample. Participants were sampled by age, 
















Glucose not done: 27 
Unable to fast: 98 
Prediabetes: 55 




Did not respond: 387 
Type 1 diabetes: 8  
Declined screening: 967 
Cross-sectional study: 
Phenotype of dysglycaemia in HIV 
n=338 
 
Declined to take part: 821 
Did not meet inclusion: 167 




























 Reasons for exclusion of 18 participants: unable to commit to a 6-month programme (6), infectious 
hepatitis (5), use of medicines associated with dysglycaemia (3), naïve to ARVs (3), pregnancy (1)  
 13 participants were surplus to purposive sample. Participants were sampled by ethnicity, sexuality 








Individualised diet and exercise 
n=33 
 
Declined intervention but 

























3.2 Phenotype of Dysglycaemia in HIV 
 
3.2.1 Principal Results Summary 
 
It was hypothesised that in HIV patients, BMI and a range of other factors are independently 
associated with impaired fasting glucose and type 2 diabetes when compared to patients with 
normal fasting glucose. The aim of this study was to phenotype dysglycaemia in this cohort, 
and describe how this has changed over time. 
Principal Results: 
 Dysglycaemia is highly prevalent in this ethnically diverse HIV cohort 
 In 2015 the mean duration of HIV infection was 11.6 years, and 92.0% were treated with 
ARVs, 58.0% were overweight or obese, 62.4% had central obesity, and 37.9% had 
hypertension, with Black African women disproportionately affected by obesity 
 The prevalence of T2D in 2005 was 6.8%, and in 2015 was 15.1% 
 Dysglycaemia was significantly associated with age, BMI, waist, hypertension, HDL, 
triglycerides, CVD, statin use, 10-year CVD risk, HIV duration, exposure to ARVs associated 
with T2D, weight gain following initiation of ARVs, lipodystrophy, hepatic steatosis, use of 
corticosteroids, physical inactivity, socioeconomic deprivation and unemployment 
 Regression models suggested that modifiable factors contribute a greater risk of 
dysglycaemia than fixed factors, most of which were HIV-related 
 Hepatic steatosis and hypertension contributed the greatest risk with odds ratios of 7.28 
and 2.58 respectively 
 
3.2.2 Analysis of Data Collected in 2005-2006 
 
Retrospective analysis of data from the CREATE study revealed missing blood glucose data for 
the majority of participants. Out of the 1021 participants 337 had confirmed fasting glucose 
data. The sample was tested for statistical representation of the cohort when analysed by 16 
demographic, medical and HIV-related factors. The sample of 337 participants was 





Table 3.1: Sensitivity Analysis for 2005 Sample and Total Cohort 
    †CREATE n=337 ††CREATE n=1021 p 
TOTAL n 337 1021  
GENDER Male  260 (77.2%) 764 (74.8%) 0.265a 
AGE Mean years 41.7 40.4 0.134b 
ETHNICITY White  184 (54.6%) 512 (50.1%) 0.407a 
BMI Mean kg/m2 25.8 25.5 0.835b 
WAIST Mean cm 91.3 90.1 0.132b 
HYPERTENSION n  66 (19.6%) 192 (18.8%) 0.891a 
LIPIDS (mean) Total Cholesterol 4.8 4.7 0.794b 
mmol/l Triglycerides 1.8 1.7 0.237b 
CURRENT SMOKER n  120 (35.6%) 378 (37.0%) 0.326a 
CVD    n 9 (2.7%) 32 (3.1%) 0.563a 
STATIN USE n 54 (16.0%) 129 (12.6%) 0.268a 
HIV DURATION Mean years 6.3 6.5 0.249b 
ARV NAIVE n 66 (19.6%) 223 (21.8%) 0.426a 
LIPODYSTROPHY                             n 92 (27.3%) 216 (21.2%) 0.336a 
HEPATITIS B n 15 (4.4%) 50 (4.9%) 0.981a 
HEPATITIS C n 12 (3.6%) 34 (3.3%) 0.831a 
NOTES 
  
† Glycaemia measured 
††Total sample including glycaemia not measured 
a  Significance of difference by Chi-squared 
b Significance of difference by ANOVA 
 
Participants were stratified according to glycaemia by either a recorded diagnosis of T2D or a 
confirmed fasting glucose: normal (≤5.9 mmol/l); prediabetes (6.0-6.9 mmol/l); and T2D (≥7.0 
mmol/l). Characteristics of the 2005 sample are presented in Table 3.2.  
In 2005 18.1% had prediabetes and 6.8% T2D, higher than that reported in the data published 
from the CREATE study due to a redefined classification of T2D to include fasting glucose of 7.0 
mmol/l or higher. The cohort had a median age of 41 years, was predominately male (77.2%), 
ethnically diverse (45.4% non-White) and largely treated with ARVs (80.4% for a mean 6.3 
years). One-quarter (23.4%) had been exposed to ARVs associated with insulin resistance and 
27.3% had current or previous lipodystrophy. One-third were smokers but mean 10-year CVD 
risk measured by the Framingham tool was low (4.4%) which may reflect the modest lipids 
levels observed (mean total cholesterol 4.8 ±1.0 mmol/l) and the relatively young median age. 






Table 3.2: Characteristics of the 2005 Sample 
 Normal Prediabetes T2D Total 
TOTAL n 253 61 23 337 
 % of total 75.1% 18.1% 6.8% 100.0% 
GENDER Male 76.7% 78.7% 78.3% 77.2% 
AGE (Years) Median 
(IQR) 
40 (35-46) 43 (38-48) 46 (44-54) 41 (35-47) 
ETHNICITY White 56.1% 49.2% 52.2% 54.6% 
 Black African 27.3% 31.1% 30.4% 28.2% 
Black Caribbean 4.7% 9.8% 8.7% 5.9% 
 Other 11.9% 9.8% 8.7% 11.3% 
BMI                              Median (kg/m2) 25.0 23.7 24.0 24.9 
 IQR 22.6-27.9 22.3-28.1 21.9-28.3 22.4-28.0 
Underweight (<18.5 kg/m2) 3.2% 1.6% 0% 2.7% 
Normal (18.5-24.9 kg/m2)  46.6% 57.4% 56.5% 49.3% 
Overweight (25.0-29.9 kg/m2)  34.4% 27.9% 21.7% 32.2% 
Obese (≥30.0 kg/m2) 15.8% 13.1% 21.7% 15.7% 
WAIST (IDF DEFINITION)          Obese 44.5% 53.6% 68.4% 47.7% 
 Median (cm) 89 94 96 91 
 IQR 81-97 88-101 91-110 83-98 
HYPERTENSION n 15.4% 27.9% 43.5% 19.6% 
LIPIDS (mmol/l)      Total Cholesterol 4.8 5.1 4.7 4.8 
 SD 1.0 1.2 1.0 1.0 
HDL: TG Ratio 1.50 1.91 1.65 1.59 
 SD 1.83 1.52 1.07 1.74 
METABOLIC SYNDROME 13.8% 46.4% 52.6% 22.5% 
SMOKING                                          No 63.6% 63.9% 65.2% 63.8% 
Yes 36.4% 36.1% 34.8% 35.6% 
CVD (including CVA) 2.0% 3.3% 8.7% 2.7% 
STATIN USE 14.1% 28.0% 26.7% 16.0% 
% 10-YEAR CVD RISK                  Mean 4.2 5.0 5.2 4.4 
(Framingham) SD 5.3 5.7 4.9 5.4 
HIV Duration (years) Mean 6.0 7.1 7.8 6.3 
 SD 0.9 0.9 0.9 0.9 
NAÏVE TO ARVs  22.5% 11.5% 8.7% 19.6% 
ARVs ASSOCIATED WITH T2D 23.7% 18.0% 34.8% 23.4% 
LIPODYSTROPHY           22.1% 37.7% 56.5% 27.3% 
HEPATITIS B  4.3% 4.9% 4.3% 4.5% 
HEPATITIS C  2.8% 3.3% 13.0% 3.6% 







3.2.3 Cohort Characteristics in 2015 
 
Characteristics of the 338 participants in the 2015 cohort are presented in Table 3.3. In terms 
of dysglycaemia, 17.2% had prediabetes and 15.1% T2D. The cohort had a median age of 49 
years (IQR 42-57) and was predominately male (74.0%). This cohort was ethnically diverse with 
the majority (50.3%) non-White. The 338 participants were born in 61 countries as illustrated 
in Figure 11, with the five most common being the UK (n=127), Uganda (n=26), Nigeria (n=19), 
Zimbabwe (n=10) and Jamaica (n=9).  
The cohort was highly treated with ARVs (92.0%), with a mean duration of treatment of 11.6 
±0.9 years. Exposure to ARVs is presented in Table 3.4. Just under half (44.1%) had been 
exposed to ARVs associated with insulin resistance and one-fifth (21.6%) had current or 
historic lipodystrophy. Taken as a whole the cohort was overweight with a mean BMI of 27.4 
kg/m2 (IQR 23.3-29.9), with the majority (62.4%) presenting with central obesity. The high rate 
of hypertension (37.9%) combined with central obesity resulted in almost one-third of the 
cohort (31.8%) presenting with metabolic syndrome. Of the two-fifths with a smoking history, 
half had successfully quit smoking (19.8% of the cohort) and half were current smokers (21.0% 
of the cohort). The mean 10-year CVD risk measured by the Framingham tool was 12.1% with 
27.2% of the cohort treated with statins. Hepatic steatosis had been diagnosed in 21.0% and 
renal impairment in 12.7% of the cohort. Almost half (48.1%) had a first or second degree 







‘Table 3.3: Characteristics of the 2015 Cohort 
 Normal Prediabetes T2D Total 
TOTAL n 229 58 51 338 
 % of total 67.8% 17.2% 15.1% 100.0% 


















































BMI                                 Median (kg/m2) 25.3 27.6 29.0 27.4 
 IQR 22.7-29.3 24.7-32.0 24.8-31.2 23.3-29.9 








































 Median (cm) 92 101 103 95 
 IQR 84-101 92-101 93-112 86-104 








LIPIDS (mmol/l)         Total Cholesterol 5.0 4.9 4.9 5.0 
  SD 1.1 1.0 1.2 1.1 
 LDLa 2.89 2.81 2.58 2.83 
 SD 0.90 1.04 0.84 0.92 
 HDL: TG Ratio 1.17 1.71 2.04 1.39 
 SD 0.96 1.33 1.63 1.19 












































 Normal Prediabetes T2D Total 
















% 10-YEAR CVD RISK                    Mean 9.0 12.6 25.5 12.1 
(Framingham) SD 9.2 10.1 16.9 12.3 
HIV Duration (years)                    Mean 10.4 13.9 14.8 11.6 
 SD 0.9 0.9 0.9 0.9 
















% WT. GAIN FOLLOWING            Mean 3.1% 7.0% 10.1% 4.9% 
INITIATION OF ARVsa                         SD 7.9 11.0 15.6 10.4 
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Variables are as defined in section 2.5.4 
The variables duration of HIV infection and duration of treatment with ARVs were highly correlated 
(Pearson’s correlation = 0.847, p<0.001) with the latter not used for further analysis. 
a – Measured in 2015 but not in 2005 
b – n=200 (not routinely measured clinically) 
c – n=337 (unknown due to adoption) 
Abbreviations: BMI – Body Mass Index; IDF – International Diabetes Federation; IQR – Interquartile 
Range; NSEC – National Socioeconomic Scale; SD – Standard Deviation 
 
 


















Table 3.4: Antiretroviral Exposure, 2015 Cohort 









Tenofovir  251  NRTI 
Emtricitabine  FTC 205  NRTI 
Lamivudine  3TC 181  NRTI 
Ritonavir  166  PI 
Efavirenz  154  NNRTI 
Zidovudine  AZT  124  NRTI 
Abacavir  121  NRTI 
Atazanavir  92  PI 
Darunavir  90  PI 
Nevirapine  86  NNRTI 
Didanosine  ddI 63  NRTI 
Lopinavir Kaletra 63  PI 
Stavudine  d4T 60  NRTI 
Saquinavir  43  PI 
Raltegravir  38  Integrase Inhibitor 
Nelfinavir  29  PI 
Fosamprenavir  24  PI 
Rilpivirine  22  NNRTI 
Zalcitabine  ddC 19  NRTI 
Maraviroc  15  CCR5 antagonist 
Indinavir  13  PI 
Etravirine  10  NNRTI 
Amprenavir  4  PI 
Enfuvirtide  T-20 3  Fusion Inhibitor 
Cobicistat  2  CYP3A Inhibitor 
Delavirdine  1  NNRTI 
Dolutegravir  1  Integrase Inhibitor 
Elvitegravir  1  Integrase Inhibitor 
Tipranavir  1  PI 
 
 
Given the piloting of a diet and exercise intervention, the relationship between these factors 
and dysglycaemia was examined. Usual daily intake of portions of fruit and vegetables is 
illustrated in Figure 12, with 28.2% meeting or exceeding the 5 portions per day target. All 
participants reported eating at least one portion per day. There was no association between 





Figure 12: Fruit and Vegetable Intake, 2015 
 
 
Regarding exercise, almost half (46.6%) of participants were physically inactive (Figure 13). 
Physical activity was significantly associated with dysglycaemia (p<0.001) with those 
participants with prediabetes and T2D performing half the number of mean hours per week of 
activity compared to those with normoglycaemia. 






Men were more likely to exercise than women: mean hours per week 3.34 (2.77-3.90) and 
0.98 (0.65-1.32) respectively (p<0.001). Physical inactivity was correlated with age (p=0.017).  
Given the association between socioeconomic status and diabetes in the general population, a 
closer examination of relationship was performed in this cohort. Three-quarters (77.2%) had 
achieved further education after school, 38.5% were unemployed or retired and 18.0% 
reported financial struggle. The relationship between National Socioeconomic Classification 
and glycaemic status is illustrated in Figure 14, where unemployment was significantly 
associated with T2D (p=0.003). 




The majority of participants with T2D were unemployed, with a relatively small proportion of 
those working employed in higher categories. Examination of socioeconomic status using the 
MacArthur UK scale corresponded with the National Socioeconomic Classification, with those 
with T2D categorised with a lower mean classification (p=0.023). However, the MacArthur 
Community score was statistically similar across glycaemic status groups (p=0.736).  
 
For comparison data from the 2015 cohort and data from the general population in London 
and England as a whole (Public Health England, 2015b) are shown in Table 3.5. Although data 
was collected using different methodologies it appears that rates of T2D are higher than the 
general population, whereas rates of overweight and obesity were similar. The HIV cohort was 






Table 3.5: Comparison of 2015 Cohort with General Population Data 
 Prevalence 
HIV Cohort London England 
Type 2 Diabetes 15.1% 6.0% 6.2% 
Current Smoker 21.0% 17.0% 18.0% 
Inactive (Physical Activity) 46.6% 27.0% 27.7% 
Meet 5-a-day Fruit and Vegetable Target 28.2% 50.5% 53.3% 
Overweight or Obese 58.0% 58.4% 64.6% 
Cardiovascular Disease 5.6% 2.1% 3.3% 
Source: Public Health England (2015) 
 
 
3.2.4 Dietary Intake, 2015 
 
Sensitivity of Sample of Returned Diaries: 
Five-day food diaries were received from 198 participants, a response rate of 58.6%. A 
sensitivity analysis is presented in Table 3.6. Diet diary responders were significantly older 
(51.7 vs 49.4 years, p=0.019). There was a trend for those with prediabetes and those of White 
ethnicity to be more likely to return completed diaries but these were not significant (p=0.064 
and 0.078 respectively). There was also a trend for those currently experiencing financial 
hardship and people of Black African ethnicity not to return completed diaries, but these were 
not statistically significant (p=0.070 and 0.187 respectively). For all other measures the sample 
of participants who returned diaries was a sensitive representation of the total cohort. 
Energy Balance: 
Analysis of the 198 diaries is presented in Table 3.7. Mean energy intake overall was 2155 (CIs 
2059-2251) kcal, with a mean of 2248 (2148-2349) kcal in men and 1806 (1571-2041) kcal in 
women. Mean energy expenditure was calculated to be 2130 (2087-2173) kcal overall, with a 
mean of 2212 (2171-2253) kcal in men and 1829 (1740-1918) kcal in women. Energy 
expenditure was significantly higher in those with prediabetes compared to those with 
normoglycaemia and T2D (p=0.016). Mean energy balance in men and women was 37 (-56 to 
129) kcal and -22 (-272 to 228) kcal respectively (not significantly different by gender, 
p=0.594). Mean energy balance appeared to be lower for those with T2D (mean -157 kcal 
compared to 69 and 6 in those with normoglycaemia and prediabetes respectively). However, 





Table 3.6: Diet Diary Sensitivity Analysis Comparing Responders with the Entire Cohort 
    Diaries n=198 Total n=338 Difference 
p 
GLYCAEMIC STATUS     Normoglycaemic 63.1% 67.8% 0.276a 
 Prediabetes 23.7% 17.2% 0.064a 
 T2D 13.1% 15.1% 0.533a 
GENDER Male  78.8% 74.0% 0.209a 
AGE Mean years 51.7 49.4 0.019b 
ETHNICITY White  57.6% 49.7% 0.078a 
 Black African 26.3% 31.7% 0.187a 
 Black Caribbean 8.6% 7.7% 0.713a 
 Other 7.6% 10.9% 0.203a 
BMI Mean kg/m2 27.3 27.4 0.839b 
WAIST Mean cm 97.2 96.9 0.798b 
HYPERTENSION  37.4% 37.9% 0.909a 
HDL: Triglycerides Ratio                  Mean 1.48 1.39 0.440b 
CURRENT SMOKER  19.2% 21.0% 0.615a 
CVD     6.1% 5.6% 0.833a 
STATIN USE  30.8% 27.2% 0.375a 
LIPODYSTROPHY                              24.2% 21.6% 0.480a 
PHYSICAL ACTIVITY  Mean hours / week 2.81 2.72 0.814b 
UNEMPLOYED  30.1% 29.6% 0.868a 
RETIRED  11.1% 8.9% 0.674a 
FURTHER EDUCATION 76.3% 77.2% 0.800a 
FINANCIAL STRUGGLE 12.1% 18.0% 0.070a 
NOTES 
  
Variables as defined in section 2.5.4 
Responders and the entire cohort tested for significance of difference: 
a  Significance of difference by Chi-squared 
b Significance of difference by ANOVA 
 
Negative energy balance can be a surrogate marker for underreporting of intake as well as a 
true reflection of lower energy intake than expenditure. A method for calculating the level of 
underreporting has been devised based on the original Goldberg method, using the lower 95% 
confidence interval as the cut-off (Livingstone and Black, 2003). The percentage of participants 
with a negative energy balance below the lower 95% CI of -65.0 kcal was 46.5%. Women were 
more likely to underreport than men but this was not statistically significant (48.7% and 38.1% 
respectively, p=0.227). Black Caribbean and Black African participants were more likely to have 
a negative energy balance (65.4% and 76.5% respectively) compared to Whites and Others 
(51.8% and 46.7% respectively, p=0.019). More participants with T2D had a negative energy 





statistical significance (69.2% compared to 56.8% and 51.1% respectively, p=0.179). The mean 
BMI of those reporting a negative energy balance was 28.5 kgm2 compared to 25.6 kgm2 in 
those reporting a positive balance (p<0.001). A simpler method for estimating under and over 
reporting has been used in the NHS Nurses study (Mendez et al., 2011). A reported mean daily 
intake of less than 500 kcal or more than 3,500 kcal was deemed to be unfeasible. Using this 
method seven participants (3.5%) would be deemed to have reported an unfeasible energy 
intake, with all seven exceeding a mean daily intake of 3,500 kcal. 
Macronutrient Intake: 
Across the cohort protein contributed a mean 18.6 ±4.9%, fat 35.5 ±6.7% and carbohydrate 
46.0 ±14.5% of daily energy intake. Protein, fat and carbohydrate did not contribute 
significantly differently to total energy intake when compared by glycaemic status (p=0.879, 
0.260 and 0.522 respectively.  
Fatty Acid Intakes: 
Across the cohort the mean contribution made to total daily energy intake by 
monounsaturated, polyunsaturated and saturated fatty acids was 12.4%, 6.3% and 12.8% 
respectively. There were no statistically significant differences when comparing any fatty acid 
group by glycaemic status, gender or ethnicity. 
Sugar, Wholegrains and Fibre: 
Across the cohort 40.9% of carbohydrate consumed was sugar (including milk sugar), with 
22.5% of total carbohydrate intake provided by wholegrain foods. There was no statistically 
significant difference in either sugar or wholegrain intake between those with 
normoglycaemia, prediabetes or T2D. 
Across the cohort mean intake of fibre, defined as non-starch polysaccharide (NSP), was 16.0 
±6.2g per day. There was no statistically significant difference in fibre intake when participants 
were grouped by glycaemic status, gender, ethnicity, or history of lipodystrophy. 
Fruits and Vegetables: 
Across the cohort the mean intake of fruits and vegetables was 1.6 and 2.2 portions per day 
respectively. There were statistically significant differences between groups. Those with 





(1.8 and 1.6 portions respectively, p=0.009). Those with normoglycaemia consumed more 
vegetables (2.4 portions per day) compared to those with prediabetes and T2D (1.8 and 1.9 
portions respectively, p=0.012).  
Fish: 
Mean intake of fish was 2.8 portions per week, with no statistically significant differences 
between participants grouped by gender, ethnicity or glycaemic status. 
Micronutrients: 
Across the cohort the mean daily intake of sodium was 2624 mg, with no statistically 
significant differences between participants grouped by glycaemic status. The mean daily 
calcium intake for the cohort was 944 mg with no statistically significant differences between 
participants grouped by glycaemic status. The mean iron intake for the cohort was 13.1 mg per 
day. Those participants with prediabetes consumed significantly more iron (15.1 mg per day) 
than those with normoglycaemia or T2D (12.7 and 11.4 mg respectively, p=0.010). The mean 
daily folate and vitamin C intakes for the cohort were 320 μg and 120 mg respectively, with no 





Table 3.7: Analysis of Dietary Intake by Glycaemic Status, Phenotype Study 
Daily Mean (unless otherwise stated) 
Normal Glycaemia Prediabetes Type 2 Diabetes Total 
p 
Mean 95% CIs Mean 95% CIs Mean 95% CIs Mean 95% CIs 
Energy Intake (kcal) 2158 2029, 2287 2245 2075, 2416 1976 1719, 2232 2155 2059, 2251 0.274 
Protein (% Energy) 18.7 17.8, 19.7 18.3 17.4, 19.2 18.5 16.8, 20.3 18.6 17.9, 19.3 0.879 
Total Fat (% Energy) 35.3 34.3, 36.6 35.0 33.0, 37.1 37.5 35.3, 39.9 35.5 34.7, 36.6 0.260 
Saturated Fat (% Energy) 12.7 12.2, 13.3 12.7 11.6, 13.7 13.5 12.1, 14.9 12.8 12.3, 13.3 0.508 
MUFA (% Energy) 12.1 11.5, 12.7 13.0 12.0, 14.1 13.1 12.0, 14.3 12.4 12.0, 12.9 0.126 
PUFA (% Energy) 6.1 5.7, 6.5 6.5 5.8, 7.2 6.8 5.8, 7.9 6.3 5.9, 6.6 0.290 
Total carbohydrate (% Energy) 46.1 44.6, 49.7 46.2 42.3, 52.2 42.7 40.0, 47.4 46.0 44.7, 48.7 0.522 
Starch (g) 143.3 132.8, 153.8 164.0 146.7, 181.3 136.0 114.3, 157.6 147.3 139.0, 155.5 0.070 
Non-starch Polysaccharide (g) 16.1 14.9, 17.2 16.4 14.5, 18.3 14.5 12.7, 16.2 16.0 15.1, 16.8 0.408 
Sugars (% Carbohydrate) 42.0 39.4, 44.5 39.1 31.8, 46.3 36.8 31.8, 41.7 40.9 38.8, 43.1 0.215 
Wholegrains (% Carbohydrate) 22.2 18.1, 26.2 27.4 15.5, 39.4 20.7 11.9, 29.5 22.5 19.0, 25.9 0.621 
Portions Fish per Week 2.8 2.2, 3.4 2.5 0.8, 4.3 2.8 1.8, 3.8 2.8 2.3, 3.3 0.922 
Fruit (portions per day, mean) 1.8 1.5, 2.1 1.2 0.9, 1.4 1.6 1.1, 2.0 1.6 1.5, 1.8 0.009a 
Vegetables (portions per day, mean) 2.4 2.2, 2.7 1.8 1.4, 2.2 1.9 1.6, 2.2 2.2 2.0, 2.4 0.012a 
Sodium (mg) 2704 2297, 3110 2468 2184, 2752 2523 2132, 2914 2624 2356, 2892 0.741 
Calcium (mg) 949 857, 1040 980 861, 1098 855 725, 985 944 878, 1009 0.546 
Iron (mg) 12.7 11.8, 13.5 15.1 12.8, 17.3 11.4 10.1, 12.6 13.1 12.3, 13.8 0.010a 
Folate (µg) 323 295, 350 323 287, 358 300 244, 355 320 299, 340 0.757 
Vitamin C (mg) 149 118, 179 100 82, 117 110 79, 142 132 112, 152 0.091 
Notes: Abbreviations: CI - Confidence Interval; MUFA - Monounsaturated Fatty Acid; PUFA - Polyunsaturated Fatty Acid 
Significance calculated by ANOVA 
aPost-hoc tests (Tukey’s HSD): Fruit – Normoglycaemia different to Prediabetes, p=0.006; Vegetables – Normoglycaemia different to Prediabetes, p=0.020; Prediabetes different 





3.2.5 Comparison of Phenotype of Dysglycaemia, 2005 
and 2015 
 
Differences between the cohorts in 2005 and 2015 are summarised in Table 3.8. Compared to 
2005, taken as a whole the 2015 cohort was older (p<0.001), heavier (p=0.019), more 
hypertensive (p<0.001), and had been HIV positive for longer (p<0.001). They were more likely 
to have been treated with ARVs (p<0.001), but had lower rates of smoking (p=0.019) and 
lipodystrophy (p=0.007). The 10-year CVD risk calculated by the Framingham tool and the use 
of statins were both significantly higher in 2015 compared to 2005 (p<0.001 for both). The 
prevalence of dysglycaemia was 25.9% in 2005 and 32.3% in 2015 (Figure 15). The prevalence 
of impaired fasting glucose excluding T2D did not differ between the cohorts (2005: 18.1 vs 
2015: 17.2%, p=0.763). However, the prevalence of T2D was significantly higher in 2015 
compared to 2005 (6.8 vs 15.1 %, p=0.003).  
 






Table 3.8: Comparison of the 2005 and 2015 Cohorts 
 2005 2015 p 
NUMBER OF PARTICIPANTS 337 338  
GENDER Male 77.2% 74.0% 0.335a 
AGE (Years) Median (IQR) 41 (35-47) 49 (42-57) <0.001b 
ETHNICITY White 54.6% 49.7% 0.525a 
 Black African 28.2% 31.7% 0.355a 
Black Caribbean 5.9% 7.7% 0.445a 
 Other 11.3% 10.9% 0.903a 
GLYCAEMIC STATUS           Normoglycaemic 75.1% 67.8% 0.041a 
 Prediabetes 18.1% 17.2% 0.763a 
 T2D 6.8% 15.1% 0.003a 
BMI (kg/m2) Median (IQR) 24.9 (22.4-28.0) 27.4 (23.3-29.9) 0.019b 
Underweight (<18.5 kg/m2) 2.7% 2.4% 0.625a 
Normal (18.5-24.9 kg/m2)  49.3% 39.6% 0.016a 
Overweight (25.0-29.9 kg/m2)  32.2% 34.3% 0.683a 
Obese (≥30.0 kg/m2) 15.7% 23.7% 0.009a 
WAIST (IDF DEFINITION)                      Obese 47.7% 62.4% 0.024a 
Median cm (IQR) 91 (83-98) 95 (86-104) 0.055b 
HYPERTENSION  19.6% 37.9% <0.001a 
LIPIDS (mmol/l)          Total Cholesterol (SD) 4.8 ±1.0 5.0 ±1.1 0.242b 
HDL: Triglyceride Ratio (SD) 1.59 ±1.74 1.39 ±1.19 0.180b 
METABOLIC SYNDROME (IDF DEFINITION)     22.5% 31.8% <0.001b 
SMOKING Current 
Smoker 
35.6% 21.0% 0.019a 
CVD (includes stroke)  2.7% 5.6% 0.055a 
STATIN USE  16.0% 27.2% <0.001a 
% 10-YEAR CVD RISK Mean (SD) 4.4 ±5.4 12.1 ±12.3 <0.001b 
HIV Duration (Years) Mean (SD) 6.3 ±0.9 11.6 ±0.9 <0.001b 
ANTIRETROVIRAL NAÏVE   19.6% 8.0% <0.001a 
ARVs ASSOCIATED WITH T2D 23.4% 44.1% <0.001a 
LIPODYSTROPHY           27.3% 21.6% 0.007a 
HEPATITIS B  4.5% 9.2% 0.021a 
HEPATITIS C  3.6% 4.7% 0.433a 
Notes:  
Variables as defined in section 2.5.4 
p = significance of difference between the cohorts calculated by a Chi-squared, b ANOVA; 








To compare changes in phenotype, participants with prediabetes and T2D were combined into 
a single category “dysglycaemia”. Factors associated with dysglycaemia are shown in Table 3.9. 
Those factors significantly associated with dysglycaemia at both time points included age and 
waist circumference (2005 and 2015, p<0.001), hypertension (2005 p=0.001 vs 2015 p<0.001), 
duration of HIV infection (2005 p=0.046 vs 2015 p<0.001) and the use of ARVs (2005 p=0.018 
vs 2015 p=0.009). Figure 16 illustrates the association between age and dysglycaemia in 2015. 
Figure 16: Distribution of Dysglycaemia by Age, 2015 
 
 
Exposure to ARVs associated with diabetes and BMI were both significantly associated in 2015 
only (2005 p=0.878 vs 2015 p=0.002, and p=0.423 vs p=0.001 respectively). In both 2005 and 
2015 there was no association between dysglycaemia and ethnicity, gender, total cholesterol 
and hepatitis B or C coinfection. Factors measured only in 2015 significantly associated with 
dysglycaemia were hepatic steatosis, low levels of physical activity and weight gain following 
initiation of ARVs (p<0.001 for all), exposure to corticosteroid therapy (p=0.014), 
unemployment (p=0.003) and the National Socioeconomic Classification and MacArthur UK 
scales (p=0.002 and 0.022 respectively). The Macarthur UK tool asks participants to score 
themselves on a Likert scale comparing themselves against others across the UK whereas the 
Community tool asks participants to score themselves against others in their own self-defined 
community. In contrast to the UK scale this was not significantly associated with dysglycaemia 
taken as a whole (p=0.547). Similarly financial insecurity was not significantly associated with 























Table 3.9: Univariate Analysis - Associations with Dysglycaemia, 2005 and 2015 
 2005 2015 
r p r p 
GENDER  0.02 0.721b 0.03 0.311b 
AGE Years 0.19 <0.001c 0.60 <0.001c 
ETHNICITY White 0.07 0.325b 0.08 0.531b 
 Black African 0.06 0.506b 0.08 0.358b 
 Black Caribbean 0.10 0.108b 0.06 0.253b 
BMId Median (kg/m2) 0.04 0.423c 0.17 0.001c 
WAISTd Median 0.24 <0.001c 0.27 <0.001c 
HYPERTENSION  0.02 0.001b 0.39 <0.001b 
LIPIDS Total Cholesterol 0.09 0.118c 0.05 0.438c 
 HDL 0.05 0.335c 0.13 0.016c 
 LDLa   0.10 0.072c 
 Triglyceridesd 0.11 0.038c 0.30 <0.001c 
HDL: Triglyceride Ratio 0.08 0.130c 0.27 <0.001c 
METABOLIC SYNDROME  0.58 <0.001b 0.63 <0.001b 
SMOKING Current 0.01 0.716b 0.12 0.905b 
CVD   (excluding stroke)  0.10 0.170b 0.11 0.050b 
STATIN USE  0.14 0.043b 0.40 <0.001b 
STROKE    0.10 0.109b 
% 10-YEAR CVD RISK      Framingham, mean 0.07 0.210c 0.39 <0.001c 
HIV DURATION  0.11 0.046c 0.18 <0.001c 
ARV NAÏVE   0.13 0.018b 0.17 0.009b 
ARVs ASSOCIATED WITH  DYSGLYCAEMIA 0.01 0.878b 0.16 0.002b 
% WT GAIN AFTER INITIATION OF ARVsa      0.34 <0.001c 
LIPODYSTROPHY           0.20 0.061b 0.15 0.007b 
HEPATITIS B  0.01 0.873b 0.04 0.421b 
HEPATITIS C  0.09 0.170b 0.01 0.930b 
CD4 NADIRa    0.01 0.082c 
VITAMIN Da    0.11 0.134c 
HEPATIC STEATOSISa     0.45 <0.001b 
CHRONIC KIDNEY DISEASEa   0.10 0.073b 
CORTICOSTEROID THERAPYa    0.14 0.014b 
1st or 2nd DEGREE RELATIVE WITH T2Da   0.10 0.076b 
PHYSICAL ACTIVITYa    0.20 <0.001c 
FRUITS & VEGETABLESa    0.06 0.260c 
FURTHER EDUCATIONa    0.09 0.087b 
SOCIOECONOMIC  SCALESa        NSEC Mean   0.27 0.002c 
         MacArthur UK  Mean   0.18 0.022c 
MacArthur Community  Mean   0.05 0.547c 
EMPLOYMENTa                           Unemployed   0.31 0.003b 
FINANCIAL STRUGGLEa                      Current   0.01 0.921b 
NOTES:  Variables as defined in section 2.5.4 
Dysglycaemia - impaired fasting glucose and type 2 diabetes aggregated 
a Data not collected in 2005; b Significance by Pearson Chi-squared test and Phi;  
c Pearson correlation and significance; d – Non-normal distribution, data log-transformed for analysis. 





3.2.6 Statistical Modelling 
 
Three binary logistic regression models were constructed for data from 2015 to distinguish the 
independent contribution of modifiable and fixed factors to dysglycaemia. Results from the 
three models are in Tables 3.10-3.12, with a summary presented in Table 3.13. 
Collinearity was observed between the variables waist and BMI (Pearson correlation 0.851) 
and between HIV Duration and CD4 Nadir (Pearson correlation 0.365); the latter of each pair 
was excluded from regression modelling. All other Pearson correlation values were less than 
0.300 and considered non-significant. 
 
Model 1: Modifiable Factors 
Model 1 included the modifiable factors hypertension, waist (cm), hepatic steatosis, HDL: 
triglyceride ratio and physical activity (hours per week), all of which had been demonstrated to 
be significantly associated with dysglycaemia in univariate analysis (see Table 3.9). The model 
as a whole was statistically significant (Chi-square (4, n=336) = 107.21, p<0.001), indicating 
that the model was able to distinguish dysglycaemia. The model as a whole explained between 
27.3% (Cox and Snell R squared) and 38.2% (Nagelkerke R squared) of the variance in 
dysglycaemia and correctly classified 78.9% of cases.  
 
As illustrated in Table 3.10 at step 1 of Model 1 the independent variable Waist no longer 
made a unique statistically significant contribution to the model and was removed, leaving 
Hypertension, Hepatic Steatosis, HDL: Triglyceride Ratio, and Physical Activity remaining 
statistically significant at step 2.  
 
The strongest predictor of dysglycaemia in Model 1 was Hepatic Steatosis, recording an odds 
ratio (OR) of 6.738. This indicated that study participants with hepatic steatosis were almost 
seven times more likely to have dysglycaemia when controlling for all other factors in the 
model. With HDL: Triglyceride ratio, the OR of 1.562 indicated that for every whole unit 
increase above a ratio of 1, participants were 1.56 times more likely to have dysglycaemia 
when controlling for other factors. Similarly, participants with hypertension were almost 3 
times more likely to have dysglycaemia. However, regarding Physical Activity, the likelihood for 





Table 3.10: Logistic Regression Model 1 (Modifiable Factors) 
  B Standard 
Error 
Wald p Odds 
Ratio 
OR 95% CIs 
Lower Upper 
Step 1 
Hypertension 1.094 0.294 13.811 0.000 2.987 1.677 5.319 
Waist (cm) -0.004 0.011 0.159 0.690 0.996 0.974 1.017 
Hepatic Steatosis 1.971 0.373 27.970 <0.001 7.175 3.457 14.892 
HDL: TG Ratio 0.449 0.125 13.000 <0.001 1.567 1.227 2.000 
Physical Activity 
(hours per week) 
-0.102 0.049 4.283 0.038 0.903 0.820 0.995 
Constant -1.702 1.066 2.551 0.110 0.182   
Step 2 
Hypertension 1.073 0.289 13.749 <0.001 2.925 1.659 5.158 
Hepatic Steatosis 1.908 0.336 32.163 <0.001 6.738 3.485 13.027 
HDL: TG Ratio 0.446 0.124 12.887 <0.001 1.562 1.225 1.993 
Physical Activity 
(hours per week) 
-0.099 0.048 4.148 0.042 0.906 0.824 0.996 
Constant -2.112 0.296 50.786 <0.001 0.121   
Notes: n=336 
Variables as defined in section 2.5.4 
B – Coefficient constant (intercept); Wald – tests the significance of the coefficients 
 
Model 2: Fixed Factors 
Model 2 included the fixed factors: duration of HIV infection, weight gain following initiation of 
ARVs, age, exposure to ARVs associated with diabetes and lipodystrophy (historic or current), 
all of which had been demonstrated to be significantly associated with dysglycaemia in 
univariate analysis (Table 3.9). Taken as a whole model 2 was statistically significant (Chi-
square (3, n=294) = 53.14, p<0.001), indicating that the model was able to distinguish 
dysglycaemia. The model as a whole explained between 16.5% (Cox and Snell R squared) and 
22.8% (Nagelkerke R squared) of the variance in dysglycaemia and correctly classified 71.4% of 
cases.  
As illustrated in Table 3.11 at steps 1 and 2 of Model 2 lipodystrophy and ARVs associated with 
dysglycaemia no longer made unique statistically significant contributions and were removed, 
leaving duration of HIV infection (OR 1.059), weight change following ARV initiation (OR 1.072 
for every percentage point gain in weight in first year following initiation of ARVs) and age (OR 
1.058 for every year) statistically significant at step 3. This model indicated that when 
controlling for all other factors in the model study participants were 1.07 times more likely to 
have dysglycaemia for each percent weight gain experienced in the year following initiation of 





Table 3.11: Logistic Regression Model 2 (Fixed Factors) 
  B Standard 
Error 





Duration of HIV 
(years) 
0.066 0.025 7.155 0.007 1.068 1.018 1.121 
Wt. Gain Following 
ARV Initiation (%) 
0.071 0.018 16.108 <0.001 1.073 1.037 1.111 
Age (years) 0.056 0.014 16.184 <0.001 1.058 1.029 1.087 
ARVs Associated 
with Diabetes 
0.162 0.337 0.232 0.630 1.176 0.607 2.279 
Lipodystrophy 0.074 0.357 0.043 0.836 1.076 0.535 2.166 
Constant -4.946 0.935 28.006 <0.001 0.007   
Step 2 
Duration of HIV 
(years) 
0.064 0.023 7.538 0.006 1.067 1.019 1.117 
Wt. Gain Following 
ARV Initiation (%) 
0.071 0.018 16.117 <0.001 1.073 1.037 1.111 
Age (years) 0.056 0.014 16.136 <0.001 1.057 1.029 1.087 
ARVs Associated 
with Diabetes 
0.180 0.327 0.304 0.581 1.197 0.631 2.272 
Constant -4.868 0.854 32.511 <0.001 0.008   
Step 3 
Duration of HIV 0.057 0.020 8.586 0.003 1.059 1.019 1.100 
Wt. Gain Following 
ARV Initiation (%) 
0.069 0.017 15.878 <0.001 1.072 1.036 1.109 
Age (years) 0.056 0.014 16.110 <0.001 1.058 1.029 1.087 
Constant -4.680 0.779 36.055 <0.001 0.009   
Notes: n=294 
Variables as defined in section 2.5.4 
B – Coefficient constant (intercept); Wald – tests the significance of the coefficients 
 
Model 3: All Factors 
Model 3 included all factors from models 1 and 2. Taken as a whole model 3 was statistically 
significant (Chi-square (5, n=293) = 121.686, p<0.001), indicating that the model was able to 
distinguish dysglycaemia. The model as a whole explained between 34.0% (Cox and Snell R 
squared) and 47.0% (Nagelkerke R squared) of the variance in dysglycaemia, and correctly 
classified 81.6% of cases. As illustrated in Table 3.12, at steps 1 to 5 of model 3 lipodystrophy, 
ARVs associated with diabetes, waist, duration of HIV infection and physical activity were 
removed, leaving the following statistically significant at step 6: weight change following ARV 





initiation), age (OR 1.07 for every year), hypertension (OR 2.58), hepatic steatosis (OR 7.29) 
and HDL: triglyceride ratio (OR 1.73 for each unit).  
 
Table 3.12: Logistic Regression Model 3 (All Factors Together) 
  B Standard 
Error 






Duration of HIV 
(years) 
0.036 0.030 1.465 0.226 1.037 0.978 1.099 
Wt. Gain Following 
ARV Initiation (%) 
0.058 0.020 8.375 0.004 1.059 1.019 1.101 
Age (years) 0.062 0.017 14.030 <0.001 1.064 1.030 1.100 
ARVs Associated with 
Diabetes 
0.193 0.406 0.226 0.634 1.213 0.548 2.685 
Lipodystrophy 0.035 0.426 0.007 0.935 1.035 0.449 2.385 
Hypertension 0.885 0.336 6.937 0.008 2.422 1.254 4.678 
Waist (cm) 0.008 0.013 0.365 0.546 1.008 0.983 1.033 
Hepatic Steatosis 1.761 0.435 16.384 <0.001 5.821 2.481 13.659 
HDL: TG Ratio -0.060 0.057 1.119 0.290 0.942 0.843 1.052 
Physical Activity 
(hours per week) 
0.520 0.141 13.540 <0.001 1.683 1.275 2.220 
Constant -7.057 1.684 17.550 <0.001 0.001   
Step 2 
 
Duration of HIV 
(years) 
0.037 0.028 1.723 0.189 1.037 0.982 1.096 
Wt. Gain Following 
ARV Initiation (%) 
0.058 0.020 8.428 0.004 1.059 1.019 1.101 
Age (years) 0.062 0.017 14.049 <0.001 1.064 1.030 1.100 
ARVs Associated with 
Diabetes 
0.183 0.387 0.224 0.636 1.201 0.562 2.565 
Hypertension 0.886 0.335 6.995 0.008 2.426 1.258 4.680 
Waist (cm) 0.008 0.013 0.364 0.546 1.008 0.983 1.033 
Hepatic Steatosis 1.758 0.433 16.477 <0.001 5.801 2.482 13.557 
HDL: TG Ratio -0.060 0.056 1.113 0.291 0.942 0.844 1.052 
Physical Activity 
(hours per week) 
0.521 0.141 13.619 <0.001 1.684 1.277 2.221 
Constant -7.055 1.684 17.541 <0.001 0.001   
Step 3 
 
Duration of HIV 
(years) 
0.030 0.023 1.587 0.208 1.030 0.984 1.079 
Wt. Gain Following 
ARV Initiation (%) 





  B Standard 
Error 




Age (years) 0.062 0.017 13.996 <0.001 1.064 1.030 1.100 
Hypertension 0.892 0.335 7.096 0.008 2.440 1.266 4.704 
Waist (cm) 0.008 0.013 0.366 0.545 1.008 0.983 1.033 
Hepatic Steatosis 1.757 0.433 16.441 <0.001 5.798 2.479 13.558 
HDL: TG Ratio -0.058 0.056 1.068 0.301 0.944 0.846 1.053 
Physical Activity 
(hours per week) 
0.520 0.141 13.551 <0.001 1.681 1.275 2.217 
Constant -6.861 1.627 17.780 <0.001 0.001   
Step 4 
 
Duration of HIV 
(years) 
0.027 0.023 1.399 0.237 1.028 0.982 1.075 
Wt. Gain Following 
ARV Initiation (%) 
0.055 0.019 8.123 0.004 1.057 1.017 1.098 
Age (years) 0.062 0.017 13.903 <0.001 1.064 1.030 1.099 
Hypertension 0.924 0.331 7.797 0.005 2.519 1.317 4.818 
Hepatic Steatosis 1.871 0.391 22.872 <0.001 6.495 3.017 13.984 
HDL: TG Ratio -0.064 0.055 1.355 0.244 0.938 0.843 1.045 
Physical Activity 
(hours per week) 
0.525 0.141 13.897 <0.001 1.690 1.283 2.227 
Constant -6.097 0.999 37.219 <0.001 0.002   
Step 5 
 
Wt. Gain Following 
ARV Initiation (%) 
0.054 0.019 7.807 0.005 1.055 1.016 1.095 
Age (years) 0.065 0.016 15.948 <0.001 1.067 1.034 1.102 
Hypertension 0.884 0.328 7.281 0.007 2.421 1.274 4.601 
Hepatic Steatosis 1.970 0.382 26.561 <0.001 7.168 3.389 15.160 
HDL: TG Ratio -0.068 0.054 1.599 0.206 0.934 0.840 1.038 
Physical Activity 
(hours per week) 
0.543 0.140 15.038 <0.001 1.720 1.308 2.263 
Constant -5.902 0.968 37.142 <0.001 0.003   
Step 6 
 
Wt. Gain Following 
ARV Initiation (%) 
0.057 0.019 9.016 0.003 1.059 1.020 1.099 
Age (years) 0.064 0.016 15.971 <0.001 1.067 1.033 1.101 
Hypertension 0.950 0.324 8.590 0.003 2.585 1.370 4.879 
Hepatic Steatosis 1.985 0.380 27.260 <0.001 7.283 3.456 15.345 
HDL: TG Ratio 0.547 0.139 15.488 <0.001 1.728 1.316 2.269 
Constant -6.071 0.955 40.407 <0.001 0.002   
Notes: n=293 
Variables as defined in section 2.5.4 





This final model suggests that when controlling for all other factors participants with hepatic 
steatosis were 7.3 times more likely to have dysglycaemia, 2.6 times more likely with 
hypertension, 1.7 times more likely for every unit increase in HDL: triglyceride ratio, 1.07 times 
more likely for each additional year of age, and 1.06 times more likely for each percent weight 
gain experienced in the year following initiation of ARVs.  
 
A summary of the three logistic regression models is presented in Table 3.13. Overall the 
modifiable factors hepatic steatosis and hypertension contributed the largest OR when 
controlling for all other variables significantly associated with dysglycaemia. 
 
Table 3.13: Summary of Logistic Regression Models 















Physical Activity  
(Hours per week) 
0.91 
(0.82-1.00) 
















Weight Gain Following 


















Note: Variables as defined in section 2.5.4 
 
Receiver Operator Characteristic Curve Analysis: 
The probability of each model predicting dysglycaemia correctly was plotted using ROC curves 
(Figure 17). The area under the curve (AUC) with 95% confidence intervals for each of Models 
1, 2 and 3 was 0.838 (0.790-0.887), 0.752 (0.693-0.812), and 0.863 (0.818-0.908) respectively. 
Model 1 (Modifiable Factors) predicted dysglycaemia more efficiently than Model 2 (Fixed 
Factors). The difference in proportions of the AUC between Models 1 and 2 was statistically 





Figure 17: Receiver Operator Characteristic Curves for Regression Models 
 
 
3.2.7 Disease Risk Modelling 
 
Cardiovascular Disease: 
As described in Sections 1.8 and 2.5.5 four CVD risk prediction tools were compared for the 
2015 cohort. Three were general tools: the Framingham Risk Score (FRS), QRisk2, and the Joint 
British Societies Score (JBS3). The fourth was the HIV-specific Data Collection on Adverse 
Events of Anti-HIV Drugs Study (D:A:D) risk tool. Results are described in Table 3.14. Overall, 
the D:A:D score attributed the lowest mean 10 year CVD risk (6.8%) compared to 7.7% for 
JBS3, 9.6% for QRISK2 and 12.1% for FRS. The D:A:D score classified significantly fewer 
participants as high risk compared to the other three models when using the threshold of 10% 
risk of CVD over 10 years and also the D:A:D study investigators’ recommended threshold of 






Table 3.14: Cardiovascular Disease Risk Estimation Using Four Equations 
 
Framingham 
(FRS) QRISK2 JBS3 D:A:D 










High Risk Patients (>10%, 10 years) 132 (39.1%) 95 (28.1%) 77 (22.8%) 65 (19.2%) 
High Risk Patients (>5%, 5 years)    69 (20.4%) 
Note: Risk tools as defined in section 2.5.5 
 
Correlation between the D:A:D risk equation and other tools is reported in Table 3.15. There 
was agreement in predicting between 8 and 9 out of 10 participants at high risk of developing 
CVD. Correlation was highest between D:A:D and QRisk2.   
 
Table 3.15: Correlation Comparison of CVD Risk Tools 
 
Comparison of Risk Tools 
D:A:D & FRS D:A:D & QRISK2 D:A:D & JBS3 
Observed Agreement of High Risk  78.4% 86.3% 89.4% 
Pearson's r Coefficient 0.84 0.85 0.78 
Note: Risk tools as defined in section 2.5.5 
 
Type 2 Diabetes: 
The QDiabetes tool was used to calculate relative T2D disease risk. The relative risk for this HIV 
cohort was 2.4 (95% CI 2.1-2.8) compared to the QDiabetes UK cohort (2.5 million patients 
from GP surgeries in England and Wales). Receiver Operator Characteristic curves for 
prediction of prediabetes and T2D (Figure 18) suggested that for prediabetes FINDRISK was the 
most sensitive and specific of the three tools correctly identifying 81% (AUC=0.804, 95% CI 
0.751-0.858, p<0.001) compared to QDiabetes (AUC=0.611, 0.533-0.688) and D:A:D 
(AUC=0.540, 0.469-0.612).  For prediction of T2D, FINDRISK had the greatest specificity 
followed by D:A:D, identifying 90% and 80% respectively (AUC=0.825; 95% CI: 0.775-0.875; 
p<0.001 for FINDRISC; AUC=0.814; 95% CI 0.759-0.869; p<0.001 for D:A:D). QDiabetes had a 
comparable specificity of 84% (AUC= 0.676; 95% CI: 0.605-0.747; p<0.001) but the poorest 
















3.3  Diet and Physical Activity Intervention 
 
3.3.1 Principal Results Summary 
 
It was hypothesised that in people living with HIV and prediabetes a 6-month intervention of 
diet and physical activity advice, individualised to address ethnic and socioeconomic 
differences, would result in a clinically significant reduction in glucose incremental area under 
the curve over a three-hour meal tolerance test. Secondary objectives were to measure the 
change from baseline at 6 months for insulin incremental area under the curve measured in a 
3-hour meal tolerance test, indices of insulin resistance/sensitivity, dietary change, physical 
activity, lipids, anthropometry and body composition, frailty, blood pressure, cardiovascular 
and diabetes risk, quality of life, bowel habits and gut symptoms. 
 
Principal Results: 
 At 6 months, the mean glucose incremental area under the curve measured in mmol 
per minute was 18% lower (p=0.023) 
 The mean insulin incremental area under the curve measured in units per minute was 
31% lower (p=0.017). Baseline fasting glucose and insulin means were significantly 
lower at 6 months: reductions of 6% and 24%, p=0.003 and 0.021 respectively. 
 Participants achieved significant reductions in mean weight (4.6%), waist (6.2%), 
percentage body fat (5.9%), systolic blood pressure (7.7%), triglycerides (36.2%), 10-
year cardiovascular risk (13.9%) and a significant increase in mean HDL (12.6%) and life 
satisfaction score (17.6%) 
 Out of the 28 participants, only 6 achieved or exceeded the goal to lose 7% of body 
mass over the 6-month intervention period. However, the mean reduction of 4.1 kg 
(4.6%) was highly significant (p<0.001) 
 Participants experienced significant change in diet and physical activity. There were 
significant reductions in mean intake of energy (20.6%), fat (14.5%), sugars (29.5%) 
and sodium (21.4%), and significant increases in mean total activity (52%), and intake 






3.3.2 Intervention Cohort Characteristics 
 
Intervention participants ranged in age from 40-71 years (Table 3.16). Three-quarters of 
intervention participants were male, and all women who took part were of Black African or 
Caribbean ethnicities. The mean BMI was 30.7 kgm2. Metabolic comorbidities were common. 
The mean duration of HIV infection was 16 years. Regarding socioeconomic status, 36% were 
unemployed or retired. Intervention participants (n=33) and participants with prediabetes 
from the phenotype study (n=58) were similar, although the intervention participants had a 
higher mean BMI and rate of hepatic steatosis. 
Table 3.16: Intervention Cohort Characteristics 
 Intervention 2015 IFG COHORT p1 
n 33 58  
Age (years)                              Mean             53.8 53.2 0.966c 
Range 40-71 38-71  
Gender                                  % Male 72.7% 77.6% 0.195b 
Ethnicity                                  White 57.6% 53.4% 0.080b 
Black African 27.3% 29.3%  
Black Caribbean 12.1% 6.9%  
Other 3.0% 10.3%  
BMI 30.7 28.8 0.019c 
Central Obesity (IDF) 84.8% 74.1% 0.070b 
Hypertension 60.6% 53.4% 0.450b 
Metabolic Syndrome 78.8% 72.4% 0.268c 
Hepatic Steatosis 63.6% 46.6% 0.016b 
CVD 6.1% 8.6% 0.528b 
Statin 51.5% 37.9% 0.068b 
Smoker                                 Current 6.1% 13.8% 0.082b 
Duration HIV Infection 15.8 13.9 0.055c 
CD4 Nadir 195 186 0.391c 
Duration Treated with ARVs 10.8 10.6 0.906c 
ARVs Associated with T2D 48.5% 53.4% 0.408b 
% Weight Gain following ARVsa 6.3 7.0 0.704c 
Lipodystrophy 18.2% 24.1% 0.362b 
Relative with T2D 57.6% 53.4% 0.450b 
Working / Student 63.6% 63.8% 0.538b 
Unemployed 30.3% 25.9%  
Retired 6.7% 10.3%  
Financial Struggle 9.1 % 13.8% 0.330b 
Further Education 72.7% 75.9% 0.378b 
Notes:  
Variables as defined in section 2.5.4 
Difference between intervention and all prediabetes participants (p1) 
a % weight gain in 12 months following initiation of ARVs; b Chi-square; c ANOVA 





3.3.3 Participant Achievement of Diet and Physical 
Activity Goals 
 
Participants were set 10 goals to achieve over the 6-month intervention (Figure 19 and Table 
3.17). Achievement of 6-10 goals was considered as good adherence to the intervention, 3-5 as 
moderate, and achieving 2 or fewer goals considered poor. Using this criteria 22% were good 
achievers, 63% moderate, and 15% poor. Participants achieved a mean 4.4 goals, with men 
achieving 4.1 and women achieving 5.1 (p=0.185). 
Figure 19: Number of the 10 Intervention Goals Achieved by Each Participant 
 
Most participants (85%) achieved the target to reduce salt intake to less than 6g per day. The 
majority of participants also achieved targets to walk more than 10,000 steps per day, to 
reduce added sugar below 25g per day, and to reduce saturated fat intake to less than 10% of 
total daily energy intake (63%, 59% and 59% respectively). The most challenging goal to 
achieve appears to have been maintaining intake of monounsaturated fats above 15% of total 
daily intake. Achievement of at least 7% weight loss was met by high achievers only.  
 
In addition to dietary goals, other changes in the nutritional composition of the diet were 




















Weight Loss ≥ 7% 22% 0 0 6 
Energy Deficit ≥ 600 kcal per Day 48% 1 7 5 
Steps per Day ≥10,000  63% 0 11 6 
Wholegrains ≥50% of Carbohydrate 41% 1 6 4 
Waist: Achieve IDF Target 26% 0 7 0 
Added Sugar ≤ 25g per day 59% 0 11 5 
Saturated Fats ≤ 10% Total Energy 59% 1 11 4 
Monounsaturates ≥15% Total Energy 15% 1 2 1 
Fruits & Vegetables ≥ 7 Portions / Day 26% 0 2 5 
Sodium ≤ 2.5 g per Day 85% 3 14 6 
Notes: n=28 
Classification of goal achievement: High – 6-10 goals, Moderate – 3-5 goals, Poor – 0-2 goals 
IDF – International Diabetes Federation 
 





Δ Mean 95% CIs pa 
Lower Upper 
Energy Intake (kcal)  2450 1946 -505 -309 -701 <0.001 
Energy Balance (kcal) 51 -424 -475 -267 -684 <0.001 
Carbohydrate (% TEI) 41.8 44.3 2.6 0.7 5.8 0.122 
Protein (% TEI) 18.6 22.1 3.5 1.6 5.4 <0.001 
Fat (% TEI) 35.9 30.7 -5.2 -2.1 -8.3 0.002 
Saturated Fats (% TEI) 12.6 9.7 -2.8 -1.3 -4.4 0.001 
Monounsaturated Fats (% TEI) 13.8 11.4 -2.4 -0.7 -4.1 0.009 
Polyunsaturated Fats (% TEI) 6.4 6.1 -0.3 -1.1 0.5 0.474 
Alcohol g 15.8 9.1 -6.7 -1.1 -14.4 0.088 
Non-starch Polysaccharide g 16.6 19.5 2.9 0.3 5.4 0.028 
Sugar g 35.2 24.8 -10.4 -1.1 -19.7 0.029 
Wholegrains (% carbohydrate) 13.2 41.4 28.1 19.6 36.7 <0.001 
Oily Fish (portions/week) 0.8 1.2 0.4 0.1 0.6 0.003 
Fruit (portions/day) 1.1 1.7 0.7 0.2 1.1 0.004 
Vegetables (portions/day) 1.5 2.9 1.4 1.1 1.8 <0.001 
Sodium mg 2709 2128 -581 -170 -992 0.007 
Calcium mg 1102 921 -181 10 -373 0.063 
Iron mg 16.4 14.3 -2.2 1.3 -5.7 0.216 
Notes: n=28 
Baseline and Endpoint = Days 1 and 180 of the 180-day intervention. 
a Paired Samples t-test for change in mean 





















































3.3.4 Primary Outcome: Changes in Glucose and Insulin 
 
The primary outcome was 6-month change in glucose incremental area under the curve (IAUC) 
measured by a 3-hour frequently sampled liquid meal tolerance test, performed at baseline 
(Day 1) and post-intervention (Day 180). Glucose IAUC had a mean reduction of 45 
mmol/l/minute (7-83 reduction, p=0.023). Insulin IAUC had a mean reduction of 4078 
mIU/l/minute (797-7358 reduction, p=0.017). These reductions were equivalent to 17.6% for 
glucose and 31.4% for insulin. Graphs comparing mean glucose and mean insulin at time points 
across the 3-hour test at baseline and post-intervention are shown in Figures 21 and 22 
respectively. Statistical analyses of results are presented in Table 3.19. Comparing baseline to 
post-intervention, there were significant reductions in fasting glucose and insulin. Fasting 
glucose had reduced by 0.35 mmol/l (95% CIs 0.13-0.57, p=0.003) and insulin by 3.4 units (0.5-
6.2, p=0.021). 





Δ Mean Δ Mean 95% CIs pa 
Lower Upper 
Glucose (fasting)                  6.04 5.68 -0.35 -0.57 -0.13 0.003 
Glucose Maximum  8.6 8.2 -0.4 -0.9 0.1 0.114 
Glucose AUC 1266 1189 -77 -143 -11 0.024 
Glucose Incremental AUC 255 210 -45 -83 -7 0.023 
Insulin (fasting) 14.4 11.1 -3.4 -6.2 -0.5 0.021 
Insulin Maximum 183 117 -66 -113 -19 0.008 
Insulin AUC 15361 11010 -4351 -7871 -831 0.017 
Insulin Incremental AUC 12989 8911 -4078 -7358 -797 0.017 
Notes: n=28 
Measured by Frequently sampled liquid meal tolerance test, 11 samples over 3 hours 
a Paired Samples t-test for change in mean 
Glucose measured in mmol/l; insulin in international units; AUC in units x minute 
AUC: Area under the curve 
 
Comparing baseline and post-intervention, mean glucose excursions over the 180 minute test 
followed very similar patterns, albeit with a reduced level at each time point (Figure 21). For 
mean insulin early phase secretion appears very similar, with later phase secretion reduced 







3.3.5 Changes in Anthropometry 
 
Across the 6-month intervention the cohort experienced statistically significant mean 
reductions in all measures. Changes in anthropometry measured manually and by Bioelectric 
Impedance Analysis (BIA) are presented in Table 3.20. Percentage reduction in weight, waist 
and body fat were 4.6%, 6.2% and 5.9% respectively. The cohort also experienced a 1.7% 
reduction in hip size, and a 3.3% loss in lean body mass. An examination of 95% confidence 
intervals shows reductions for all measures at upper and lower levels, with all changes 
reaching statistical significance. 





Δ Mean 95% Confidence Intervals pb 
Lower Upper 
BMI kg/m2 30.66 29.55 -1.41 -1.87 -0.97 <0.001 
Weight kg 88.82 84.75 -4.08 -5.41 -2.74 <0.001 
Waist cm 107.1 100.5 -6.60 -8.37 -4.84 <0.001 
Hips cm 107.0 105.2 -1.78 -3.05 -0.51 0.008 
% fata 29.32 27.58 -1.73 -3.01 -0.46 0.010 
Dry muscle kga,c 15.6 15.1 -0.51 -0.94 -0.09 0.021 
Notes: n=28 
a Measured by Bioelectrical Impedance  
b Paired Samples t-test  














3.3.6 Intervention: Analysis of Incretin Hormones 
 
The incretin hormones were measured at four time points during the FSLMTT: 0, 30, 60 and 






































presented in Figures 23 and 24. Post-intervention there was a significant reduction of 25.1% in 
incremental area under the curve for GIP (mean reduction 9058 ng/l/minute, 95% CIs -15320 
to -2796, p=0.006), with no statistically significant change observed for GLP-1. 







95% CIs pa 
Lower Upper 
GIP (fasting) 41.0 29.6 -11.4 -36.7 13.7 0.359 
GIP AUC 40817 40584 -233 -7123 6657 0.945 
GIP Incremental AUC 36078 27020 -9058 -15320 -2796 0.006 
GLP-1 (fasting) 19.5 14.7 -4.8 -13.3 3.6 0.252 
GLP-1 AUC 4146 4062 -84 -2010 1842 0.929 
GLP-1 Incremental AUC 1390 1790 400 -593 1393 0.416 
Notes: n=28 
Units: GIP – ng/l; GLP-1 – pmol/l; AUC – units x minute 
a Paired Samples t-test for change in mean 





























Figure 25: Effect of Intervention on Mean and Standard Error of GIP 
 
Note: n=28 








































3.3.7 Modelling of Insulin Resistance and Glucose 
Disposal 
 
Modelling of insulin resistance and glucose disposal is described in Section 2.6.6 and results 
are presented in Table 3.22. The intervention resulted in statistically significant improvement 
in insulin resistance measured by the HOMA-IR and McAuley indices, whereas the QUICKI and 
Matsuda indices showed trends to improvement of insulin resistance but were not statistically 
significant.  
The baseline and post-intervention mean HOMA-IR index values remained within the range 
defining insulin resistance, however the mean reduction of 1.05 (CIs 0.26-1.84) was statistically 
significant (p=0.011). The baseline and post-intervention McAuley index were both above the 
threshold defining insulin resistance and post-intervention a statistically significant 
improvement of a mean increase of 1.40 was observed (95% CIs 0.29-2.51, p=0.016). The mean 
baseline QUICKI and Matsuda index levels indicated insulin resistance. Post-intervention both 
had mean values in the normal range suggesting resolution of insulin resistance, however the 
CIs were wide for both measures and the trend to improvement was not significant (p=0.088 
and 0.171 respectively). 
The glucose disposal rate, a measure of insulin sensitivity calculated by the Mari method (see 
Section 2.6.6) showed a significant improvement post-intervention compared to baseline, 
increasing by a mean 45 mmol/minute/m2 (95% CIs 18-72, p=0.002). 
 





Δ Mean 95% CIs pa 
Lower Upper 
HOMA-IR 3.93 2.88 -1.05 -1.84 -0.26 0.011 
QUICKI 0.325 0.349 0.024 -0.004 0.051 0.088 
MATSUDA 3.62 5.99 2.37 -1.11 5.86 0.171 
McAULEY 6.08 7.48 1.40 0.29 2.51 0.016 
OGIS (Mari) 314.7 359.6 44.9 17.8 72.0 0.002 
Notes: 
a Paired Samples t-test for change in mean 
Insulin resistance defined as: HOMA-IR ≥2.6; QUICKI ≤0.33; Matsuda <4.3; McAuley ≤5.8 










Medical outcomes are presented in Table 3.23. Surrogate measures for control of HIV and 
strength of the immune system were unaffected by the intervention. Mean CD4 count 
remained constant (p=0.826). At baseline, out of the 29 participants only one had a detectable 
viral load and 28 were undetectable. All were undetectable post-intervention.  
Both systolic and diastolic blood pressure were significantly reduced by 7.7% and 8.3% 
respectively (p=0.006 for both).  
No statistically significant changes were noted in fasting levels of total cholesterol and LDL 
cholesterol although there was a trend for reduction in mean total cholesterol (p=0.155). In 
this cohort 51% were prescribed statins. In a sub-analysis change in LDL cholesterol was 
compared in those prescribed statins versus those not prescribed. There was no difference 
between groups using the ANOVA test (mean reduction in statin group 0.06 mmol/l, 95% CIs -
0.38 to 0.26; mean reduction in non-statin group 0.08 mmol/l, 95% CIs -0.35 to 0.18; p=0.909).  
Across the intervention there was a significant 36.2% reduction in mean fasting triglyceride 
level (mean reduction 0.75 mmol/l, 95% CIs 0.31-1.12, p=0.002) and a significant 12.6% 
increase in fasting HDL cholesterol (mean increase 0.16 mmol/l, 95% CIs 0.06-0.26, p=0.002).  
Cardiovascular risk estimated by the QRisk2 equation saw a significant reduction (mean 
reduction of 1.3% in 10-year risk, 95% CIs 0.60-2.07, p=0.001). Similarly risk for type 2 diabetes 
saw a significant reduction (mean reduction in 10-year risk was 3.1%, 95% CIs 1.72-4.48, 
p<0.001). 
Frailty measured by hand grip strength was statistically unchanged across the 6-month 
intervention. There was no change in mean frequency of opening bowels to pass stools or 
mean Bristol Stool Chart score (p=0.947 and 0.477 respectively). Although change in 
gastrointestinal symptom score was not statistically significant there was a trend for 














95% CIs pa 
Lower Upper 
CD4 652 662 10 -99 80 0.826 
HIV Viral Load Undetectable  1 0 -1 -3 1 0.326 
Systolic Blood Pressure  135.5 125.1 -10.4 -17.6 3.2 0.006 
Diastolic Blood Pressure  81.6 74.8 -6.8 -11.5 2.2 0.006 
Total Cholesterol  4.88 4.72 -0.17 -0.40 0.07 0.155 
LDL Cholesterol 2.78 2.70 -0.07 -0.27 0.12 0.429 
HDL Cholesterol  1.27 1.43 0.16 0.06 0.26 0.002 
Triglycerides  2.07 1.31 0.75 -1.12 -0.31 0.002 
10-year CVD Risk % (QRisk2) 9.59 8.27 -1.33 -2.07 -0.60 0.001 
10-year Diabetes Risk % (QD) 17.2 14.1 -3.1 -4.48 -1.72 <0.001 
Frailty (Grip Strength) 34.4 35.0 0.6 -1.9 3.1 0.602 
Frequency open bowels / day 1.6 1.6 0.0 -0.2 0.2 0.974 
Bristol Stool Chart Score 3.6 3.8 0.2 -0.4 0.8 0.477 
Gastrointestinal Symptom 
Score 
7.6 5.8 -1.8 -3.6 0.1 0.062 
Notes:  
HIV Viral Load: Expressed as number undetectable out of total cohort of 29 participants 
QD: QDiabetes risk equation; 10-year CVD and Diabetes risk controlled for age 
Blood pressure – units of mm Hg; Lipids – mmol/l; Grip Strength – kg; Bristol Stool Chart – mean score 
from 1-7 scale; gastrointestinal symptom score – mean score on scale 0 (no symptoms) – 33 
(maximum possible).  
a Paired Samples t-test for change in mean 
 
 







95% CIs pa 
Lower Upper 
Satisfaction with Life 64.8 76.2 11.4 4.0 18.8 0.004 
Health Concerns 89.4 89.8 0.4 -4.2 5.0 0.855 
Financial Concerns 75.4 75.8 0.3 -6.8 7.4 0.929 
HIV Medication Concerns 86.9 91.4 4.5 1.0 8.0 0.014 
Mastery of Living with HIV 90.5 89.3 -1.2 -7.6 5.3 0.720 
HIV Disclosure Concerns 62.0 69.0 7.0 -3.0 17.0 0.164 
Relationship with Doctors 72.3 80.2 7.8 -5.1 20.8 0.225 
Sexual Functioning 54.4 61.6 7.2 -5.1 19.5 0.240 
Overall Quality of Life 75.3 80.5 5.2 -0.2 10.7 0.060 
Notes:  
Measured by the HIV-specific HAT-QoL instrument 
Scores are expressed as percentage, where 100% is the highest possible quality of life. For example a 
higher Financial Concerns score equates to fewer concerns 







Quality of Life Outcomes 
Quality of life was measured using the HIV-specific HAT-QoL instrument (Table 3.24). Each 
component was scored as a percentage where 100% is equivalent to the highest possible 
quality of life. The change in mean overall quality of life score showed a trend for 
improvement over the 6-month intervention (increase of 5.2%, 95% CIs -0.2 to 10.7, p=0.060). 
Of the individual components of the instrument, the intervention had the greatest impact on 
the mean score for life satisfaction (increase of 11.4%, 95% CIs 4.0-18.8, p=0.004). The 
intervention also had a statistically significant effect on concerns about HIV medicines (fewer 
concerns post-intervention) but not on any other factor. There were no statistically significant 
correlations between individual or combined quality of life measures and achievement of 
intervention goals. 
 
Physical Activity Outcomes 
In addition to steps per day measured by pedometer (results presented in Table 3.17) physical 
activity was also measured using the International Physical Activity Questionnaire (IPAQ) with 
results presented in Table 3.25. Although a reduction in sedentary time was observed across 
the intervention, this was not statistically significant (p=0.217). The intervention increased 
time spent walking and performing intense activities (mean increase 53%, p=0.015, and 213%, 
p=0.022 respectively) but changes in moderate activities were not statistically significant 
(p=0.450). Metabolic equivalents (METs) were calculated with the change in mean total value 
being highly significant with an increase of 52% (95% CIs 29-76%, p<0.001). 







95% CIs pa 
Lower Upper 
Sedentary                   (minutes) 462 411 -51 -132 31 0.217 
Walking                       (minutes) 517 789 273 57 488 0.015 
Moderate Activity    (minutes) 351 413 62 -104 227 0.450 
Intense Activity         (minutes) 37 116 79 12 146 0.022 
Walking                    (MET mins) 1705 2605 900 189 1611 0.015 
Moderate Activity (MET mins) 1403 1650 248 -414 909 0.450 
Intense Activity      (MET mins) 297 931 634 99 1170 0.022 
Total Activity          (MET mins) 3405 5186 1782 989 2575 <0.001 
Notes:  
Measured by the International Physical Activity Questionnaire 
Scores are expressed in minutes per week. MET=Metabolic equivalent 





3.4 Qualitative Investigation 
 
3.4.1 Principal Results Summary 
 
Twenty-three participants consented to be interviewed, 19 who took part in the pilot 
intervention, and 4 who declined to take part. Analysis of interviews identified key themes of 
confidentiality and fear of disclosure of HIV status. Those who declined participation or 
achieved fewer intervention goals exhibited an external health locus of control, blaming 
diabetes risk on HIV medicines. Those who achieved more goals considered prediabetes 
treatable. Enablers included a desire to avoid adding to pill or disease burden, and a strong 
support network. Deliberate weight loss leading to loss of cultural identity and disclosure of 
HIV status were significant barriers. Participants found the intervention largely acceptable. 
They suggested that future interventions should offer a range of methods of support and 
consider logistics of research appointments. 
 
3.4.2 Sampling and Cohort Characteristics 
 
As described in Section 3.1.3, a total of 44 out of 55 participants screened to have prediabetes 
and treated with antiretroviral medicines were invited to interview. Of these 44, 23 (52%) 
consented to be interviewed, 19 who took part in the intervention and 4 who declined to take 
part in the intervention.  
Women were more challenging to recruit to interview whether they declined to take part or 
took part in the intervention. As shown in Figure 10, 22 participants with prediabetes did not 
meet inclusion criteria or declined to take part in the intervention and all were invited to 
interview. Of these 22, 13 were male and 9 female. None of the 9 women consented to be 
interviewed whereas 4 of the 13 men agreed to take part. Additionally, of the 9 women who 
took part in the intervention, 5 agreed to be interviewed and 4 declined. All of the men taking 
part in the intervention who were invited to interview agreed to take part.  
Both participants diagnosed with T2D at baseline of the intervention and withdrawn at that 
stage consented to be interviewed. Two further participants dropped out of the intervention. 





The demographic of the interview cohort is described in Table 3.26. Although 
disproportionately male, the group interviewed otherwise represented the demographic of the 
larger cohort. The mean age of those interviewed was not significantly different to the mean 
age of those with prediabetes from the larger phenotype study presented in Section 3.2.3 
(54.6 and 53.3 years respectively, p=0.110). 
Most interviewees had been diagnosed with HIV and treated with anti-HIV medication for a 
considerable length of time (mean duration 15.6 and 11.8 years respectively) although a range 
was represented.  
 




Participation Status (n)        Declined Intervention 4 0 4 
Completed Intervention 11 5 16 
Withdrawn (Diabetes Diagnosis) 2 0 2 
Dropped Out of Intervention 1 0 1 
Total 18 5 23 
Age (years)                                                         Range 40-71 42-58 40-71 
Mean 56.5 49.7 54.6 
Ethnicity (n)                                                        White 13 0 13 
Black African 2 5 7 
Black Caribbean 2 0 2 
Other 1 0 1 
Employment Status (n)                                Working 7 4 11 
Unemployed 3 1 4 
Retired 8 0 8 
Sexuality (n)                                          Heterosexual 7 4 11 
Gay 9 0 9 
Not disclosed 2 1 3 
Years Since HIV Diagnosis                                Mean 15.5 16.0 15.6 
Range 3-28 10-22 3-28 
Years of Treatment with ARVs                        Mean 11.4 13.5 11.8 










All participants were offered a choice of interviewer, either myself or one of the Health 
Advisers (trained counsellors) from the HIV clinic. Interviews were conducted at a place and 
time to suit the participant. Venues offered included the participant’s own home or workplace, 
a meeting room in a non-clinical area of St. Thomas’ Hospital, an interview room in the Clinical 
Research Facility at St. Thomas’ Hospital or a consultation room at the charity Terence Higgins 
Trust near King’s Cross in London. All 23 participants interviewed chose me to conduct the 
interview. Two participants requested to be interviewed at home, and one at their workplace. 
Of the remainder, nine chose to be interviewed in a non-clinical room at St. Thomas’ Hospital 
and eleven at the Clinical Research Facility.  
All 23 interviews were conducted with only the interviewer and interviewee present and in a 
private location where security of confidentiality was assured. Interview number 21 conducted 
at the participant’s home was briefly disrupted by the behaviour of the participant’s dog, with 
the interview and recording paused for four minutes and restarted. This disruption did not 
affect the overall quality of the interview. All other interviews progressed without interruption. 
The mean duration of interviews was 44 minutes. Interview number 1, essentially a pilot, 
lasted for 21 minutes. Interview number 20 was also brief, lasting 20 minutes. The participant 
was unexpectedly called to work shortly before the interview began and the interview could 
not be rearranged. Topics for discussion were prioritised by the interviewer. The duration of 
interviews other than numbers 1 and 20 ranged from 28 to 84 minutes. No repeat interviews 
were conducted. 
3.4.4 Development in Framework Analysis 
 
The initial framework construct for analysing interview data was based on the three topic 
guides developed (Appendix 7.7). The topic guides divided the flow of the interviews through a 
general introduction, attitudes to being diagnosed with dysglycaemia, participation in this 
study, enablers and barriers to change, design of the study, and finally attitudes to research 
participation in general. The initial Framework coding tree (Table 3.27) was tested at Interview 
1, and although the Framework continued to employ these initial primary nodes, further nodes 






Following interview 2, a code was added regarding attitudes to body shape prior to the 
intervention and for those who had dropped out or completed the intervention, current body 
shape. Analysis following interview 4 suggested that support was a key element in behaviour 
change in this cohort and was separated from other elements and added as an independent 
code. 
The final novel code added at interview 21 was regarding gay men who self-identify as ‘bears’. 
This theme is explored fully in Section 3.4.8. As an introduction, the bear community is a sub-
section of gay men who reject normative idealised male lean muscularity, and are more likely 
to be hairier, heavier and more masculine (as defined below, with images of men who self-
identify as bears in Appendix 7.9) than mainstream gay men (Moskowitz et al., 2013). To quote 
interviewee 23: 
“In terms of masculinity [being a bear is…] more about a rejection of what would be 
considered the traditional kind of gay attributes or qualities. There is a kind of 
appreciation of people with big bellies and that broad look and with the beards and all 
that kind of stuff, and obviously there’s the beer drinking as well, the culture of that”. 
[Interviewee No. 23, male, aged 41]. 
Table 3.27: Interviews: Initial Coding Tree in Framework Analysis (Added to Subsequently) 
Interview Section Primary Analysis Code Secondary Analysis Code 
Introduction General Health Comorbidities 
Current attitudes Living with HIV - diagnosis 
Current Behaviours Diet 
Physical Activity 
Attitudes to Diagnosis of 
Prediabetes or Type 2 
Diabetes 
Living with prediabetes or T2D Reaction to diagnosis 
Beliefs about diabetes 
HIV and Diabetes Together Opportunities 
Concerns 
Taking Part in this Study Enablers  
Barriers 






Intervention Design Acceptable Aspects  
Less Acceptable Aspects 
Suggestions for Future Design 






3.4.5 Purposive Sampling 
 
The preliminary design purposively sampled participants to include maximum diversity:  
 Gay men who exercise 
 Gay men with a higher BMI 
 Black African-origin men and women  
 Those who withdrew from the intervention 
 Those who were eligible but declined to take part in the intervention 
Preliminary thematic analysis following interview 11 suggested no new significant data was 
emerging from interviews with White male participants who had achieved most targets during 
the 6-month intervention. From this point, only those White males who had achieved fewer 
targets were invited to interview; six White male participants who performed well in the 
intervention were not invited to interview. New data continued to emerge from analysis of 
interviews with non-White participants and invitation to interview for this group continued. 
Data saturation was achieved for White male participants only. 
 
3.4.6 Thematic Analysis 
 
Development of themes for analysis progressed (Table 3.28 to Table 3.35) resulting in an 
expansion of themes from 21 to a total of 76 themed codes and sub-codes arranged as 
separate columns within the Framework. On receipt of each interview transcription, coding 
was completed systematically with references placed in each cell within the Framework. With 
all 23 interviews completed, the grid now had data coded and distributed between 1748 cells. 
Empty cells were noted as absence of a theme was considered potentially significant.  
Table 3.28: Interview Analysis: Development of Introductory Themes 
General Health Comorbidities 
 Mental Health 
 Attitude to Life 
Living with HIV Optimistic Approaches 
 Concerns and worries 
 Disclosure 
 Medication Issues 
Current Diet Behaviours Perception of behaviours 
Current Physical Activity 
Behaviours 





Table 3.29: Interview Analysis: Development of Diagnosis Themes 
Living with Prediabetes Reaction to diagnosis 
 Concerns / worries 
 Optimism 
Diagnosis of Type 2 Diabetes Reaction to diagnosis 
 Concerns / worries 
 Optimism 
 Pragmatism 
Diabetes and HIV Implications of comorbidity 
 Concerns / worries 
 Disclosure 
 Medication Issues 
 
Table 3.30: Interview Analysis: Development of Body Image Themes 
General Body Image Acceptance or positive views 
 Unhappiness with  body image 
 HIV-specific 
African Attitudes General 
 HIV-specific 
 Changing Attitudes 
Gay Male Body Image General 
 HIV-specific 
 
Table 3.31: Interview Analysis: Development of Lifestyle Themes 
Behaviour Examples Healthier  
 Less Healthy  






Opportunity to change,  
e.g. physical activity 






Motivation to change,  












Table 3.32: Interview Analysis: Development of Support Themes 
Support Types of support received 
Participation with Others 
 Active Support from Others 
 Lack of Support from Others 
Isolation Seeking Support to Circumvent Isolation 
 Opposition from Others 
 Physical Isolation 
 Social Isolation 
 
Table 3.33: Interview Analysis: Development of Bear Themes 
Bear Identity Definitions 
 Culture 




Table 3.34: Interview Analysis: Development of Intervention Design Themes (Process Analysis) 
Recruitment Advertising 
 Methods of contact 
Logistics Clinical Research Facility 
 Duration of Intervention 
Measurement of Primary 
Outcome 
Attitudes to FSLMTT 
Support Frequency of review 
 Flexibility of appointments 
Participant Information Appreciative opinion 
 Critical opinion 
Future Design New technologies 
 Delivery 
 
Table 3.35: Interview Analysis: Development of Research Participation Themes 
Participation in this 
Intervention 
Motivations to participate 
Barriers to participation 
Confidentiality / Disclosure 
HIV-specific Research History of participation  
Motivation to participate 
 Barriers to participation 
 Confidentiality / Disclosure 
Research Participation 
in General 
History of participation in non-HIV 
research 
Attitudes to research in general 
Motivation when not HIV-related 





3.4.7 Health Issues 
 
General Health: 
During the introductory phase of the interview participants were asked broad questions 
regarding their general health. Participants volunteering positive examples of general health 
experiences projected a sense of optimism during the interview. Interviews with those 
participants who focused on negative health experiences were characterised by a sense of 
pessimism. Having a positive outlook on life reflected acceptance of health issues: 
“I’m quite enjoying my life. I’m not going to break down and cry about [health issues], I 
mean I’ve got them. You live with them”. [Interviewee No. 12, male, aged 63]. 
A prevalent theme was negative experience of multiple morbidities and health challenges 
other than HIV. These included arthritis, liver disorders, chronic fatigue, cancer, cardiovascular 
disease, hypertension, chronic pain and vulnerable or chronically poor mental health. 
Participants reported struggling to cope with multiple comorbidities: 
 “I get a lot of pain in my back, I’m blind in my left eye, and in my right eye I’m now 
getting intermittent loss of vision every now and again. And that’s worrying me”. 
[Interviewee No. 2, male, aged 64]. 
“Your mental health does have a knock-on effect with everything, whether it be 
anxiety or depression, whatever it is you’re suffering from at the time. So that’s a big 
obstacle to get over – with me it is”. [Interviewee No. 3, male, aged 44]. 
 
Living with HIV: 
Participants discussed both positive and negative impacts of being diagnosed and living with 
HIV. Acceptance of HIV and rationalisation of the condition as a controlled, quiescent infection 
was associated with a positive attitude: 
“HIV seems to be under control, so no worries there. It’s just very, very routine and uh, 
not a problem”. [Interviewee No. 17, male, aged 67]. 
“I’ve lived with HIV for a long time now and each extra year I live is a bonus”. 





“Now [HIV is undetectable] I can do so many things”. [Interviewee No. 8, female, aged 
48]. 
Others were resigned to the HIV diagnosis but mentioned associated health implications 
including pill burden and social concerns: 
“Having lived with the HIV and obviously [the HIV medicines are] keeping me alive, but 
I do feel that my quality of life has deteriorated”. [Interviewee No. 7, female, aged 49]. 
Prevalent themes were negative aspects of being diagnosed and living with HIV: 
“HIV is my worst nightmare”. [Interviewee No. 13, male, aged 40].  
“You meet someone, a boyfriend or whatever. You mention I’m HIV positive, you start 
seeing them distancing themselves and whatever it is you think is going to happen, 
they leave and it’s really sad”. [Interviewee No. 15, female, aged 42]. 
The health burden of living with HIV was commonly mentioned. This included chronic 
medication side effects including lipodystrophy, changes in skin pigmentation, gastrointestinal 
problems, and the legacy of HIV and opportunistic infections, including peripheral neuropathy, 
scarring, blindness and arthropathy.  
Denial of HIV infection was mentioned as a coping strategy: 
“I’m not thinking of HIV at all. I don’t have it. That is the attitude which I’ve got. I didn’t 
think about it because I don’t have it”. [Interviewee No. 14, female, aged 51]. 
“HIV denial is common among us African people”. [Interviewee No. 4, female, aged 
55]. 
HIV stigma and fear of disclosure of HIV status was a prevalent concern: 
“People they think you are bad, you’ve maybe been sleeping around but as I told you 
before, how I got HIV, I found out I was positive, there was only one partner that I had, 
and I knew straight away where I got my sickness from. People they sort of 
discriminate against you”. [Interviewee No. 7, female, aged 49]. 
“I think the biggest thing for me is disclosure – I have an issue with that. I’ve had bad 






Diagnosis of Prediabetes: 
Almost all participants in both the intervention and interviews were diagnosed with 
prediabetes less than three months prior to participation in this research programme. 
Thematic analysis of reaction to the prediabetes diagnosis indicated polarity of response. 
Interviewees with a more optimistic response to the diagnosis were characterised by surprise 
but resignation or by lack of surprise and acceptance of the diagnosis. These participants 
discussed the potential reversibility of the condition: 
 “So I was surprised to hear that [prediabetes diagnosis] and at the same time not that 
surprised because the thing runs in the family”. [Interviewee No. 8, female, aged 48]. 
 “Not exceptionally concerned no, because as far as I was concerned, something like 
that you can deal with by checking your diet and exercise”. [Interviewee No. 11, male, 
aged 63]. 
Participants with a negative reaction to the diagnosis commonly blamed the HIV medications 
for developing prediabetes. Others blamed poor diet or increasing obesity, alone or in 
combination with medication, with one participant expressing embodiment of feelings: 
“What made me borderline? HIV medication and cakes”. [Interviewee No. 1, male, 
aged 71]. 
“I tend a bit to blame the drugs more than dietary and hereditary factors”. 
[Interviewee No. 22, male, aged 46].  
“I was horrified, a bit outraged actually. How dare my body betray me like this”. 
[Interviewee No. 9, male, aged 60]. 
Those with a negative reaction to the diagnosis of prediabetes mentioned the fear of 
progression to type 2 diabetes itself. Participants talked about direct observation of diabetes-
related morbidity and mortality, where family members and friends experienced loss of vision, 
amputation and premature death. Participants also talked about the diagnosis of prediabetes 
adding to the burden of multiple health concerns. 
 “I’ve got so many health issues, getting other bad news about my health, I don’t feel 






Diagnosis of Type 2 Diabetes: 
Those participants who were diagnosed with T2D itself discussed the impact this had on their 
lives. As with those diagnosed with prediabetes, adding to disease and pill burden were 
common themes: 
 “I’ll be given a bottle of metformin and I’ll have to add that to my pill burden, it’ll be 
another thing”. [Interviewee No. 22, male, aged 46].  
“I’ve got HIV, I’ve got bone problems, and now this diabetes so I might not last long. 
It’s like too much weight for one body. I have HIV but I’ll live until maybe 60 years. But 
now I’ve reduced it to 55. So I felt bad. I sat down and cried, honestly”. [Interviewee 
No. 7, female, aged 49]. 
However reactions to the diabetes diagnosis ranged from this extreme of fearing reduced life 
expectancy to lack of understanding and denial: 
“I think I asked you, does that mean I’ve got to start injecting myself? And of course 
when you said probably not yet well I though that's alright, it’s not serious”. 
[Interviewee No. 12, male, aged 63]. 
 
HIV and Diabetes Together: 
Participants discussed their fear of potential for interaction between both HIV and T2D 
diseases and between their respective medications: 
“I don’t really know if one will react with the other in any way”. [Interviewee No. 16, 
male, aged 71]. 
“Taking HIV and diabetes medicines, so it would be very hard, yeah”. [Interviewee No. 
8, female, aged 48]. 
There was discussion at length regarding which of the two conditions was worse, with a 
spectrum of views from one condition being much more serious than the other or both being 
of equal consequence and burden. Those participants who believed HIV was worse than 





length about his HIV-related kidney disease and how for him this was much more of a health 
priority than diabetes. Interviewees mentioned management of diabetes through diet and 
exercise whereas HIV required daily medication and was potentially transmissible: 
“Diabetes is not as life-threatening as HIV. Diabetes is a disease but I know it can be 
easily tackled with food without taking any medicine. But HIV is not like that, no”. 
[Interviewee No 16, male, aged 71]. 
The relative ease and difficulty of disclosing diagnosis of diabetes and HIV was introduced. One 
participant described how she would not be fearful of telling friends about diabetes as no-one 
would potentially link this with HIV. Another explained that he had truncated the title of the 
research study from “STOP Diabetes in HIV” to “STOP Diabetes”: 
“I told them I was part of a research thing called Stop Diabetes and you had identified 
it through my blood, but not that it was linked with HIV. I don’t tell anyone about that 
at all”. [Interviewee No. 11, male, aged 63]. 
In addition to those who had experienced significant diabetes-related morbidity and mortality 
among family members, diabetes was thought to be worse than HIV by those who had not 
themselves experienced significant HIV-related disease burden: 
 “For me, I think diabetes is probably worse actually. For me, because I’ve been lucky 




3.4.8 Body Image 
 
African Body Image: 
African women who participated in both the phenotype and intervention studies had a higher 
mean BMI than participants of other ethnicities. Interviewees discussed the acceptability and 
social valorisation of larger body sizes among African people. They suggested that in women, 
malnutrition is equated with infertility and conversely overweight and obesity is associated 





Changing attitudes among second generation Africans in the UK were mentioned, where 
pressure to achieve a lower BMI was thought to be more prevalent. Peer pressure among 
African women was mentioned, where during an open discussion about reducing diabetes risk 
deliberate weight loss was discouraged: 
“I said ‘Oh look how big I am’. They said, ‘Oh no, no, no, you’re not big, that is the right 
thing, the good right thing’. I said, ‘I need to lose weight’. They said, ‘no, no, no, don’t 
lose weight’”. [Interviewee No. 14, female, aged 51]. 
The association of thinness with AIDS among African people was an issue. One participant told 
a story about her church congregation in the UK, largely of African origin, where a member 
who was rapidly losing weight was wrongly assumed to be ill with AIDS and subsequently 
isolated socially. Social pressure to remain overweight to mask HIV infection was discussed by 
all women interviewees of African-origin: 
“But if you’re big, people will think, oh you’re normal because you’re big. Yeah, with 
African women some wants to be big you know like, especially if you are HIV positive”. 
[Interviewee No. 4, female, aged 55]. 
 
Body Image Among Gay Men: 
Gay male participants reported pressure to achieve a perceived ideal of a lean muscular body: 
 “Well, I looked at myself side on in the mirror and I thought would you sleep with you 
and I thought no I wouldn’t”. 
 
Not all participants in the intervention were overweight. Those participants with the lowest 
BMIs were gay men who had been living with HIV for many years, exposed to more 
metabolically toxic medications in the past. Development of dysglycaemia was problematic for 
those with lower BMIs who expressed a sense of unfairness that this had happened to them 
when diabetes is largely associated with obesity. Wasting and lipodystrophy were discussed 
and although participants had been living with a self-assessed suboptimal BMI for many years, 





“I don’t want to keep get thinner and thinner – I strive to put on as much weight as I 
can. But what can I do not to lose weight, and at the same time decreasing my sugar 
intake?” [Interviewee No. 1, male, aged 71]. 
 “...what I wanted to do was to work on that and to build up my muscles and things 
like that”. [Interviewee No. 10, male, aged 44]. 
 
Gay Men Who Identify as Bears: 
The sub-section of gay men who reject normative idealised male lean muscularity and adopt a 
hairier, heavier, masculine appearance self-identify as bears (Appendix 7.9). The bear 
community within the gay scene was presented as a supportive non-judgemental 
environment. Participants reported a fun, beer-drinking community, contrasting this with the 
lean body-beautiful aesthetic they felt was predominant among other gay men: 
“I like to go to a bear pub where I know a lot of people and they’re nice people. I’ve 
never been short of people who are attracted to me or think I’m attractive. And so I 
suppose you get a lot of your confidence from that. My partner likes me being a bigger 
guy, yeah”. [Interviewee No. 23, male, aged 41]. 
 “My ex said I was a fake gay man because I didn’t do like the things gay men are 
supposed to do like go to the gym”. [Interviewee No. 22, male, aged 46]. 
A diversity of people was described within the bear culture, with varying body shapes and 
levels of fitness. Participants who identified as bears vocalised a tension between remaining 
overweight to be part of the group whilst acknowledging the health risks that brings: 
 “I mean everyone’s still different even when you’re within a group [bears]. I think 
you’ve got some extremes where people are into really big guys and also like feeding 
and that kind of thing. I have one friend who’s into really big guys, a lot bigger than 
me, and he says he has a moral issue with his preference but also the fact that he 






Remaining immersed within bear culture was seen as a risk for body dysmorphia, where 
continual positive acceptance of being obese was resulting in a loss of perspective. Deliberate 
weight loss, although acknowledged to be healthy, was described negatively, as a loss: 
“Losing weight would take away their bearness. Being a bear is like a licence to be fat”.  
[Interviewee No. 22, aged 46]. 
 
HIV-related Body Image Issues 
Weight gain following initiation of ARVs was an issue for interviewees, with obvious and 
excessive weight gain readily associated with medication commonly mentioned: 
“The weight gain was almost immediately coinciding with the drug, the protease 
inhibitor regime, especially the central weight gain”. [Interviewee No. 22, male, aged 
46]. 
“Being big is one thing every woman doesn’t like. I wasn’t even happy about my size 
because all along I’ve been someone who was small”. [Interviewee No. 7, female, aged 
49]. 
“I have a problem because of the medication I’m taking which makes me put on 
weight… because I know my HIV contribute to my weight”. [Interviewee No. 6, male, 
aged 40]. 
Weight loss, deliberate or unplanned, was reported as problematic. For some interviewees this 
was an HIV-related concern but not for others: 
“For example, if I lose weight, get very small and even if I wasn’t HIV positive, the first 
thing they will point at, that one has got AIDS. Because of the weight you have lost”. 
[Interviewee No. 7, female, aged 49]. 
“Friends hadn’t seen me for about 4 or 5 months, I said to them ‘can you notice any 
difference in me?’ and they said yes your face looks much thinner, you’ve lost weight. 
And I said ‘oh yeah I’m on a special diet for blah blah blah’. I thought, I knew exactly 






“People thinking I was positive because of this weight loss? No. That never crosses my 
mind. People, people ask me if I have cancer”. [Interviewee No. 10, male, aged 44]. 
Body shape changes as a legacy of lipodystrophy were a concern. Central fat accumulation was 
associated with development of diabetes risk: 
“Well borderline diabetes was a shock to start with but it was something I expected 
because I’ve been on medication for the last seventeen years and my body kept on 
changing. I used to get big on the upper part of my body. Normally kept getting big and 
getting smaller on the bottom part of my body”. [Interviewee No. 18, male, aged 45]. 
“Yeah, the fat thing’s horrible cos you don’t want to wear a tight T shirt. It’s 
embarrassing when you go swimming because it stands out as a fat lump”. 
[Interviewee No. 18, male, aged 45]. 
“The HIV medicines. One, my stomach. Some people suspect, every time I go to the 
gym people think I’m pregnant. So that was another problem. In fact, one time I was 
travelling and some lady told me, oh are you going to maternity, antenatal clinic?”  




3.4.9 Enablers and Barriers to Behaviour Change  
 
Enablers and barriers to behaviour change are categorised using the Theoretical Domains 
Framework and COM-B (Michie et al., 2011b, Cane et al., 2012), summarised in Figure 26.  
Knowledge  
Interviewees valued improved knowledge as an enabler to behaviour change. Understanding 
of the importance of good nutrition and regular exercise, healthy and less healthy behaviours, 
and a better understanding of diabetes risk were all highlighted:  
 “We now always try and buy the low calorie, low fat foods, all the spreads are the low 





 “I’m very fond of herring, so one tells oneself it’s terribly good for one but not when 
it’s, you know, sizzling away in butter. In winter time I used to like putting a mutton 
curry together and thinking oh gosh I’m being terribly authentic because I’m using 
ghee but now I know ghee is basically butter”. [Interviewee No. 9, male, aged 60]. 
Conflicting advice from health professionals and from the media, for example advising to take 
medications or products that would have no benefit or potentially an adverse effect, 
negatively impacted on gain in knowledge: 
 “The pharmacist he said [to help lose weight] if I’m drinking water he told me add 
sodium bicarbonate. I should try and put at least a spoon and drink it”. [Interviewee 
No. 7, female, aged 49]. 
“There are too many conflicting evidences about this and that out there. I think a lot of 
people are not too sure. I was drinking loads of Lucozade. I thought you had bad sugars 
and good sugars so I thought glucose was OK”. [Interviewee No. 19, male, aged 57]. 
Participants discussed knowledge of sustainability of behaviour change, commenting that 
drastic changes and traditional weight loss diets are unlikely to be sustainable. This increase in 
efficacy was attributed to maintaining focus across the intervention. 
Skills  
Participants discussed new or enhanced skills as enablers to behaviour change, for example 
improved understanding of nutritional information on food packaging and planning skills. 
Social Role and Identity  
Adopting unfamiliar food habits and eating unfamiliar foods were mentioned as both enablers 
and barriers to change, with participants embracing or avoiding the unfamiliar. 
“Where I come from our diet is based on carbohydrates which is, there is a lot of sugar 
in it. So that is the main food that we have. If I’m not eating that, what else can I eat?” 
[Interviewee No. 8, female, age 48].  
“African food doesn’t taste nice without salt and oil”. [Interviewee No. 4, female, aged 
55]. 
Isolation or the need for peer support as barriers to change were sufficient to discourage 





“I always wanted to go to the gym but was lazy or always want company. I didn’t have 
the motivation to go by myself”. [Interviewee No. 8, female, aged 48]. 
Self-identifying as part of a group and normalising the inevitability of obesity was a barrier to 
change: 
“I’m at that sort of age where you get a gut anyway. You know, I don’t see it as being a 
big deal”. [Interviewee No. 12, aged 63]. 
Beliefs, Capabilities and Self-confidence 
Barriers within this domain were HIV-specific whereas enablers were general in nature. 
Enablers included understanding that change may be difficult at first but that persistence 
delivers results, with success sustaining progress. Interviewees felt that the intervention would 
improve overall health, not just prevent diabetes, and found this motivating. Belief that food 
can act as a health enabler was mentioned as an enabler by one participant: 
“OK I would say food is a medicine. Before if I eat vegetables, if I don't eat vegetables, 
it doesn’t matter. All I knew of is weight. People tell you this or that thing makes you 
put on weight. But this six months, I’ve realised that your eating habits also really help 
in my so many sicknesses, something like that, yeah helps fight diseases for you”. 
[Interviewee No. 7, female, aged 49]. 
In terms of barriers, participants with HIV-related illness such as peripheral neuropathy were 
not used to doing physical activity: 
“I started one session but I was sick, I have joint pain because I’m not exercising for 
years. So with the job I can’t cope with that so I stop”. [Interviewee No. 6, male, aged 
40]. 
Participants reported not being able to invest in lifestyle change, believing this was futile given 
the legacy of HIV infection and ARV side effects: 
“I really thought it was just like as you get older and you’re on these drugs, this 
[diabetes] is just going to happen. There’s nothing you can do. You can try to be 
healthy but you’re not going to avoid it, it’s just going to happen. So I actually thought 
I’d probably just go on metformin. I was like, you know, let’s treat it medically, it’s 





Participants with lower BMIs felt that with HIV-related weight loss the intervention was 
personally less relevant. Lipodystrophy was cited as a barrier to exercising, with interviewees 
expressing embarrassment about their body shape. 
Optimism 
Optimism was associated with enablement to lifestyle change. Interviewees talked about 
enjoying changing eating behaviours, interest in trying new or different foods or enjoying the 
challenge of trying out different methods of physical activity. Pleasure was expressed 
regarding eating healthier foods. Optimism was associated with resilience in the intervention: 
“And so there is a feeling that I should um you know, take this opportunity. So when 
you told me that on the phone [about prediabetes] I was surprised but then I was 
thinking, oh well actually this is good I can do something”. [Interviewee No. 22, male, 
aged 46]. 
 
Beliefs about Consequences and Outcomes 
Although the intervention was designed to reduce diabetes risk it could have a positive impact 
on a wider range of health issues. This was an enabler to change for participants with 
comorbidities. The desire to prevent diabetes was a motivator, particularly for those who had 
observed diabetes-related morbidity or mortality among friends or family members. The 
recognition that progression to diabetes was not inevitable and that lifestyle change could 
reduce risk was described as a powerful motivator: 
“It doesn’t just get rid of a fat belly um it actually is good for the heart and I think it 
might be good for one mentally as well”. [Interviewee No. 9, aged 60]. 
“You know, I want to control it before I get to a stage where I have to take insulin or 
something”. [Interviewee No. 15, aged 42]. 
“You can’t do anything about HIV, you can’t take the blood off from your body and get 
new blood. But with diabetic, you can avoid it”. [Interviewee No. 14, aged 51]. 
An HIV-related enabler was avoiding the consequence of adding to pill burden through 





“To have to start diabetes medicine as well, on top of the HIV ones. And I thought that 
is going to be like very hard. And it was hard for me as well to be on the HIV one 
because I’m not used of taking medicine as well. And like to take everything every day, 
regularly, is very hard. Yeah, so if I would have like gone over, my sugar level was high 
and I am diabetic, I have to take that one, I don’t know, maybe regularly as well it 
would have been very hard, yeah and it would have been very hard”. [Interviewee No. 
8, female, aged 48]. 
Similarly concerns about disclosure of HIV status through deliberate weight loss were 
sufficiently powerful to lead to declining to participate in the intervention. Additionally, weight 
loss was believed to indicate AIDS-related wasting. The strength of emotion regarding this was 
sufficient to lead to the desire to reverse successful loss of weight on exiting the 6-month 
intervention: 
Interviewer: “You said that you were happy that you were reducing your risk of 
diabetes, is that right?” 
Interviewee: “Right, but I wasn’t happy with the effect on my face. I’d rather have 
diabetes and a full face. Because you have to have fillers that need to be done every 
month, and eventually you got to pay for them and they’re not cheap. So I’d rather be 
a diabetic injecting myself every day, than look like I look now.” 
Interviewer: “How do you feel about how you look now?” 
Interviewee: “Shit. I look in the mirror! I see a gaunt looking face that I didn’t have 
before I started this.” 
Interviewer: “Ok, what are you going to do over the next few months now you’ve 
finished?” 
Interviewee: “Eat as much crap as I can to put weight on. I ate 2 boxes of Maltesers 
last night.” [Interviewee No. 2, male, aged 64]. 
Reinforcement, Incentives and Punishment  
Enablers within these domains were general and not HIV-specific. Participants found ways 





New approaches to shopping, cooking and exercising were reported as less expensive, and an 
incentive to continue with the intervention: 
“I stopped driving, that’s the first thing. I stopped driving everywhere, cos I was 
walking. So I saved money on the fuel. That’s the first thing that sort of like balanced 
out the expense of the fruit and veg initially. And afterwards, I discovered that if I go to 
the fruit and vegetable markets, on the Sunday, I can buy the fruits and vegetables I 
need for the week. I can buy at probably a third of the price in the supermarket”. 
[Interviewee No. 15, female, aged 42]. 
For those who were relatively isolated, frequent contact with health professionals was an 
enabler to ongoing participation. Exercising was a means to increase social interaction as well 
as improving mental health: 
“So that come in handy, the exercise and, and talking to people. Because it helps me a 
lot when I get out and talk”. [Interviewee No. 10, male, aged 44]. 
An emotionally strong enabler was the desire to get back into shape, particularly for those who 
were previously fit. A practical incentive to achieve pedometer step goals was the realisation 
that during the London rush hour it is often quicker to walk than take public transport: 
“You know, I would have just jumped on the bus. But now I don’t mind walking back 
and forth to the station, it’s not that far. It’s quicker and I quite enjoy it. Walking you 
see a lot more as well”. [Interviewee No. 16, male, aged 71]. 
Intentions 
Within this domain enablers to change included commitment to succeed during the 
intervention as participants who had not performed well during the first three months wanted 
to know if they had developed type 2 diabetes. There was also a desire in general to tackle 
obesity. The link between obesity, diabetes and reduced life expectancy had been made and 
participants expressed the desire to live longer to see their grandchildren grow up. 
Barriers to participation and changing behaviour included a general lack of commitment and 
lack of willpower. Participants recognised that behaviours needed to change and that diabetes 







The intervention was designed with 10 goals to achieve. This was appreciated by participants, 
particularly those with mental health challenges and those with physical disability: 
 “The motivation is the scheme – having goals set is really important”. [Interviewee No. 
3, male, aged 44]. 
"I was guilty of the sin of pride achieving daily goals. I was guilty of the sin of pride 
when my waist got smaller and smaller and, um, I was guilty of the sin of pride when I 
was getting close to averaging 10,000 a day”. [Interviewee No. 9, male, aged 60]. 
“To do the six months, it motivated me quite a lot, and especially the chats because I 
was saying ah, I want to meet my 10,000 goal”. [Interviewee No. 14, female, aged 51]. 
“Well I mean I, I’m hooked on it. When I did, you know, that 14,000 steps one day, I 
was staggered”. [Interviewee No. 17, male, aged 67]. 
Memory, Attention and Decision Processes  
Within this domain barriers to participation and achievement of goals included HIV-related 
memory loss. This was a factor in the decision not to participate in the intervention. It was felt 
that achieving daily goals and attending appointments would be stressful given the degree of 
memory loss experienced: 
“I just kind of feel I’ve missed so many appointments, um, I’m not certain why I’ve 
missed them. There was something that was showing up on the blood test – the 
cholesterol – it was something to do with the liver. I can’t remember – it was 
something that was abnormally high. They did it at the GP surgery, and I had three 
tests, and then they made an appointment for an ultrasound, and I got the dates all 
mixed up. I mean I was going, but in the end it was like I just got it all mixed up. I’m not 
so good at keeping appointments or making commitments to things any more”. 
[Interviewee No. 5, male, aged 63]. 
Within the trial, participants with impaired memory were able to achieve goals through use of 





The relative chaos in daily living experienced by some people living with HIV was cited as a 
barrier to change, in terms of the effect on attention to achieving goals and overall decision 
making. However, through careful attention they were able to overcome this barrier: 
 “I was a bit more careful of what I was eating. I paid a bit more attention to the food 
in front of me than I used to do. Doing this study made me think before I ate 
something”. [Interviewee No. 2, male, aged 64]. 
Environmental Context and Resources  
Logistics were found to be both barriers and enablers to change. Some found the location easy 
to get to whereas others found the distance problematic. Work life prevented participation 
where time off to attend research appointments would either not be granted or would result 
in the participant being compelled to disclose health issues. Work pressures limited ability to 
adopt healthier eating behaviours and the ability to exercise. However, careful attention to 
this, particularly seeking support from colleagues, proved to be an enabler. Here participants 
felt able to disclose to colleagues and managers risk of diabetes but not HIV status. 
Barriers to participation included attending too many healthcare appointments at present. It 
was felt that regular research appointments would add to this burden. Additionally, a feeling 
that too much was happening in life in general was a barrier to committing to taking part. 
Healthier foods were generally perceived to be more expensive. For example among African-
origin participants increasing consumption of leafy green vegetables was prohibitively 
expensive for those who ate imported African greens exclusively. Some African participants 
found cheaper UK-grown greens acceptable, as did those of Caribbean-origin. Participants 
talked about strategies to limit this extra expense but for most this continued to present as a 
barrier. Reimbursement of travel expenses was appreciated as an enabler to participation. 
Weather, rain, cold and extremes of heat, and fewer hours of daylight in the winter were 
reported to limit the ability to exercise. 
Social Influences and Group Norms 
Social life both enabled and prevented change: 
"And then it comes to lunch. I have with me my creatively designed with all colours in 





“It’s very, very difficult to give these up especially when you go to some party. They 
will give you more sweets and you have to say them ok control, control, you shouldn’t 
eat that but that won’t come all of a sudden”. [Interviewee No. 13, male, aged 40]. 
Drinking culture in pubs and clubs was challenging for those who habitually consumed higher 
amounts of alcohol.  Eating with family was a barrier to change:  
“My son who loves, enjoys me having that fish and chips on a Friday and some of my 
grandchildren’s food cos sometimes I eat with my grandchildren. So I had to sort of 
reduce eating with them. Cos their food is normally a lot fattier and all that”. 
[Interviewee No. 4, female, aged 55]. 
Societal pressure to lose weight and attain a normal BMI was evident as a motivator. 
“I looked at myself side on in the mirror and I thought would you sleep with you and I 
thought no I wouldn’t”. [Interviewee No. 9, male, aged 60]. 
“It was good and it has made me lose weight and made me look even, yeah, it makes 
me look even younger, let me say”. [Interviewee No. 8, female, aged 48]. 
Among gay men who self-identified as bears, lack of partner support, positive acceptance of 
overweight and the confidence gained from having a higher BMI and being attractive were 
barriers to change, limiting motivation to lose weight: 
“My partner likes me being a bigger guy. A few months in when I was struggling and I 
mentioned, he said, well, you know, I told you, I told you not to do this and you 
ignored me”. [Interviewee No. 23, aged 41]. 
Emotions, Anxiety and Fears  
Fear of developing diabetes was a powerful motivator to change behaviour. Other factors 
within this domain were HIV-specific. Fear that deliberate weight loss would disclose HIV 
status was a barrier to achieving goals. Concerns about confidentiality and disclosure of HIV 
status, and trial participation being a constant unwelcome reminder of living with HIV were 







Behavioural Regulation and Self-monitoring  
For those with an external health locus of control the pedometer was cited as a useful tool to 
self-monitor physical activity levels, particularly as a way to gradually increase towards or 
maintain goals. In terms of healthier eating, planning, eating in moderation, and a stepwise 
approach were all enablers to change: 
“So it was just finding means of, as opposed to having excuses, I started thinking OK, 
here’s a challenge but how can I make it work? So I did not use excuses. I found 
solutions for the challenges and to me it was a vegetable market. So Sunday take my 
little trolley instead of getting into a car and walk to the market and pick up all sorts of 
different fruit and vegetables for whatever’s planned on my menu for the week. So I’m 
not wasting money going into the express supermarkets. I’ve got everything at home. 
Buying things randomly you end up spending a whole lot of money”. [Interviewee No. 
15, female, aged 42]. 
“But if you eat smaller proportions, portions, model yourself on our dear Queen. If she 
can stay thin, so can we”. [Interviewee No. 11, male, aged 63]. 
“What I do now is I don’t eat them as often. Steak and kidney pudding with mash. 
Then I won’t have that for another fortnight”. [Interviewee No. 3, male, aged 44]. 
 
 
Synthesis of Enablers and Barriers: 
General Enablers 
Having positive beliefs, self-confidence and an optimistic approach were key to successfully 
achieving goals. A belief that lifestyle change could reduce disease risk and a desire to prevent 
diabetes had a positive impact. Societal pressure to lose weight was evident as a motivator to 
change. Improved knowledge and skills, overcoming isolation, commitment to succeed and a 
desire to tackle obesity were strong enablers. Planning, a stepwise approach and use of a 
pedometer as a tool to monitor building towards and achievement of goals were enablers. 







Cultural and societal barriers included the societal valorisation of obesity in African cultures 
and among gay men identifying as bears. Lack of support from partners, friends and the wider 
community was problematic. Conflicting advice regarding healthier options and behaviours 
was cited as a barrier. Healthier foods were perceived to be more expensive and, for some, 
unfamiliar. Lack of commitment and willpower were significant barriers to change. An excess 
of external pressures at work or home, bad weather and fewer daylight hours in the winter 
months and pressures in social life all limited ability to change behaviours. 
HIV-specific Enablers 
Those who felt that HIV was largely controlled and a lesser health burden compared to 
diabetes were motivated to change behaviours. Avoiding adding to pill burden was an enabler. 
HIV-specific Barriers 
Those who felt diabetes was a lesser health concern compared to HIV were less motivated to 
change behaviours. Across ethnicities but particularly among the African community, thinness 
may be associated with AIDS and this fear of disclosure of HIV status or association with 
memories of AIDS acted as a barrier to achieving weight loss goals. Lipodystrophy, HIV-related 
memory loss, a lower BMI secondary to HIV-related illness and HIV-related illnesses 
themselves all limited ability to change behaviour. Lifestyle change was considered futile given 













Figure 27: Enablers and Barriers to Lifestyle Change 
 
 








- Societal pressure to lose weight
- Improved knowledge
- Overcome isolation 
- Desire to tackle obesity
- Planning ahead
- Stepwise approach
- Use of tools e.g. pedometer
- Ease of access to intervention
- Support from others
HIV-specific Enablers
- HIV a lesser health concern 
compared to diabetes
- Prevention of diabetes avoids 
adding to HIV pill burden
General Barriers
- Societal valorisation of obesity in 
African cultures
- Societal valorisation of obesity 
among gay men identifying as bears
- Conflicting advice from 
professionals or society
- Healthier options more expensive
- Healthier options unfamiliar
- Lack of willpower
- Work or home pressures
- Bad weather or winter darkness
- Social pressures
- Lack of support
HIV-specific Barriers
- Diabetes a lesser health concern 
compared to HIV
- Fear that deliberate weight loss 
might disclose HIV status
- Weight loss associated with AIDS
- Lipodystrophy limits exercise
- HIV-related memory loss
- HIV-related illness limits exercise
- Futility of change given legacy of 






Interviewees found methods of recruitment to the study acceptable. Detailed description of 
study procedures, time commitment and explanation of potential benefit and risk was 
appreciated. Opinion was divided regarding patient information. The patient information 
leaflet was overly-long and complex for some, whereas others reported reading it through 
from start to finish and finding it helpful. Food diaries were problematic for some to complete, 
whereas others reported finding them helpful as a tool to aid dietary change: 
“I’m not sure if the food diary was mentioned to me at the start. I found that a bloody 
nuisance. I’d forget to write down what I’d had, and I’d have to scribble down on bits 
of envelopes. I then had to transfer and keep checking the book. I found it just a bit… a 
bit too much”. [Interviewee No. 2, male, aged 64]. 
“I won’t say I’m OCD but once I get going, I like to note everything down. The food 
diary was quite interesting. I find it quite interesting to see what, and to note what one 
does eat and how often and what, that sort of thing. It was quite an interesting piece 
of work really”. [Interviewee No. 11, male, aged 63]. 
Typical duration for the visit on Day 1 was four hours. The Frequently Sampled Liquid Meal 
Tolerance Test (FSLMTT) procedure itself was 3 hours 15 minutes, assuming initial cannulation 
was successful. In total 90ml blood was taken via the cannula. Interviewees again offered a 
spectrum of views, from no concerns or issues to the procedure through a middle ground of 
dislike of phlebotomy but resignation to the necessity of the test, to an outspoken intolerance 
of the procedure: 
“I must admit, it didn’t bother me. I mean, they’ve taken so much blood over the 
years, it’s no big deal”. [Interviewee No. 12, male, aged 63]. 
“A nightmare… This one was maybe three hours. So that was the part of it. It was the 
fact that the needle was in my arm all the time and the blood being pulling. I would 
wish that it could have done in a shorter time”. [Interviewee No. 10, male, aged 44]. 
Questionnaires were largely acceptable. They were reported as being fun and a distraction 
from the 3-hour blood test although some interviewees found questions regarding sexual 
functioning and financial position intrusive.  
Regarding intervention design participants found the frequency of the monthly appointments 





appointments. Interviewees who declined to take part in the intervention attributed in part 
this decision to being unwilling or unable to attend monthly appointments: 
“Well in my case just having to drag myself up there regularly during the rush hour 
when I’ve fasted because I find fasting very very difficult because I don’t have the 
reserves of fat, so when I fast I’m really really hungry and I feel weak”. [Interviewee 
No. 1, male. Aged 71]. 
Food samples provided on Day 30 were found useful to explore reduced fat, reduced salt or 
wholegrain alternatives. Interviewees valued the opportunity to try foods outside their usual 
consumption. Some anxieties were expressed regarding receipt of free samples and the cost 
involved to the funder of the study. Use of the Clinical Research Facility for appointments and 
joint support from myself and the research nurse, described by the participants as 
collaboration, was particularly welcomed: 
“Very relaxed. Very nice environment. Felt quite at home”. [Interviewee No. 2, male, 
aged 67].  
“It was seeing a place like this which was very quiet in comparison to the rest of the 
world, the surrounding hospital”. [Participant No 11, male, aged 63]. 
“We were chatting and all, all of us were participating. I feel a part of what was going 
on”. [Interviewee No 10, male, aged 44]. 
Behaviour change techniques were largely acceptable, with interviewees appreciating the 
stepwise approach to achieving goals. However, a more directive and educational model was 
also suggested: 
“I think there is a degree where you would need some kind of intervention. Not so 
much people coming back all the time to be measured and weighed but you know like 
a trainer that you work out with three times a week or something that forces the 
average person to do this who just isn’t naturally inclined to do it. I think that would be 
great. You’re talking about gyms or trainers, that’s really expensive. If we’re talking 
about skyping with a dietary counsellor, I think that would be cost-effective, probably”. 





Support from myself was appreciated, as were motivational and reminder texts and emails. 
Interviewees suggested additional support from exercise instructors, online resources and 
group sessions: 
“So it’s actually touched in so many different parts of my life you know, that, which I 
could have never done on my own, without this and without your support”. 
[Interviewee No. 15, female, aged 42]. 
“Maybe have other things tied into it, like a gym group, or an exercise group, or having 
contacts that people can then contact themselves. Because if they approach an 
organisation themselves, that is self-motivating”. [Interviewee No. 3, male, aged 44]. 
 
3.4.11 Attitudes to Research Participation 
 
The interviewees’ motivation for research participation was for reasons of altruism and 
directly described personal benefit. Rather than one or the other most participants mentioned 
a combination of the two motivators for participating in this and other research studies: 
“What I’m doing might help people further down the line. I’m on my way out, so, for 
the younger people that are coming in with these problems, what I’m doing may help 
them”. [Interviewee No. 2, male, aged 64]. 
“If I think the research will benefit me and it’s not going to be a huge burden, I’ll 
consider it”. [Interviewee No. 22, male, aged 46]. 
“I think a lot of people think it might be no benefit to them, but I think all increased 
knowledge is beneficial to me”. [Interviewee No. 19, male, aged 57]. 
Practical barriers to research participation were mentioned, including logistic issues such as 
difficulty taking time off work and financial issues despite being able to reclaim travel costs. 
Participation in commercial product development studies was compared with medical 
research, with the suggestion made that financial incentives might encourage research 
involvement. Interviewees suggested offering evening or weekend research appointments. 
Confusing or over-technical participant information was a barrier to participation, with 
interviewees stating that they were unlikely to read large documents. Participants also 





the desire to find out more about the effects of HIV and HIV medicines and the potential to 
find a cure for HIV. The frequency of extra support and monitoring was described as reassuring 
by participants who had lived with HIV for a longer duration and previously experienced illness 
and side effects. Barriers included being reminded about HIV-related illness: 
“I think Mae West once said it’s better to be looked over than overlooked [laughs]. 
And I think it’s that sort of situation really with research, you know”. [Interviewee No. 
17, male, aged 67]. 
“The other problem I think is, particularly with something like HIV and diabetes, is that 
if you’re doing the research it constantly reminds you that you’ve got something 
wrong with you and you might want to ignore it. That’s a sort of psychological thing 
that if you’re taking part in the research, that means you’re ill and you can’t ignore it”. 
[Interviewee No. 21, male, aged 59]. 
Participants discussed avoidance of participation in trials of HIV medicines. Experiences from 
previous trials had been unfortunate for some and others were wary of the level of 
invasiveness of the study: 
“I don’t like those medicine studies because I don’t know what they are trying on me”.   
[Interviewee No. 8, female, aged 48]. 
“When we talked I found out it’s nothing to do with anything being put in my body. It’s 
just taking blood out and testing on it and me making changes here and there. I was 
happy doing that because it did not involve me consuming anything that’s artificial into 
my body”. [Interviewee No. 15, female, aged 42]. 
Experience by a sub-group of participation in previous research studies was mixed. Participants 
described taking part in trials of new HIV medicines and how they felt this had kept them alive, 
whereas others described more negative experiences with unfortunate side-effects, attributing 
this historic exposure to current poor health: 
“I was asked by [Doctor’s name] to do the hepatitis C trial. God, I wish I’d said no. It 
was the worst time of my entire life. Diarrhoea, vomiting, everything, you name it. I 
suffer for the year or 53 weeks or something, I can’t remember how long. But it’s 





Research participation was described as fun by some. The social aspect of contact with health 
professionals was valued. Others wanted to participate but felt disenfranchised by being over 
the eligible age limit for most studies or felt they had been used:  
“I felt a bit like I was being treated well when I was of interest and then I kind of got 
dumped when I wasn’t eligible, and I think there is something there about making sure 
people don’t feel like they’re being used”. [Interviewee No. 23, male, aged 41]. 
Confidentiality was paramount for participants. Reassurance of non-disclosure of status, use of 
identity codes rather than names when recording study data, sensitivity to methods of contact 
and confidentiality when disseminating findings were all mentioned as facilitators to research 
participation:  
“I need to keep it to myself. I don’t want to tell for everybody. It’s, [HIV] it’s 
confidential”. [Interviewee No. 20, male, aged 50]. 
“I remember my worry was, the first question I asked you is I don’t want my status of 
HIV to come open, and you say no, everything is confidential. So after you’ve told me, I 
was like comfortable with everything”. [Interviewee No. 7, female, aged 49]. 
“And then also even though I knew it’s confidential, at the back of your mind you’re 
kind of like thinking who else is going to be looking at this information. I know you sort 
of explained to me that it’s all confidential and we number each person by number as 
opposed to a name. But still at the back of my mind I was kind of thinking to myself oh, 
it’s just one of those tricks those people use”. [Interviewee No. 15, female, aged 42]. 
Fear of disclosure of HIV status prevented participation in this study: 
“I wouldn’t have felt I’d been able to do it because I might have to explain to people at 
work what I was doing and I wouldn’t necessarily want to do that”. [Interviewee No. 
18, male, aged 45]. 
Interviewees suggested that to encourage others to take part in research, clear explanation of 
benefit and risk should be made. Dissemination of results to participants was felt to be key. To 
improve recruitment to studies, interviewees suggested that patients should be approached 






3.4.12 Overarching Typologies 
 
Typologies were developed to apply a range of phenomena to categories of participant. For 
this exercise those who were withdrawn from the study were not included as their response to 
the intervention is unknown. The remaining 16 participants included in the typology were 
comprised of 4 who declined to take part in the intervention, 4 who completed the 
intervention achieving 2 or fewer goals and therefore classified as poor achievers, and 8 who 
completed the intervention performing moderately or well by achieving 3 or more goals. The 
typology constructed has multiple linkages where more than one position from each 
dimension is found in certain cells (Table 3.36). 
















Lack of success blamed 
on HIV medicines, 
HIV-related illness, or 
social pressures 
Internal: 
Recognised diabetes risk 
could be mitigated through 
change in own behaviour 
Identity Not applicable Weight loss was  
associated with loss of 
identity 
Weight loss not associated 
with loss of identity 
OR 
Content with change in 




HIV worse than 
diabetes 
HIV worse than diabetes 
OR  
Same as each other but 
unmanageable 
Diabetes worse than HIV 
OR 
Same as each other but 
manageable 
Support Somewhat or 
completely isolated 
Limited support or 
opposition  
High level of support  
 
Priorities Trivialisation of 
diabetes risk and 
prioritisation of 
other issues 
Prioritisation of keeping 
HIV secret 
Participants prioritised 
overcoming barriers through 
self-efficacy or with support 
 
Those Who Declined to Take Part in the Intervention: 
Using this typology those participants who declined to take part in the intervention were 
characterised by a sense of loss of control over their health. HIV medicines were blamed for 
their increased diabetes risk and weight issues, either obesity or underweight. They expressed 





“I think most diabetics it’s their own fault, so I’m very annoyed if you think I might get it, 
because I think I’m a very sensible eater, and my lifestyle is pretty good”. [Interviewee No 
1, male, aged 71].  
“Well I knew that as soon as I went on a protease inhibitor based regime that it [diabetes 
risk] would go up. [Interviewee No. 22, male, aged 46]. 
HIV was felt to be a more serious condition than type 2 diabetes. Diabetes as a condition was 
trivialised or deprioritised. Other issues were given priority, including relatively minor health 
concerns. Those who declined to take part were also either profoundly self-isolating from 
society or tended to self-isolate with interactions limited to partners or online. 
Those Who Achieved Intervention Goals Poorly 
Those participants who achieved 2 or fewer of the 10 intervention goals were also 
characterised by a sense of loss of control over their health. HIV medicines were blamed for 
their underachievement in the intervention along with HIV-related illness and social issues 
such as pressure of work. Deliberate loss of weight, an intervention goal, was associated with 
loss of identity. Here, being overweight was self-identified as an attribute within the bear or 
African communities. They had expressed relative contentment with body image before 
embarking in the intervention: 
“Well I’m not vain about that [body shape before intervention]. No it doesn’t bother me. 
For 67, not too bad”. [Interviewee No. 17, male, aged 67]. 
HIV was believed to be either a more serious or equal health concern compared to type 2 
diabetes. A lack of support or indeed opposition to achieving intervention goals characterised 
this group. Additionally they sought less support from health professionals throughout the 
intervention. In terms of barriers to change, this group was characterised by a either a fear of 
disclosure of HIV status through deliberate weight loss or, in the absence of this, limited self-
efficacy. 
Those Who Achieved Intervention Goals Moderately or Well 
Those participants who achieved 3 or more of the 10 intervention goals were characterised by 
a sense of control over their health. They recognised the possibility of mitigating diabetes risk 





change. Deliberate weight loss was not associated with loss of identity or for those who 
recognised this was a possibility, they came to terms with this: 
“I don’t need the approval of other people to the extent that I would put my health at 
risk to maintain an unhealthy shape”. [Interviewee No. 23, male, aged 41]. 
Diabetes was felt to be either a more serious health concern than HIV or of equal concern to 
HIV. However, both were considered to be manageable. There was a high level of support from 
others, or a high level of support sought from health professionals from those who were 
relatively isolated. 
Implications of typologies are discussed in Section 4.4, along with a general discussion of 





4   DISCUSSION 
 
4.1   Principal Findings 
 
In this thesis I have presented, to the best of my knowledge from literature and trial registry 
reviews, the first cross-sectional study describing in detail the phenotype of dysglycaemia in 
people living with HIV in the UK, a diet and exercise intervention specifically designed to 
reduce insulin resistance in people living with both HIV and prediabetes and an in-depth 
investigation of attitudes to diet and exercise change in people living with HIV. In this section I 
have presented a summary of key findings, and subsequently discuss each of these in turn. 
In this ethnically diverse antiretroviral-experienced London-based HIV cohort, type 2 diabetes 
was highly prevalent. In 2005, 6.8% had been diagnosed with T2D and by 2015 this figure was 
15.1%. This compares with a London-wide prevalence of T2D of 4.5% in 2005 rising to 6.0% in 
2015 (Diabetes UK, 2015). Almost two-thirds of the 2015 HIV cohort had central obesity, four 
out of ten had hypertension and three out of ten metabolic syndrome.  
Logistic regression analysis suggested that the conventional risk factors hepatic steatosis (OR 
7.28) and hypertension (OR 2.58) made a greater contribution to association with risk of 
dysglycaemia than other factors. HIV-specific factors also contributed to dysglycaemia risk, 
principally weight gain in the first year following initiation of anti-HIV therapy and duration of 
HIV infection. Modifiable factors made a significantly greater contribution to association with 
risk of dysglycaemia than fixed factors (probability of predicting dysglycaemia 0.838 and 0.752 
respectively, p=0.029 for difference in proportions), suggesting that lifestyle change mitigating 
hepatic steatosis and hypertension through weight loss has an important role in diabetes 
prevention among people living with HIV. 
The 28 participants with prediabetes and HIV who completed the 6-month diet and physical 
activity intervention experienced a mean reduction in weight of 4.1 kg (4.7%) and waist 6.6cm 
(6.2%). Following the lifestyle intervention these clinically significant outcomes were 
‘the effectiveness of the pilot intervention demonstrates the 





accompanied by reductions in fasting levels and 3-hour incremental area under the curve for 
insulin and glucose, the HOMA insulin resistance index and the glucose disposal rate calculated 
using the Mari method. Significant reductions were made in other secondary outcomes 
including percentage body fat, triglyceride levels and blood pressure, and significant increases 
in HDL and life satisfaction. 
The intervention was largely acceptable to participants. Confidentiality issues and fear of 
disclosure of HIV status were key themes emerging from interviews. There was a diversity of 
achievement of intervention goals within the 28 intervention participants; the qualitative 
research study identified enablers and barriers to achievement of diet and exercise change.  
Those who declined participation or achieved fewer intervention goals blamed diabetes risk on 
HIV medicines, and inability to adopt healthier lifestyle behaviours on external factors such as 
bad weather or financial barriers. They were characterised by an external health locus of 
control, and prioritised factors other than diabetes risk-related health. Those who achieved 
more goals expressed an internal health locus of control. They considered prediabetes 
treatable and type 2 diabetes avoidable. They found ways to prioritise overcoming barriers, 
either through internal health locus of control or through seeking support. 
The most prominent enablers to lifestyle change were a desire to avoid adding to pill or 
disease burden and a strong support network. The most significant barriers were fear of 
deliberate weight loss leading to loss of cultural identity and disclosure of HIV status.  
 
4.2 Phenotype of Dysglycaemia in HIV 
 
4.2.1 Discussion of Results 
 
This study aimed to describe the phenotype of prediabetes and type 2 diabetes in people living 
with HIV in the UK and how this has changed over time. In summary, approximately 1 in 3 of 
this ethnically diverse, London-based cohort had prediabetes or T2D. Comparing data with that 
collected 10 years earlier T2D prevalence was observed to have more than doubled from 6.8% 
to 15.1%. A range of HIV-specific and conventional risk factors appears to be associated with 
this disproportionate increase in T2D, with the modifiable risk factors hepatic steatosis and 






The 2015 cohort reflected the diversity of people living with HIV in the UK, with 2014 figures 
for the UK previously described on page 21. The use of ARVs was widespread in this cohort, 
exceeding the WHO target of 90% of PLWH receiving therapy. The prevalence of 
undernutrition was very low at 2.4%, reflecting the benefits of successful ARV treatment, prior 
to which rates of undernutrition were 10 times as high, as described in Table 1.4. Conversely, 
the rates of overweight and obesity were 58.0% in 2015 compared to 47.9% ten years earlier, 
now comparable to the 58.4% rate in the general London population (Public Health England, 
2015b). The cohort experienced considerable metabolic burden, with high rates of 
hypertension, hyperlipidaemia requiring statin therapy and central obesity. These contributing 
factors resulted in a metabolic syndrome prevalence of almost one third. This metabolic 
burden is greater than that published by investigators from two large studies of people living 
with HIV, one from the USA and one multinational, where the prevalence of overweight and 
obesity was 25% and 43% respectively (Willig et al., 2015, Yuh et al., 2015). This observed 
difference may be due to the diversity of ethnicity in the UK cohort where non-Whites 
comprise the majority, compared to the USA and multinational cohorts where White 
participants comprise the majority. Hypertension and obesity are more common in African and 
Caribbean origin people living in the UK (Public Health England, 2015b). This appears to be 
polarised among participants in this HIV study, where, for example, 16.6% of White women 
were overweight or obese, compared to 84.3% of Black African women. 
Health habits of this HIV cohort differ from those of the general London population. Although 
smoking rates in this cohort were significantly lower in 2015 compared to 2005, at 21.0% they 
remain higher than the overall London rates of 17% (Public Health England, 2015b). Almost 
one half of participants are sedentary, compared to a London-wide rate of one quarter (Public 
Health England, 2015b). However, these comparisons should be treated with caution as 
sampling and data collection methods were different. The reduction in rates of smoking is 
significant among a population at higher risk for CVD and cancer, as described earlier in Table 
1.3. However, encouraging physical activity should be a key message for self-care. 
Prevalence of Dysglycaemia 
The burden of prediabetes in this cohort appears to have remained steady with an 18.1% 
prevalence in 2005 compared to 17.2% in 2015, whereas T2D appears to be highly prevalent, 





general London population is around 6%. However, the median age of Londoners is 39 years, 
10 years younger than this HIV cohort. Diabetes prevalence data from the general England and 
Wales population has been stratified by 10-year age band (Diabetes UK, 2015). The prevalence 
of T2D among those aged 40-49 and 50-59 in England and Wales is 10.7% and 18.9% 
respectively. This compares to a prevalence from this HIV cohort of 13.9% and 19.2% 
respectively. I have presented these comparisons for illustrative purposes only, as without 
recruiting HIV negative participants and matching them to HIV positive participants by age, 
gender, ethnicity, and BMI, for example, the value of extrapolating population comparisons is 
extremely limited. 
There is little published information about changes in prevalence of T2D in PLWH elsewhere, 
but a change in incidence of T2D has been observed in an ethnically diverse HIV cohort in 
France (Capeau et al., 2012). Investigators reported an incidence of T2D of 2.7 per 1000 person 
years of follow up in 2005, rising to 5.0 in 2009. This rise in incidence was associated with age 
and obesity, and historic exposure to ARVs linked with metabolic toxicities. A study of a Danish 
population showed no increased risk for T2D in HIV. However, this study was confined to 
White participants, the cohort was relatively young, and had lower levels of obesity compared 
to the cohort presented in this thesis (Rasmussen et al., 2012).  
The very high prevalence of T2D in 2015 in the cohort presented in this thesis exceeded the 
upper end of a range in HIV patients that in a review (Hadigan and Kattakuzhy, 2014) has been 
described as 2.6% (Rasmussen et al., 2012) to 14% (Brown et al., 2005). This may in part reflect 
collection of data from this cohort as recently as May 2015 and may be a portent of changes 
occurring more widely.  This may also reflect socioeconomic challenges faced by a high 
proportion of participants. There was a strong correlation between employment status and 
dysglycaemia. The majority of those with T2D were unemployed. This resonates with a French 
study which found unemployment conferred a five times higher risk for developing T2D in 
PLWH (Dray-Spira et al., 2012). 
It is not clear how rates of prediabetes and T2D in this cohort may change over the next 10 
years. Without prevention strategies, assuming a continuation of T2D incidence observed 
between 2005 and 2015, and assuming continued HIV diagnosis rates (Public Health England, 
2015a), the prevalence of T2D in this HIV cohort could reach 25% by 2025. Extrapolated to the 
wider UK HIV cohort, this would equate to 15,000 new diagnoses of T2D by 2025. It could be 





reflecting the widespread cessation of use of those ARVs associated with increasing diabetes 
risk. However, the regression analysis presented in Section 3.2.5 suggested that modifiable 
factors associated with obesity (hepatic steatosis and hypertension) provide the greater 
contribution to diabetes risk in this population. Obesity rates increased from 47.9% in 2005 to 
58.0% in 2015. If this rate of increase continues, by 2025 up to 70% of this HIV cohort may be 
overweight or obese, and this may exacerbate the T2D incidence rate. There appears to be a 
clear imperative to treat and prevent both obesity and T2D risk in people living with HIV. 
Factors Associated with Dysglycaemia 
The duration of HIV infection, ARV treatment and particularly the use of metabolically toxic 
ARVs, weight gain following initiation of ARVs and the presence of lipodystrophy were all 
significantly associated with an increased risk of dysglycaemia. These findings agree with 
studies from a range of cohorts (Samaras, 2012) (Achhra et al., 2015). However, in contrast to 
these studies there was no correlation between CD4 nadir. This could be related to different 
historic HIV treatment guidelines in the UK where ARVs were largely initiated before the CD4 
count could decline below 350 (Asboe et al., 2012). 
Age was strongly associated with dysglycaemia: all participants with prediabetes or T2D were 
aged 39 or over. Central obesity, BMI, hypertension, HDL, triglycerides, hepatic steatosis, 
corticosteroid exposure, physical activity and statin use were all associated with dysglycaemia. 
Again, these findings resonate with other studies of HIV cohorts. However, there was no 
significant correlation between either ethnicity or gender and dysglycaemia in either 2005 or 
2015. Although the lack of correlation between ethnicity and diabetes risk is consistent with 
other investigations of European HIV cohorts (Capeau et al., 2012), there is a direct contrast 
with European-wide systematic review findings where, for example, controlling for other 
factors those of sub-Saharan origin were found to have an odds ratio of 2.6 for development of 
T2D compared to the host populations studied (Meeks et al., 2016). The lack of correlation in 
HIV may be due to the unique diversity of the London-based cohort studied, with participants 
born in over 60 countries. Alternatively confounders including age, polarised gender and 
ethnic differences, or contribution to diabetes risk from HIV-related factors may have 
increased comparative risk among Whites. 
T2D in this HIV cohort was significantly associated with lower socioeconomic status and 
unemployment. This resonates with findings from the UK as a whole, where in terms of risk for 





and women respectively (Tanaka et al., 2012). Lower socioeconomic status despite high levels 
of further education reflect the legacy of chronic illness in this HIV cohort, where onset of HIV 
infection occurred at a relatively young age leading to many experiencing long periods of poor 
health, an uncertain future and unemployment (Ibrahim et al., 2008). Although three-quarters 
of the cohort had completed further education, a high attainment level, almost one-third were 
unemployed and one-fifth reported to be in current financial crisis. This high level of 
unemployment and its association with diabetes risk warrants concern. A holistic approach to 
healthcare for PLWH might include onward referral for support for those who are unemployed 
or in financial crisis (Pelham-Burn et al., 2016). 
Modifiable factors contributed significantly more to risk of dysglycaemia than fixed factors, 
including age. Hepatic steatosis and hypertension contributed the greater risk for 
dysglycaemia. These findings add weight to the argument for early diagnosis of risk factors, 
screening for dysglycaemia and diet and exercise interventions implemented in HIV clinics, 
aimed at preventing T2D rather than providing diabetes treatments that may be suboptimal 
(Han et al., 2012). Findings from this study suggests that lifestyle change mitigating hepatic 
steatosis and hypertension through weight loss may have an important role in diabetes 
prevention among people living with HIV. 
Dietary Analysis 
The diet diary completion and return rate of 58.6% was relatively high compared with other 
studies (Cantwell et al., 2006). Taken as a sub-set, diary completers were statistically similar to 
the complete cohort in all factors measured in the sensitivity analysis other than age 
(p=0.019). However, the mean age difference of 2 years should not be considered clinically 
significant.  
The adapted Goldberg method as a marker of underreporting (Livingstone and Black, 2003) 
identified 46.5% of participants likely to have underreported intake, and the NHS Nurses study 
method (Mendez et al., 2011) suggested that 3.5% of participants reported an unfeasible 
intake. This relatively high rate of underreporting using the Goldberg method compares to high 
rates observed in other studies, for example 34% in a recently published UK–based 
investigation (Pettitt et al., 2016) and 25.1% in a US study (Murakami and Livingstone, 2015), 
and may in part be due to an overestimation of energy expenditure, perhaps likely given the 
high levels of sedentary behaviour in this cohort. However, under-reporters had a significantly 





have proposed excluding those participants with unfeasibly low energy intakes from dietary 
cohort analyses to reduce inaccuracy of analysis (Smith et al., 1994). However, investigators 
conducting a recent analysis of the NHS Nurses study (Rhee et al., 2015) found that excluding 
under-reporters using the Goldberg method resulted in selection bias. They repeated the 
analysis using the simple unfeasible intake method, and found dietary correlations were 
supported by biomarker analysis. They concluded that there was no benefit from using 
complex estimation equations for assessment of misreporting dietary intake.  
Further investigation of underreporting or unfeasible intakes should be taken in future 
analyses of data produced from this study. Exclusion of 46.5% of participants suggested by the 
Goldberg method might result in selection bias given the associations between BMI and 
underreporting, and between BMI and ethnicity, prediabetes and T2D. 
Future studies should consider use of new technologies to minimise underreporting and 
observer bias. Micro-cameras or use of in-app photography has been shown to improve 
accuracy of analysis of dietary intake (Pettitt et al., 2016). 
Disease Risk Modelling 
Current NICE guidelines suggest those with a 10-year CVD risk of 10% or more should be 
prescribed statins (NICE, 2014b). Prediction of 10-year CVD risk was performed using four 
tools, with between 19% and 39% of participants scoring a 10% or higher 10-year risk 
depending on prediction equation used. Previous studies investigating the use of CVD 
prediction equations in PLWH have demonstrated that the Framingham tool under-predicted 
risk for myocardial infarction and other CVD outcomes in women, in former smokers and in 
those with T2D, but over-predicted risk in never smokers (Friis-Moller et al., 2010). Analysis of 
data from this study suggests that in terms of identifying those at risk the QRisk2 tool 
recommended for use in the general UK population (NICE, 2014b, Hippisley-Cox et al., 2008) is 
comparable to the HIV-specific D:A:D prediction tool (Friis-Moller et al., 2010). For simplicity 
the QRisk2 tool may be used for estimating CVD risk in HIV patients pending further 
development of HIV-specific tools. 
Three tools for predicting prediabetes and T2D were examined. The FINDRISC tool (Lindstrom, 
2003) appears to confer a small improvement in detection of both prediabetes and T2D over 
the UK-based QDiabetes tool (Hippisley-Cox et al., 2009) and the HIV-specific D:A:D tool 





Further examination of disease risk estimation should work towards simplification of screening 
and assessment. Development of a strategic approach for estimating chronic comorbid disease 
risk in PLWH has been called for in order to ease burden in the clinical setting (Peters et al., 
2013a). Development of a single simplified tool may be possible through further analysis of 
data from this study. 
 
4.2.2 Discussion of Study Design and Procedures 
 
Strengths of Design and Procedures 
The study design had three key strengths:  purposive stratified random sampling to represent 
the diversity of the 2015 cohort; characterisation of participants by glycaemia measured in a 
carefully assessed fasting state in 2005 and 2015; and data collection within the broadly similar 
cohort of patients in 2005 and 2015 allowing a comparison over time.  
The purposive sampling method combined stratification by key factors associated with 
dysglycaemia to ensure the sample represented the cohort. Goals to recruit a sample 
representative by 10-year age band, gender and ethnicity were achieved, but I was unable to 
recruit any participants aged 18-22. Additionally, no participants were recruited who had 
acquired HIV through vertical transmission, although this was not stipulated as a recruitment 
goal. To minimise recruitment bias, every third patient on clinic lists was screened. Clearly 
there was no control over which patients consented or declined to participate.  
As reported elsewhere (Loutfy et al., 2014), in this study recruitment of women participants 
was challenging, with female quotas taking six weeks longer to meet than male quotas. 
Towards the end of this period I sent emails to health professional colleagues in the outpatient 
clinics raising awareness of the shortfall in recruiting women participants of Caribbean origin. 
This may have resulted in colleagues applying persuasion to potential participants to come 
forward. However, ethical procedures were followed at all times regarding gaining written 
consent to participate.  
It could be argued that the stratified sampling design is open to volunteer bias. For example, 
participants responding to advertising might be first to fill quotas as opposed to those 
randomly chosen from outpatient clinic lists. Those coming forward in response to advertising 





dysglycaemia, or have a family history of type 2 diabetes. They might also have achieved 
higher levels of education and be more open to research participation, a form of volunteer bias 
observed in other studies (Martinson et al., 2010). In fact, few participants were recruited in 
response to advertising, contributing 1% of the final total. However, three quarters of 
participants had completed further education, compared to 40% in the UK, and reported rates 
of up to 60% of job-seekers in London (The Office for National Statistics, 2013). Further work is 
needed to ascertain whether the high level of educational attainment observed in study 
participants is representative of the wider cohort. 
Limitations of Design and Procedures 
Limitations included a difference of sampling methods between the two time points. The 2005 
cohort was selected at random and represented a 40% sample of the cohort. By 2015 the 
numbers of patients attending HIV outpatients had increased significantly. Taken together with 
time constraints, recruiting a 40% sample in 2015 was unfeasible. When comparing changes 
between 2005 and 2015 an assumption must be made that both samples are statistically 
representative of their respective cohorts as this cannot be proven.  
Medical records predating 1996 were rarely available, with data collection instead relying on 
participant recollection; 18.6% of participants were diagnosed with HIV prior to 1996, and 
8.9% of participants initiated ARVs prior to 1996. Variables such as date of diagnosis of HIV, 
date of initiation of first ARVs, and weight change following initiation of HAART potentially 
took place up to 25 years prior to data collection, and recollection may not have been wholly 
accurate. However, investigators have demonstrated that recall of past weight over 10-year 
age bands can be relatively accurate (Kyulo et al., 2012). They reported that recall of weight 
from 26 years previously was underestimated by a mean of 0.67 kg, becoming more inaccurate 
as participant age increased over 70 years.  There was the potential for misreporting of 
smoking status, physical activity and consumption of fruits and vegetables secondary to a 
perceived need to please the researcher. 
Hepatic steatosis rates may have been overestimated in those with dysglycaemia due to 
selective clinical screening in those perceived to be at risk of hepatic fibrosis. Conversely, 
although a sizeable minority of participants had been screened, given the association of 
overweight with hepatic steatosis (Price et al., 2014), and the relatively high mean BMI of the 
cohort, cases of steatosis may have been missed. It could be argued that direct assessment of 





sectional study, and additionally pre- and post-intervention. The test is non-invasive, can be 
performed in 15 minutes and requires limited training (Sasso et al., 2016). However, due to 
financial and logistical constraints and recent development of the technique it was not possible 
to include this technique in the studies presented in this thesis. I would recommend future 
studies include assessment of hepatic steatosis using either Fibroscan or computed 
tomography scanning techniques, although the latter method involves exposure to radiation 
(Sasso et al., 2016). 
The glycaemic status of participants was defined by a single measure of fasting glucose. It 
could be argued that given the inherent variability of fasting glucose measures, a repeat 
measure to confirm glycaemic state would have been preferred. In a meta-analysis of studies 
where the reproducibility of glucose measures was investigated, statistical analysis of repeated 
measures indicated poor to fair agreement for IGT and moderate agreement for IFG (Balion et 
al., 2007). The average reproducibility was lowest (49%) for prediabetes compared to diabetes 
(73%) or normoglycaemia (93%). Given the lower reproducibility with prediabetes, future 
investigations should consider the use of repeated measures and protocol decisions where 
disagreement occurs.   
Choice of Methodologies 
Data collection procedures were acceptable, with virtually no missing data resulting and with 
clinical assessment visits lasting less than 60 minutes, there was minimal burden for 
participants. Scales used to measure socioeconomic status were acceptable as no direct 
questions were asked regarding income. Studies have found that non-response rates for 
questions regarding income are higher than questions generally regarded as highly sensitive 
including number of sexual partners or date of first menses (Tourangeau and Yan, 2007). The 
MacArthur scales used additionally to the National Socioeconomic Classification (NSEC) proved 
useful. The MacArthur UK scale asked participants to place themselves on a Likert scale 
comparing themselves against others in the UK in terms of employment, financial situation, 
education level and influence (Adler et al., 2000). Scoring on this scale agreed with the NSEC, 
since both indicated participants with T2D to be socially disadvantaged compared to others. 
However, the MacArthur Community scale scores were statistically similar. This scale asked 
participants to place themselves on a Likert scale comparing themselves against others within 
their own self-defined community. The implication here is that support or influence at the 





investigating PLWH outside of Europe (Basavaraj et al., 2010) and warrants a fuller 
investigation in people living with HIV in the UK. 
The logistic regression models stratified factors associated with dysglycaemia according to 
whether they were fixed or modifiable. It could be argued that models stratifying factors 
according to whether they were HIV-specific or general might have been an appropriate 
method. In fact the overlap between the two stratifications was minimal, with age being the 
only non-HIV related factor included in the fixed category alongside other factors that were all 
HIV-specific. 
 
4.3 Diet and Physical Activity Intervention 
 
4.3.1 Principal Findings 
 
This study aimed to investigate the effectiveness of a 6-month individualised diet and physical 
activity intervention on markers of insulin resistance in people living with HIV. Participants 
were given individualised advice in order to meet 10 diet and physical activity goals. On 
average, men achieved 4 goals and women 5. Most participants met or exceeded the goal to 
walk 10,000 steps per day. This level of achievement of goals was sufficient to result in a 
significant change in the primary outcome as well as many of the secondary outcomes.  
The primary outcome was post-intervention change in glucose incremental area under the 
curve measured by a 3-hour frequently sampled liquid meal tolerance test, performed at 
baseline on Day 1 and post-intervention at 6-months. Post-intervention, the mean glucose 
incremental area under the curve measured in mmol x minute was 18% lower.  
At 6 months, the mean insulin incremental area under the curve measured in units per minute 
was 31% lower. Baseline fasting glucose and insulin means were significantly lower at 6 
months: reductions of 6% and 24%. Participants achieved significant reductions in mean 
weight, waist, percentage body fat, systolic blood pressure, triglycerides, 10-year 
cardiovascular risk, and a significant increase in mean HDL and life satisfaction score. Out of 
the 28 participants, only 6 achieved or exceeded the goal to lose 7% of body mass over the 6-






4.3.2 Markers of Insulin Resistance 
 
The choice of Frequently Sampled Liquid Meal Tolerance Test (FSLMTT) for measuring the 
primary outcome was made in order to allow study of postprandial excursions of glucose and 
insulin as well as investigating the incretin effect. It was also chosen for practical reasons as it 
is less expensive to administer than the hyperinsulinaemic-euglycaemic clamp and less 
burdensome for participants. I also decided to extend the test from 120 to 180 minutes. To 
date searches have found no studies published or planned using the FSLMTT in HIV patients. 
The test has generated significant results, and demonstrated that glucose and insulin do not 
return to baseline levels within a two-hour period.  
Graphs showing mean glucose and insulin excursions over the three hour FSLMTT (Figures 23 
and 24 on page 147) suggest that the intervention had a different effect on glucose compared 
to insulin. The reduction in baseline glucose of 0.4 mmol/l is more or less consistent at each 
time point across the 3 hours. Post-intervention the postprandial glucose excursion at 30 and 
60 minutes is moderately but not significantly less. With insulin, early phase secretion is 
statistically identical pre and post-intervention. However, insulin secretion from 30 minutes 
onwards shows a significant reduction comparing post to pre-intervention. This reduction in 
later phase insulin secretion may reflect the reduced requirement of insulin to achieve glucose 
disposal. Measured by Mari’s method (Mari et al., 2002), the glucose disposal rate was 14% 
higher post intervention, increasing from 315 to 360 mmol/minute/m2. There appear to be no 
clear changes in levels of incretin hormones that might explain changes in glucose or insulin 
dynamics. 
It may be concluded that the intervention significantly reduced insulin resistance. The 
observed reduction in mean waist size, 36% reduction in fasting triglyceride levels and 
increased glucose disposal (oral glucose insulin sensitivity) rate measured by the Mari method 
support this theory. Additionally, exercise has been shown to improve skeletal muscle insulin 
sensitivity (Stanford and Goodyear, 2014). Increased physical activity levels observed across 
the pilot intervention might account for a component of the increased glucose disposal rate.  
Although not measured, it is possible that the intervention mitigated levels of hepatic 
steatosis. Reduced ectopic fat would be associated with an improvement in hepatic insulin 
resistance with improved hepatocyte insulin sensitivity leading to suppression of 





(Farese et al., 2012). Improvements in hepatic insulin sensitivity and suppression of hepatic 
glucose production are associated with a reduction in fasting glucose levels (DeFronzo and 
Tripathy, 2009), a phenomenon observed post-intervention in this pilot study. These changes 
in hepatic function were not measured directly in this study and can only be inferred. Also not 
measured were C-peptide and glucagon. C-peptide is considered to be a more accurate 
surrogate marker of β-cell function than insulin (Tura et al., 2006). Additionally, measurement 
of glucagon levels could add information to future studies allowing a fuller understanding of 
the mechanisms leading to the observed reduction in both fasting glucose and incremental 
area under the curve. 
Other intervention studies have demonstrated a clinically significant outcome through modest 
weight loss. In a study of a 16-week intervention in 8 participants with poorly controlled type 2 
diabetes compared to 10 normoglycaemic participants, a reduction of 8kg achieved 
normoglycaemia in those with diabetes (Petersen et al., 2005). This was associated with a 
reduction in intrahepatic fat and an associated significantly reduced rate of hepatic glucose 
production. A future randomised controlled trial based on the intervention presented here 
could also measure intrahepatic fat in order to compare findings with previous studies.  
Outside of HIV-specific research, a meta-analysis of diet and exercise intervention studies in 
people with prediabetes found a pooled effect size from 24 studies of a reduction in fasting 
glucose of 0.18 mmol/l (Appuhamy et al., 2014). The reduction in fasting glucose observed in 
the pilot intervention presented in this thesis (0.40 mmol/l) was outperformed in 3 of the 24 
studies from the meta-analysis, and was considerably less than the intervention effect of a 
reduction of 1.6 mmol/l observed in the UK-based PREPARE study (Yates et al., 2009). 
Regarding BMI, 29 studies were included in the meta-analysis, and the pooled effect size was a 
reduction of 1.61 kg/m2. This compares to a reduction of 1.41 kg/m2 in the pilot intervention, 
outperformed by 14 of the 29 studies from the meta-analysis. Finally, the observed reduction 
of 10.4 mm Hg in systolic blood pressure from the pilot intervention compared to a pooled 
reduction of 2.8 mm Hg, outperforming all 23 studies included in the meta-analysis. 
A study from the USA aiming to mitigate cardiovascular risk compared the effects of a 12-
month highly intensive diet and lifestyle intervention with added metformin or placebo (Fitch 
et al., 2012). Participants (n=38) were HIV positive and had metabolic syndrome. At 12 months, 
fasting glucose levels in the intervention plus placebo group had increased by 0.17 mmol/l 





(10.3%). In terms of secondary outcomes, in the US study lifestyle intervention alone resulted 
in an increase in mean waist and weight, whereas lifestyle plus metformin achieved mean 
reductions of 1.0% in waist and 3.2% in weight, considerably less than changes observed in the 
pilot study presented here. 
Although given the differences in design and duration direct comparisons between the two 
studies cannot be drawn, it appears that the effect on fasting glucose of the pilot intervention 
presented in this thesis outperformed the 12-month intervention from the USA, but had a 
lesser effect compared to USA intervention plus metformin. It is unclear as to why the pilot 
intervention presented here would result in a greater reduction in fasting glucose, weight and 
waist compared to the US study, given the more intensive nature of both dietetic (weekly 
appointments) and exercise support (supervised gym instruction three times per week) in the 
US study. The US study recruited only those participants with metabolic syndrome, however 
79% of participants in the pilot study presented here also had metabolic syndrome. It would 
appear that fasting glucose levels were lower in the US study, with a baseline mean reported 
as 5.47 ±0.17 mmol/l, compared to 6.13 ±0.75 mmol/l in this pilot study. This may partially 
explain the differences in intervention effect on glucose dynamics, although a more significant 
factor is undoubtedly the lack of weight loss seen in the lifestyle intervention arm in the US 
study. Changes in total daily energy intake were not reported in the US study.  It is possible 
that historic exposure to ARVs may have differed between participants in the two studies, 
although 48.5% of participants in the pilot intervention presented here had been exposed to 
these ARVs. Exposure to ARVs associated with T2D has been demonstrated to have a complex 
interaction with glucose homoeostasis, with impaired peripheral glucose uptake, β-cell 
function, and hepatic insulin sensitivity resulting (Hruz, 2011). Lipodystrophy was not recorded 
as an exclusion criteria in the US study, and was not recorded in participant baseline 
characteristics, so may be a factor that could explain the difference in results. 
There are few published studies detailing postprandial glucose and insulin excursions in HIV 
patients. In an Italian cross-sectional study of 84 HIV patients, 65 of whom were co-infected 
with Hepatitis C, 9 were found to have impaired glucose tolerance by OGTT (Gianotti et al., 
2011). For these 9 participants, mean baseline glucose was 4.6 mmol/l, rising to 8.4 at 30 
minutes and 8.9 at 120 minutes. Mean baseline insulin was 20.0 mIU/l, rising to 30.0 at 30 
minutes, and 121.0 at 120 minutes. Pre-intervention curves presented in this thesis show 
different patterns compared to the Italian study. This might be due to the effect of Hepatitis C 





al., 2016); infectious hepatitis was an exclusion criteria for the pilot intervention presented 
here. 
An investigation of leptin therapy in HIV patients (Magkos et al., 2011) measured postprandial 
glucose and insulin over 180 minutes. However, participants were treated with anti-diabetes 
medications and curves cannot be readily compared. As demonstrated in the results from the 
intervention presented in this thesis, the leptin study also shows return to baseline levels 
extending beyond 120 minutes to 180 minutes. Traditional OGTTs performed over 120 minutes 
may only partially describe dysglycaemia in HIV patients, with elevated glucose and insulin 
levels between 2-3 hours after the glucose or meal challenge missed. 
Outside of HIV-specific studies, postprandial glucose and insulin curves have been measured 
following frequently-sampled OGTTs and liquid meal tests. In adolescents undergoing a 
FSLMTT, the glucose and insulin curves show excursions are similar in shape to those from this 
pilot study, although the return to normal levels appears to occur within 2 hours in 
adolescents compared to 3 hours in this study (Bacha et al., 2013). In an RCT investigating the 
effect of caffeine on postprandial glucose and insulin, excursions of both glucose and insulin 
were very similar in shape to those reported from the pilot study presented in this thesis, 
however in the RCT they returned to normal levels after 2 hours (Gavrieli et al., 2013). 
In a study investigating the effects of non-glucose nutrients on insulin secretion in participants 
with prediabetes, those with IFG without IGT and those with IFG and IGT both experienced 
reduced postprandial glucose and increased postprandial insulin excursions with the mixed-
nutrient liquid meal compared to a glucose-only challenge (Bock et al., 2007). In both cases 
curves returned to normal between 2 and 3 hours post-challenge, similar to findings from this 
pilot study. Investigators concluded that non-glucose nutrient-induced insulin secretion 
appears to remain relatively intact in those with prediabetes and could be secondary to the 
incretin effect. Examination of the pre- and post-intervention incretin curves from this study 
does not immediately suggest an explanation for the effect of the intervention on changes in 
glucose or insulin. It is counterintuitive that secretion of GLP-1 should be slightly elevated post-
intervention, as secretion at 30 and 60 minutes post-liquid meal challenge has been shown to 
be lower in those with normoglycaemia compared to those with prediabetes (Vollmer et al., 
2008). However it is possible that the observed increase in GLP-1 at 60 minutes post-
intervention might be associated with suppression of glucagon secretion, although this was 





Diet and Exercise 
The intervention achieved a significant reduction in energy intake, with a mean reduction in 
energy balance of 475 kcal per day. However, using standard estimates that an energy deficit 
of 7,650 kcal is required to achieve a 1 kg loss of body fat (Stanton et al., 2006), with a mean 
loss of 4.1 kg over 180 days this would equate to a mean reduction of 175 kcal per day. This 
discrepancy can be attributed to at least two factors. Firstly participants may have experienced 
a reduction in lean body mass as well as fat mass over the 6-month period. A 55% smaller 
energy deficit is required for reducing protein stores compared to fat stores. Secondly, 
participants may have reported a reduced energy intake on completing the intervention. 
On average, the contribution to total daily energy intake from carbohydrates did not change, 
whereas relative contributions from protein increased and fat and alcohol decreased. 
Participants reduced their intake of saturated fats by 22%. However, contrary to the design of 
the study, intake of monounsaturated fats also reduced by 17%, reflecting the reduction in 
total fat intake. In a dietary intervention for HIV patients in Brazil commencing ARVs for the 
first time (Lazzaretti et al., 2012), intake of monounsaturated fats increased proportionately at 
the expense of saturated fats. It could be argued that given the overall positive impact on 
insulin resistance of the pilot intervention as a whole, the goal to maintain intake of 
monounsaturated fats has been shown to be unimportant. However, there is a strong 
evidence base for the importance of monounsaturated fat intake for general health including 
reducing postprandial hyperglycaemia (Bozzetto et al., 2016), and additionally given the high 
prevalence of hyperlipidaemia in HIV (Ballocca et al., 2016). How to achieve maintenance or 
increase of monounsaturated fats will require consideration in the design of future 
interventions in this patient group. 
Advice to increase intake of wholegrains was successful with a mean 41.4% of carbohydrate 
intake comprised of wholegrains at 6-months compared to 13.2% pre-intervention. Intake of 
fibre as a whole also significantly increased. Prior concerns that an increase in fibre and 
wholegrain intake might adversely affect gastrointestinal problems relatively common in PLWH 
(Neuman et al., 2012) were unfounded.  There was no statistically significant change in mean 
gastrointestinal symptom score, bowel frequency or Bristol stool chart score. 
Significant changes were observed in sodium intake with a mean reduction of 21%. Calcium 
and iron intakes also fell, although these reductions were not statistically significant. Reduction 





result is a measure of success. However, maintenance of calcium intake was a stated aim 
within the study protocol, and although the reduction in calcium observed over the 
intervention was not statistically significant, this result may influence design of future dietary 
interventions in PLWH.  
Analysis of sodium, calcium and iron intakes should be treated with caution, however, as 5-day 
diet diary analysis used in this pilot study is unlikely to provide sufficient data to provide a high 
level of accuracy (Bingham et al., 1994). Future studies may wish to include measurement of 
validated biomarkers (Prentice et al., 2011), for example urinary sodium, to increase accuracy 
of assessment of change in salt, mineral, fruit and vegetable intake, particularly where 
attempting to characterise factors associated with changes in blood pressure and other 
secondary outcomes.  
It may be clinically relevant for future trials in PLWH to focus on maintaining or increasing 
calcium and iron intake given the high burden of bone disease and anaemia in this patient 
group (Peters et al., 2013b). Additionally, future studies may wish to estimate adherence to 
the Mediterranean diet utilising a scoring system or food-frequency questionnaire approach 
(Estruch et al., 2013). 
 
4.3.3 Strengths and Limitations 
 
The pilot intervention was comprised of standardised goals to achieve. Advice to achieve these 
goals was individualised. This approach could be translated into clinical practice, as it mirrors 
the individualised approach taken by health care practitioners (Nybacka et al., 2011, 
Karagiozoglou-Lampoudi et al., 2012). The support offered to participants in the pilot 
intervention presented here was less intensive in nature than other interventions in PLWH. 
However, 6 personal appointments with a dietitian over a 6-month period may prove too 
expensive to implement widely, and investigation of less expensive treatment options may be 
warranted. 
Participants were eligible for the intervention if they presented with IFG (fasting glucose 6.0-
6.9 mmol/l), the same definition used to classify prediabetes in the phenotype study. When 
comparing the 33 intervention participants with the 55 phenotype study participants with 





significantly higher BMI (30.7 vs 28.8 kgm2) and higher rates of hepatic steatosis (63.6% vs 
46.6%). This difference may limit confidence in translating the effect of the intervention to 
those with lower BMIs and those without hepatic steatosis. A larger study could test this 
effect. 
A limitation regarding methodology was potential bias from performing measurements and 
analysis of results. As far as possible, measurements such as blood pressure and weight were 
performed by the research nurse from the Clinical Research Facility, rather than by me. 
However, we were both aware if the research appointment was baseline or post-intervention. 
As per protocol, certain measurements were used as motivators for participants. These 
included baseline and mid-point lipids, and monthly weight and waist measurements. Analysis 
of questionnaire data and glucose and insulin samples was delayed until the final participant 
had exited the intervention. However data was analysed by me, cognisant of baseline or post-
intervention.  In my opinion it is possible that bias may have occurred but would be unknowing 
and limited. Future study design should include measurement and analysis blinded to baseline 
or post-intervention, performed by a researcher not involved in delivery of the intervention. 
 
4.4  Qualitative Research Investigation 
 
4.4.1  The Study Population and Interview Details 
 
Sampling: 
The aim of recruiting a sample to represent the diversity of the cohort was partially met. The 
age range of those with prediabetes was reflected by those interviewed, as were ethnicity, 
socioeconomic status and sexuality. However there were clear difficulties in representing 
gender at interview, with 27% of women invited consenting to participate in the in-depth 
interviews, compared to 69% of men. Investigators in Canada found that the principal barriers 
to recruiting women living with HIV to research studies were, in order of importance, the 
sensitivity of the research subject followed by availability and logistics, language barriers and 
fear of disclosure of HIV status, with half of participants citing these barriers (Loutfy et al., 
2014). However, 40% also mentioned lack of trust in study personnel as a barrier. It is probable 





Data saturation was only partially achieved when the final participant exited the intervention. 
Ideally, recruitment to interview should have continued for those of non-White ethnicities, and 
for those who declined to participate in the intervention but agreed to interview. 
Those who declined to participate were challenging to recruit to interview. This perhaps is not 
surprising as potential participants were in effect being asked twice to participate, having 
already declined when asked first. The ethics of this aspect of study design had been 
questioned by members of the Research Ethics Committee. The rationale was to investigate 
whether barriers to participation and barriers to behaviour change may be interlinked. 
Recently, other studies have attempted to investigate reasons for non-participation in lifestyle 
interventions (Normansell et al., 2016, Attwood et al., 2016). Researchers here also report 
great difficulty in recruiting those who have declined participation in trials. It could be argued 
that participants who agree to interview might not be representative of the larger group who 
decline intervention participation. With this limitation in mind, the typologies described in 
Table 3.36 suggest that those who declined to participate share characteristics with those who 
performed poorly in the intervention.  
Certainly, almost all of those interviewed had been living with HIV for a long duration and 
reflected either the metabolic and health legacy of suboptimal HIV treatment or presentation 
of HIV late in the course of disease progression. In this regard findings from the interviews may 
reflect experiences from a more health-challenged group of people living with HIV. However, 
this reflects those people living with HIV most at risk of developing Type 2 diabetes. 
Conduct of the Interviews: 
Interviewees were offered a choice of interviewers: myself (male, White) or a Health Advisor 
(female, Black African origin). Those invited to interview who had not taken part in the 
intervention may have had no or limited previous clinical contact with me, or may have been 
involved in a professional relationship of varying duration. Those who had participated in the 
intervention in addition to working closely together over the 6-month period may also have 
been involved in a prior professional relationship of varying duration. None of the 23 
interviewees chose to be interviewed by the Health Advisor. Those who had experienced a 
longer duration of professional relationship with me may have felt less able to choose an 
alternate interviewer. However those who had no or limited prior contact also chose me to 





There were benefits and disadvantages to conducting the interviews myself. Benefits included 
a depth of knowledge and experience regarding diet and exercise behaviours, and for those 
interviewees who had participated in the intervention, a close knowledge of events and 
behaviours. Disadvantages included an increased likelihood of interviewees feeling less able to 
voice concerns about the management of the intervention delivered by me, and the potential 
for interviewees to talk about issues they perceived might please me. Care was taken 
throughout to distinguish between my usual clinical interviewing role and this research 
interviewer role, and to position the interviewees themselves as experts (Hunt et al., 2011). 
On reflection and re-examination of interview transcripts I have observed several examples of 
interviewees clearly attempting to praise my efforts: 
“I don’t want to disappoint myself, yeah, but I didn’t want to disappoint you either 
because I know how much effort and time you put into this”. [Interviewee No. 15, 
female, aged 42]. 
I have also observed examples where those interviewees with whom I had a prior professional 
relationship felt able to ask questions or make statements in a direct manner: 
“Do you worry about your weight, being a dietitian? I know you’re meant to ask me 
the questions”. [Interviewee No. 23, male, aged 41]. 
Interviewer: “Did you get enough support?” Interviewee: “From you? Did I get any 
support from you? I can’t remember”. [Interviewee No. 2, male, age 64]. 
The study protocol dictated offering a choice of interviewers, therefore it was not possible and 
potentially unethical for the Health Adviser alone to conduct a sample of interviews in order to 
compare the effect of prior relationship with interviewees. 
 




It was hypothesised that future interventions could be informed by an evaluation of the 
acceptability of the intervention. From my literature search, no investigations of the 





intervention was largely acceptable to participants. Those who declined to participate cited a 
range of reasons to explain their decision. However, in terms of the acceptability of the 
intervention these were limited to two areas: burden of attending for research visits and 
unease with the 3-hour frequently sampled liquid meal tolerance test. 
Participant Information Sheet: 
During design of the study efforts had been made to make the participant information as 
accessible as possible, responding to reports that graduate-level reading skills were required 
for understanding participant information materials in HIV research studies in the UK (Collins 
et al., 2015). The participant information leaflet for this study was assessed for readability, 
scoring 67 on the Flesch-Kincaid scale, indicating fair ease of readability. Although comments 
were made regarding their ease of accessibility by some interviewees, others commented on 
their complexity and admitted to skim-reading or avoiding reading materials altogether. It is a 
requirement that consent to participate in research studies is fully informed (Health Research 
Authority, 2015). Future participant information materials should be developed with this in 
mind. 
Frequently-sampled Liquid Meal Tolerance Test: 
Interviewees who experienced this 3-hour test were divided in opinion. Most found it 
straightforward, others found it challenging but had prepared for this after reading the 
information leaflets. Another group struggled with tolerance, citing discomfort, pain and 
unhappiness at the duration and amount of blood taken. Those who declined to take part in 
the intervention expressed unease with this test, suggesting this as a contributing factor to 
non-participation. One interviewee who declined the intervention also described an inability to 
fast for the test. 
More invasive tests such as the hyperinsulinaemic-euglycaemic clamp are routinely used in 
research and found to be scored as a moderate or high barrier to participation in 24% of 
potential participants compared to 35% concerned about missing work (Robiner et al., 2009). 
Participant information leaflets for future studies using the frequently-sampled liquid meal 
tolerance test should clarify the relative ease of administration and low burden of the 







Questionnaires were acceptable, with some participants describing them as fun and a 
distraction from the 3-hour tolerance test. The 5-day food diaries were acceptable and useful 
as a monitoring tool for most participants. However, some participants felt diary completion 
was a burden. Future studies should consider alternatives to written food diaries, for example 
apps using photography of foods eaten. 
Intervention Design: 
The overall design was acceptable. Most participants preferred the structure of monthly 
appointments over a 6-month period to other options discussed. Suggestions were made for 
more or less frequent appointments over a 6 or 12 month duration with alternative 
technologies supporting adherence to the intervention. Clearly a flexibility of approach should 
be incorporated into future design as recommended in UK guidelines for diabetes prevention 
and behaviour change (NICE, 2012, NICE, 2014a). 
Support: 
Flexibility of support was recommended by interviewees. Pedometers were highly valued as a 
tool to aid increasing physical activity and gym groups were suggested as an alternative. 
The high rate of acceptability of the intervention with practical suggestions for future design 
mirrors findings from other published process evaluations in diabetes-related lifestyle 
interventions (Feathers et al., 2007).  
 
4.4.3 Enablers and Barriers, Identity and Control 
 
Enablers and Barriers: 
Certain enablers and barriers to change in diet and exercise habits may be HIV-specific in 
nature and others general. General enablers and barriers elicited from a narrative literature 
review (Table 1.11 on page 52) can be compared to findings from interviewees. 
In summary, self-confidence and optimism were key to successfully achieving goals. A belief 
that lifestyle change could reduce disease risk and a desire to prevent diabetes had a positive 





commitment to succeed and a desire to tackle obesity were strong enablers. Planning, a 
stepwise approach and use of a pedometer as a tool to monitor achievement of goals were 
enablers. Those who felt that HIV was largely controlled and a lesser health burden compared 
to diabetes and avoiding adding to pill burden were motivators to change. 
Societal valorisation of obesity in African cultures and among gay men identifying as bears, lack 
of support, conflicting advice, pressures at work or home, bad weather and lack of willpower 
were all significant barriers to change. Healthier foods were perceived to be more expensive. 
Those who felt diabetes was a lesser health concern compared to HIV were less motivated to 
change behaviours. Thinness may be associated with AIDS and this fear of disclosure of HIV 
status or association with memories of AIDS acted as a barrier. Lifestyle change was 
considered futile given the legacy of HIV and associated medicines.   
Typologies: 
The typologies described in Table 3.36 suggest that those who declined to participate share 
characteristics with those who performed poorly in the intervention. Both groups appeared to 
have an external health locus of control, blaming HIV medicines and social pressures for 
inability to change or participate in the intervention. Individuals from both groups were 
isolated, and prioritised HIV over other health issues, for example prioritising keeping HIV 
secret. When asked about future intervention design, participants within this typology 
suggested daily support from dietitians regarding dietary change and provision of a personal 
exercise coach might help them achieve goals. This contrasts with those who performed well in 
the intervention who were characterised by an internal health locus of control. The external 
health locus of control associated with inability to adopt lifestyle change parallels that 
described among people with serious mental health challenges (Pearsall et al., 2014). 
However, poor mental health was widespread among participants in the study presented here 
and was not a barrier to change or a factor closely associated with inability to take control of 
health risk. The typologies suggest attitudes to loss of identity may differentiate between 
those who performed well or poorly in the intervention. This loss of identity refers particularly 








Tensions between Data 
Health locus of control and prioritisation of health-related issues may explain tensions 
observed in the analysis of interview data (Figure 27). 
Figure 28: Tensions Between Enablers and Barriers 
 
Enablers  Barriers 
Improvements in knowledge  Healthier foods unfamiliar 
Pedometer facilitated attainment  
of goal of 10,000 steps per day 
 Poor weather or short winter days 
limited ability to exercise 
 
Desire to tackle obesity 
 Valorisation of obesity  
among Black Africans and  
gay men identifying as bears 
 
Societal pressure to lose weight  Weight loss might disclose HIV status  
or be associated with AIDS 
 
Participants cited improvements in their knowledge as a powerful enabler to behaviour 
change. For example, understanding of food labelling helped participants choose lower fat and 
reduced salt options. However, despite improving knowledge regarding healthier foods, 
participants who did not change behaviours cited these foods’ unfamiliarity as a barrier. In 
effect, they were prioritising continuing to consume less healthy usual foods over reducing 
diabetes risk. Similarly, participants discussed at length the utility of the pedometer as a 
facilitator to achieve walking targets. However, those participants who struggled to achieve 
targets exhibited an external health locus of control, blaming poor weather or short winter 
days. Those who prioritised overcoming these barriers, for example by exercising at home or 
elsewhere indoors, achieved or exceeded physical activity goals.  
A desire to tackle obesity to reduce diabetes risk, and an acknowledgment of societal pressure 
to lose weight were apparently at odds with valorisation of obesity among certain groups and 
fear that weight loss might disclose HIV status or be associated with ill health. However, those 
participants of Black African origin and gay men identifying as bears who achieved weight loss 
goals prioritised reducing diabetes risk over these barriers. 
Lessons learnt from examination of these tensions can be used to inform clinical work as well 





Comparison with Published Findings 
General enablers and barriers elicited from this study mirror those found in reviews of 
enablers and barriers to diet and exercise change in people at risk of developing type 2 
diabetes (Korkiakangas et al., 2011, Morrison et al., 2014), those with cardiovascular disease 
(Murray et al., 2013), African-origin cancer patients (Oyekanmi and Paxton, 2014) and gay men 
identifying as bears (Moskowitz et al., 2013). 
Compared to other studies investigating lifestyle change in those at risk of diabetes through in-
depth interviews or video recordings of group sessions, there were no different general 
enablers or barriers. However, the relative frequency or importance varied. There were few 
health-related barriers in a study of adults at high risk of diabetes with a mean age of 49 years 
(Korkiakangas et al., 2011), contrasting with the frequent reporting of health-related barriers 
in the HIV cohort presented here. Barriers in a study of South Asian-origin people living in 
Scotland cited poor weather and employment and domestic commitments as the major 
barriers to change (Morrison et al., 2014). 
In this HIV cohort, isolation was a major barrier to change and a feature common to those 
declining to take part. Those who were able to seek support tended to achieve more goals 
during the 6-month intervention. Isolation is increasingly recognised as an important concern 
relating to poor health among older adults in the UK (Nicholson, 2012). It could be argued that 
isolation in this cohort has an HIV-specific component secondary to HIV stigma and the high 
rates of poor mental health seen among people living with HIV in the UK (Blashill et al., 2011). 
This HIV cohort has a high burden of comorbidities. Investigators in the USA conducted in-
depth interviews with people with chronic comorbid conditions including diabetes, arthritis, 
hypertension, breathing and musculoskeletal problems, and found several barriers specifically 
related to having multiple comorbidities including severe breathing issues and effects from 
polypharmacy (Bayliss et al., 2003). These findings are similar to multiple health issues and pill 
burden mentioned by interviewees in this HIV study. 
Comparing this HIV cohort with obese breast cancer survivors in the USA (Oyekanmi and 
Paxton, 2014), there are clear differences in barriers to lifestyle change. The cancer survivors 
reported few health-related barriers. Indeed the main barriers cited were lack of support, 
time, self-confidence and company, and fear of injury from being unfamiliar with exercising. 





where a range of condition-related barriers limited lifestyle change. These included 
chemotherapy side-effects and body image issues related to stoma care. These findings 
resonate with HIV-specific barriers elicited from this study. 
In an investigation of diet and exercise change in HIV positive individuals in the USA, focus 
groups were used to elicit barriers and enablers (Capili et al., 2014). The principal barriers in 
the cohort studied were financial, cultural unfamiliarity with healthier foods and exercise, lack 
of support, lipodystrophy and weight gain to mask HIV-related illness. This study mentions only 
in passing deliberate weight gain to mask HIV. This is perhaps less of a significant factor than 
expressed by interviewees in the study presented in this thesis. Facilitators were knowledge, 
group support and a positive attitude to change. These enablers and barriers were also 
prominent in the HIV study presented here.  
This study presents HIV-specific enablers and barriers not elicited in other published studies. 
These enablers and barriers may be related to diabetes risk, including the perceived relative 
health concerns of the two conditions and the enduring belief of the futility of lifestyle change 
given the legacy of HIV infection and HIV therapies.  
The fear of disclosure of HIV status should not be underestimated, affecting research 
participation and desire or ability to change behaviour. Participants felt happy to disclose 
development of diabetes but not HIV. This mirrors findings from a study in South Africa where 
participants with HIV and tuberculosis coinfection were open about their tuberculosis infection 
but not HIV (Daftary, 2012). 
It is important to consider an absence of the consideration of ageing by participants in this 
study, where the mean age of interviewees was 55 years. Age is significantly correlated with 
diabetes risk in people living with HIV, as indicated in this thesis and in other studies. The only 
reference to ageing by any interviewee was regarding central obesity: 
“I’m at that sort of age where you get a gut anyway. You know, I don’t see it as being a 
big deal”. [Interviewee No. 12, aged 63]. 
Interviewees made no mention of the link between age and diabetes risk. This contrasts with 
the strength of belief regarding a link between HIV medications and diabetes risk.  
Studies have investigated the valorisation of obesity in people of African origin in Africa itself, 





not do so due to social valorisation (Cohen et al., 2013). In Black Americans there has been 
reported a significant misperception of weight, particularly among women, when compared to 
White Americans (Hendley et al., 2011). In this study based in Atlanta, Black Americans were 
significantly less likely to classify themselves as obese. Among HIV positive American women, a 
significantly higher percentage of Black women wished to be heavier compared to others 
(Clark et al., 1999). There was no significant difference between ethnicities in the belief that 
higher BMIs masked illness. In the UK Black British women are more accepting of larger body 
sizes than White women (Shoneye et al., 2011). Studies of Black African women in the UK 
suggest that migrants retain valorisation of overweight, whereas second generation Black 
Africans’ perceptions of body image are similar to White Britons (Tovee et al., 2006, Swami et 
al., 2012). A small UK study of HIV positive women found that Black African women were more 
satisfied with being overweight than White women (Bradbeer and Bakar, 2008).  
In the study presented in this thesis, interviewees discussed valorisation of overweight in the 
African community. Those African participants who performed well in the intervention had no 
issue with losing weight and did not associate this with loss of identity, contrasting with those 
who did not perform well. 
Gay men who identify as bears have not been extensively studied and to date there is no 
published research regarding HIV positive bears. A comparison of 469 men who identify as 
bears compared with gay men who do not suggests that bears are significantly heavier 
(Moskowitz et al., 2013). In the study presented in this thesis weight loss presented a loss of 
identity for gay men identifying as bears. It is not known if this is specific to those living with 
HIV. 
In the general non-HIV population internal health locus of control has been associated with 
healthier diet and exercise habits (Cobb-Clark et al., 2014), consistent with findings from this 
study. A meta-analysis suggests that people of African and Asian origin exhibit a greater 
external health locus of control compared to those from Western White cultures (Cheng et al., 
2012). This is believed to be related to a holistic approach to health among Asian communities 
and a collectivist approach common in Africa, contrasting with a belief in Western society that 
health determinants are individual and broadly causal. An internal health locus of control has 
been associated with lower socioeconomic status (Grotz et al., 2011). An analysis of health 
locus of control in this study, differentiating by participants’ ethnicity and socioeconomic 





investigations may wish to explore the possibility of this relationship on order to maximise 
clinical application. 
Future studies should consider inclusion of tools to assess satisfaction with body shape, and 
perception of body image. A short 10-questions body appreciation scale has been developed 
and validated for use with UK-based populations (Swami et al., 2012). Given the high level of 
dissatisfaction with body image expressed by HIV positive women and men in the USA (Sharma 
et al., 2007, Sharma et al., 2006) use of this scale in clinical practice would also be warranted. 
The finding from this study that those who declined to participate in the intervention share 
characteristics with those who performed poorly in the intervention may have implications for 
other lifestyle behaviour change programmes. In this study both groups demonstrated an 
external health locus of control, prioritisation of issues other than diabetes risk, and an 
absence of or a limited support network. This might suggest that these issues require 
exploration and resolution, for example through clinical psychology or counselling, prior to 
embarking on an intervention. 
 
4.4.4 Research Participation 
 
Two frequently-mentioned enablers to participation in HIV research included altruism and the 
opportunity to potentially improve one’s own health, particularly driven by a fear of 
developing other illnesses when already dealing with the consequences of HIV. Altruism as an 
enabler to research participation may not be entirely selfless. Investigators have observed that 
even where altruism appears to be genuine, research participation could plausibly advance the 
participant’s wellbeing, for example where the research endpoint may be beneficial directly to 
themselves or their community (Largent, 2016). 
Being approached by non-clinical staff to introduce ideas regarding research participation and 
reimbursement of travel expenses were also cited as enablers. The principal barrier to 
participation identified irrespective of gender, ethnicity or active research participation was 
the potential for breach of confidentiality and disclosure of HIV status. Other barriers included 
logistic constraints, a lack of knowledge regarding research in general, poor communication 
particularly in terms of printed materials, ill-health, lack of feedback of results and a concern 





Stigma has been an issue central to people living with HIV since the start of the epidemic 
(Blashill et al., 2011). People with HIV remain highly concerned regarding confidentiality and 
disclosure of HIV status. This has the potential to impact negatively on research participation. 
 
4.4.5 Research Quality and Future Directions 
 
This is the first research study investigating the attitudes and beliefs of people living with HIV 
at risk of developing type 2 diabetes. A key strength of this qualitative study was the inclusion 
of interviewees who declined to take part or were withdrawn from the intervention in addition 
to those who completed the 6-month programme. Having the dual role of intervention 
facilitator as well as interviewer allowed insights into progression through the programme to 
inform probing questions during the interviews. Interviewees were relaxed and open in their 
communication. On reflection, my concerns regarding the potential for lack of objectivity were 
unfounded. Other researchers have suggested that the intimacy and familiarity experienced by 
anthropologists in particular helps catalyse the experience (Charmaz, 2004). I agree with this 
view and feel that the familiarity between me and participants resulted in the generation of 
important and significant data, for example issues regarding gay men who identify as bears. 
Limitations included fewer women participants than expected. No participants opted to be 
interviewed by the alternate to me. There was potential for the interviews to be adversely 
affected by the Hawthorne effect (McCambridge et al., 2014) where research participation 
itself affects behaviours: 
“I don’t want to disappoint myself, yeah, but I didn’t want to disappoint you either 
because I know how much effort and time you put into this”. [Interviewee No. 15, 
female, aged 42]. 
Future research may consider inclusion of focus groups in its design. Focus groups have been 
used effectively in research involving people living with HIV, although participants highly 
concerned about confidentiality may choose to decline attending groups (Capili et al., 2014). 
Future research should also consider recent migrants to the UK where the principal barrier to 
participation is language (Ochieng, 2013). Barriers to recruiting to health research in London 
have been characterised as difficulties in travel logistics and language barriers (Newington and 








Challenges to Recruitment 
Across the three interrelated studies presented in this thesis a total of 339 patients 
participated. Posters advertising the study placed in clinic waiting areas had limited success in 
terms of potential participants self-referring, although the effect of posters raising awareness 
among patients or staff was not measured. A total of 2,934 patients were identified through 
outpatient clinic lists or medical records, or self-referred. Prior to screening, 967 patients 
declined any research involvement or did not respond to an invitation to participate, and at 
screening a further 821 declined to take part or did not respond to invitation. Good practice 
guidelines were followed; patients were not asked to divulge reasons for declining 
participation (Health Research Authority, 2016). However, among those who volunteered 
reasons the commonest were: research fatigue (38%), problematic logistics (34%) and a lack of 
interest in research (14%).  
I was unable to recruit any participants aged less than 22 years or those who had acquired HIV 
through vertical transmission. This may have been be due to research fatigue, a phenomenon 
reported in younger PLWH (Pagano-Therrien, 2013) where over-researching has been linked 
with challenges to recruitment. This has also been reported in lifestyle interventions where 
17% of participants declining a diabetes prevention programme cited research fatigue (O'Dea 
et al., 2013). Investigators leading a qualitative research study suggested that increasing 
apathy, financial barriers and a lack of underlying support can drive research fatigue (Clark, 
2008). In a London-based study, investigators interviewed health researchers regarding 
barriers to participation (Newington and Metcalfe, 2014). The two principal barriers cited were 
travel distance and language.  
Recruitment of women to this study was challenging, particularly women from non-White 
ethnicities. This had been anticipated based on published reports from other studies of people 
living with HIV, for example a Canadian study where investigators interviewed research site 
coordinators regarding the participation of HIV positive women in trials (Loutfy et al., 2014). 
The purposive sampling method used for the cross-sectional study ensured that women were 
represented in that study. However, regarding the intervention and qualitative studies, I was 






The principal reasons for exclusion of potential participants from the phenotype study were 
being unable to provide informed consent (31% of those excluded) and being unable to 
communicate in English (also 31%). It has been recommended that efforts should be made to 
overcome language barriers in health research in the UK (Ochieng, 2013), and this should be 
considered in the design of future research projects. 
Reasons for exclusion from the intervention were: unable to commit to a 6-month programme 
(33%), infectious hepatitis (28%), use of medications associated with dysglycaemia (17%), 
naïve to ARVs (17%) and potential for pregnancy (5%). The effectiveness of the pilot 
intervention could have been compromised by liver impairment or use of medications 
associated with dysglycaemia. Together with excluding participants unable to commit to the 6-
month programme, these exclusion criteria remain justified. However, future interventions 
may wish to include those naïve to ARVs. 
A major theme from the process evaluation conducted using data from in-depth interviews 
was inclusion of a more flexible intervention design in future studies. 
In the intervention the attrition rate of 1 participant from 29 (3.5%) is very low compared to a 
diet and lifestyle intervention in HIV patients in the USA (Fitch et al., 2012). In that study, 36 
out of 50 participants completed the 12-month intervention. Six-month attrition rates were 







5   CONCLUSIONS 
 
‘people living with HIV present with particular 
barriers to change, and future interventions must 
address these to improve efficacy’ 
 
The epidemics of obesity and type 2 diabetes in this HIV cohort mirror the general population 
with HIV no longer a condition associated with wasting. Comorbid disease burden could be 
reduced by screening for dysglycaemia in HIV clinics and proactive prevention and treatment 
of obesity. The effectiveness of the pilot intervention demonstrates the potential to reduce 
risk for type 2 diabetes in HIV. However, the qualitative research presented here suggests 
people living with HIV may experience particular barriers to change and future interventions 
must address these to improve efficacy. 
 
5.1 The Phenotype of Dysglycaemia in HIV 
 
Historically HIV was a disease associated with wasting and premature death and therefore 
conventional risk factors for dysglycaemia such as age and central obesity were of little 
relevance. However, PLWH are now living longer, and wasting is very uncommon. Data from 
the phenotyping investigation has demonstrated significant trends among this ageing HIV 
cohort, suggesting that the rates of overweight and abdominal obesity among PLWH are 
increasing and are now comparable with the general population. Participants of non-White 
ethnicities experienced a particularly high rate of obesity. Coupled with an increasing 
prevalence of hepatic steatosis, hyperlipidaemia and hypertension, the burden of comorbid 






Type 2 diabetes is highly prevalent in this diverse London-based HIV cohort, and as in the 
general population, there is a significant correlation between diagnosis of prediabetes or type 
2 diabetes and increasing weight and age. As observed in the general population type 2 
diabetes in this cohort was associated with significant socioeconomic deprivation. As with 
studies of other HIV cohorts, dysglycaemia was correlated with HIV-specific factors including 
duration of HIV infection, degree of weight gain following initiation of anti-HIV medications 
and lipodystrophy. However, regression analysis suggests that rather than these HIV-related 
factors, it is the modifiable factors hepatic steatosis and hypertension that contribute the 
greater association with diabetes risk in this HIV cohort. These findings give impetus to moving 
forward with developing diabetes prevention strategies based on diet and exercise 
interventions which through weight loss can mitigate both hypertension and hepatic steatosis. 
 
5.2 Prevention of Type 2 Diabetes in HIV 
 
The pilot intervention has demonstrated the potential for dietary change, increased physical 
activity and weight loss to reduce diabetes risk in people living with HIV. This intervention 
resulted in a greater treatment effect compared to a more intensive diet and exercise 
intervention in PLWH studied in the USA, and comparable or greater treatment effects 
compared to pooled results from a meta-analysis of lifestyle interventions in participants with 
prediabetes from the general population. The underlying mechanisms at the heart of the 
intervention were not measured. Future studies should assess these, e.g. measurements of the 
degree of fatty infiltration in the liver. However, despite the significance of mean treatment 
effects participants demonstrated a range of success achieving intervention goals.  
The in-depth interviews provided a greater understanding of the success or otherwise of 
participants in the intervention. This qualitative research suggests that people living with HIV 
may present with particular barriers to both participation in clinical research and to adopting 
lifestyle change. Fear of disclosure of HIV status and worries about confidentiality were 
common themes. Common to those who declined to take part in the pilot intervention and 
those who achieved few intervention goals was an external health locus of control. Diabetes 
risk was blamed on HIV and antiretroviral medicines as well as social pressures, and type 2 
diabetes was seen as a lesser concern compared to HIV.  A loss of identity, particularly among 
African-origin participants and gay men identifying as bears, was a theme common to those 





intervention exhibited an internal health locus of control, taking responsibility for their 
diabetes risk. Common to those achieving more intervention goals was a support network, 
either well-established or proactively constructed early in the programme.  Given the range of 
achievement of intervention goals, findings from the in-depth interviews should be 
incorporated into future design of and approach to behaviour change programmes for people 
living with HIV. For example, an assessment of health locus of control might warrant 
counselling or psychology support prior to initiation of lifestyle change. For those who 
continue to view diet and exercise change as futile, alternative treatments including 
pharmacological interventions might be considered. 
 
5.3 Clinical Implications 
 
In my investigation no participants under the age of 39 were diagnosed with prediabetes or 
type 2 diabetes. This might suggest that clinical screening for diabetes risk should be targeted 
at those approaching and over the age of 40. Additionally, enhanced screening for diabetes 
risk in HIV patients should be considered. Extended screening of risk factors might include 
directed screening for hepatic steatosis in at-risk individuals. Appropriate interventions, 
including preventative measures, might extend beyond the management of modifiable risk 
factors by means of dietary and exercise advice. For example, health care practitioners might 
favour use of those ARVs with less effect on insulin resistance in those presenting with 
prediabetes or type 2 diabetes, and also those with significant risk factors.  
Particular attention may be directed to those initiating antiretrovirals for the first time. 
Demonstrated in this study and in research elsewhere is the increased risk for comorbid 
metabolic disease in those experiencing weight gain following initiation of ARVs. Prevention of 
weight gain at this time may prove a valuable investment for future health. Counselling to 
change diet and exercise is especially relevant to PLWH given low levels of physical activity and 
fruit and vegetable consumption and high prevalence of overweight and obesity compared to 
the general population. The beneficial effects of lifestyle change on a range of parameters 
demonstrated by adherence to the intervention can be applied clinically. Findings from the 
qualitative study can be used to improve clinicians’ understanding and support when 






5.4 Future Research 
 
A Randomised Trial is currently being developed with PPI input aiming to investigate the 
prevention of obesity-related comorbidities in HIV. The current design focuses on comparing 
the individualised diet and physical activity advice approach developed in the pilot 
intervention presented in this thesis with a less intensive approach employing distance 
support. It is anticipated that this RCT will be powered to enable a regression analysis of the 
contribution of individual components of the intervention to the primary outcome. However, 
eligibility criteria will require careful consideration given the recruitment challenges 
experienced in the studies presented in this thesis, and the inherent difficulties of scaling up 
into an RCT. 
The relationships between deliberate weight loss and fear of disclosure of HIV status, loss of 
identity for those of African origin, and loss of identity for gay men identifying as bears need 
further exploration. 
People living with HIV are facing increased risk of type 2 diabetes, cardiovascular disease, 
osteoporosis and chronic kidney failure. In HIV, common factors contribute to the 
development of these conditions associated with ageing. Development of a unified screening 
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7.2 Participant Information Sheet and Consent Form 
 
Prevention of Type 2 Diabetes in HIV: A Pilot Study of Effectiveness and 
Acceptability 
(the “STOP Diabetes in HIV” study) 
 
My name is Alastair Duncan, and I am a dietitian and researcher at Guy’s and St. Thomas’ 
Hospital. I am inviting you to take part in a research study. The results of the study will be used 
to see if an approach shown to prevent Type 2 Diabetes in the general population can work with 
HIV positive patients. As part of this study we are trying to find out if there are any particular 
risk factors for developing diabetes. I have overall responsibility for this study, and my contact 
details can be found towards the end of this information sheet. 
 
Before you decide to take part, it is important for you to understand why the research is being 
done and what it will involve. If you decide to take part, this part of the study will involve you 
attending the Harrison Wing clinic for a single 30 minute visit, where you will be asked some 
questions, and have some measurements taken. You might be asked to have a single blood test 
to check your blood sugar level. In addition, we will check your medical records to find 
information relevant to the study. Further details can be found below. 
  
Please take time to read the following information carefully as it will explain the study, together 
with what you will be asked to do if you take part, in more detail. Please talk to others about the 
study if you wish. You could ask at the clinic reception desk to speak with your patient advocate. 
Ask any of us if there is anything that is not clear or if you would like more information. Take all 
the time you need to decide whether or not you would like to take part in the study. 
 
What is the purpose of the study? 
 
Type 2 diabetes is a condition where the body cannot use energy from food properly any more, 
and there is a risk of sugar building up in the blood. High levels of sugar make the blood thick 
and syrupy and this can go on to cause dangerous health problems if not treated. People with 
HIV are believed to have a higher risk of developing type 2 diabetes when compared to HIV 
negative people of the same background, age and size.  
 
This might be because of a combination of three factors: 
 HIV infection causes inflammation within the body, which does not go away completely 
even when the virus is well controlled by medication 
 Some medicines for controlling HIV may increase the risk for developing type 2 diabetes 
 Many people living with HIV are overweight these days, and this is well known to 
increase the risk for developing type 2 diabetes in HIV negative people. 
  
In the study, we will ask some questions and take some measurements to find out if people living 
with HIV have risk factors for developing type 2 diabetes. We are aiming for 338 people to take 
part in this risk factors study, and we will sort everyone, including you, into one of 3 groups: 
1. People with normal blood sugar levels 
2. People with slightly high blood sugar 






The information we will get from this study will be used to design a much larger research trial 
investigating prevention of type 2 diabetes in HIV. It will also help healthcare providers, like your 
doctor, dietitian or nurse, look out for people at risk of developing diabetes.  
 
Why have I been chosen? 
 
You have been chosen because you have been diagnosed as HIV positive, you have been 
receiving care for this condition at Guy’s and St. Thomas’, King’s College Hospital, or Beckenham 
Hospital, and one of three other factors: 
1. You have normal blood sugar 
2. Your blood sugar is a little higher than usual, sometimes called “impaired fasting 
glucose” 
3. You have diabetes 
If you are in group 2, and your blood sugar is a little higher than usual, this is known to indicate 
a risk for going on to develop Type 2 Diabetes in the future. If you have not already discussed 
this condition with your GP or routine clinic doctor, you may wish to do so at your next 
appointment. 
 
Do I have to take part? 
 
No. It is completely up to you to decide whether or not to take part in this study. If you have any 
questions about the study, you can contact the Investigator Alastair Duncan (telephone number 
at the end of this Participant Information Sheet) or ask your nurse, doctor or any clinician at a 
clinic visit, or you can chat with your patient representative. After you have had all your 
questions answered and have decided to take part in the study, you will be asked, at the clinic 
visit, to sign and date the attached Informed Consent Form (see the last page). The signed 
Informed Consent Form will be kept in your medical notes, a copy will be given to you to keep, 
and a further copy will go in the hospital study file. If you do want to take part in the study, keep 
this Patient Information Sheet in case you need to read it in the future. We will write to your GP 
letting them know you are taking part in the study, and send them a copy of this information 
sheet too. 
 
What will happen to me if I take part and what do I have to do? 
 
Checking your blood sugar tests 
If you agree to take part in the study and give your written informed consent, the Investigator 
Alastair will first check your most recent blood sugar results from clinic. If the most recent result 
was from a blood test taken some time ago, or if there was a possibility this previous blood test 
was taken when you had not avoided food and all drinks other than water from the night before 
(fasting), we may arrange for this to be repeated. You would need to come to clinic fasting, and 
have one teaspoon of blood taken. We will then arrange a date for you to come to clinic for your 
30 minute visit. We will make sure the date and time suits you, fitting round work, holidays, and 
so on.     
 
The visit 
If you have been asked to have another blood sugar test, then on the day before your visit you 
will be asked to avoid eating from 10pm. You will also need to avoid most drinks after 10pm, 
although you will still be able to drink plain water freely, including the next morning. If you 
usually take your HIV medicine with food after you wake up, then as you normally do when being 
asked to fast for blood tests in clinic, you should delay taking your medicine, and bring it with 





medicine then. If you are having a blood test you will have a needle inserted into a vein in the 
crook of your elbow, and we will draw out a teaspoon of blood, in exactly the same way as you 
normally have blood drawn. If you have not been asked to have another blood sugar test you do 
not need to fast, and you can eat and take medicines as normal before coming to clinic.  
 
We will be asking you some questions, and check with you that some information from your 
medical notes is correct and up to date.  The information from your medical notes we will check 
includes social information such your ethnic background, HIV information including when you 
were first diagnosed and blood test results, relevant medical information including changes in 
body weight and shape, illnesses or conditions such as heart problems, and anti-HIV and other 
medicines used. We will ask you if anyone in your family has diabetes. We will measure your 
blood pressure, weight, height, waist, hips, and how much fat you have in your arms and legs. 
This visit will last about 30 minutes in total. 
 
What will happen to my medical notes and who will see them? 
 
Information will be taken from your medical notes at a time when they are not needed for your 
clinical care. Your direct healthcare team and the Investigator Alastair are the only people who 
may look at your medical notes for this study, and all of them will keep your identity confidential. 
At no stage will personal data such as your name or address be linked to the results that we get 
as you will always be identified by a code number only.  
 
What will happen to any blood samples I give? 
 
If you have a blood samples taken it will be used to measure blood sugar only and then 
destroyed. 
 
What are the side effects of any treatment received when taking part? 
 
For this study you are not being given any treatment at all. 
 
What are the possible disadvantages and risks of taking part? 
 
There is no additional risk to your health from taking part in this study. If you are asked to have 
a blood sugar test, a needle will be inserted so that we can take a blood sample, and this 
sometimes leads to local bruising and minor discomfort. The fasting blood test you might be 
asked to do means that you will go for up to 15 hours without eating, so you might feel a bit 
tired and hungry by the end of the test. We will give you breakfast as soon as the test is finished.  
 
What are the possible benefits of taking part? 
 
If we ask you to have a blood sugar test we might find this is a little high, or even that you have 
recently developed type 2 diabetes, and we would probably pick this up earlier than through 
normal clinic visits. You might also appreciate or benefit from some of the testing that is done 
as part of this study, for example measuring your weight and waist. We hope that the results of 
the study will be useful to the NHS and people living with HIV. If you take part in this study, you’ll 
be helping us to learn more about the best ways to treat people living with HIV who are at risk 
of developing diabetes, and what risk factors to look out for.  
 
 






Participation in this study is voluntary. Even if you agree to take part now, you are free to change 
your mind and withdraw from the study before or at the visit without affecting the standard of 
care that you receive. If you decide to withdraw from the study, any information already 
collected about you will remain anonymous and will not be used. The Investigator Alastair will 
check with you when you come for your visit to make sure you are happy, and consent to 
continue with the study. 
 
If you decide not to take part, or if you decide to withdraw, you may be asked to take part in an 
interview to find out what you thought about the study, about any advice given, procedures 
involved, about any mistakes we might have made, and about how you feel about your health. 
These interviews will help us make research trials better in the future. However taking part in 
these interviews is entirely voluntary and it would be completely up to you to decide whether 
to take part or not. 
 
Will I be paid to take part? 
 
No. Taking part in this study is entirely voluntary. However if you are asked to fast and have a 
blood sugar test taken, we will provide you with a £3 breakfast voucher to use at the Hospital at 
the end of your visit. 
 
What if there is a problem? 
 
It is very unlikely that taking part in this study will cause you any problems. However, if you have 
a concern about any part of this study, you should ask to speak with your doctor or nurse who 
will do their best to answer your questions. If you remain unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. Details can be obtained from 
the Patient Advice and Liaison Service (PALS) on the ground floor of the North Wing at St. 
Thomas’ Hospital: 
Patient Advice and Liaison Service ,KIC, Ground Floor, North Wing, St Thomas’ Hospital,  
Westminster Bridge Road, London SE1 7EH, Tel: 020 7188 8801, Email: pals@gstt.nhs.uk 
 
All staff involved hold professional indemnity to work within Guy’s and St Thomas’ 
NHS Foundation Trust. However in the unlikely event that something does go wrong and you 
are harmed during the research study there are no special compensation arrangements. If you 
are harmed and this is due to someone’s negligence then you may have grounds for a legal 
action for compensation against Guy’s and St. Thomas’ NHS Foundation Trust, but you may have 
to pay your legal costs. The 24-hour contact number for formal NHS complaints at this St. 
Thomas’ Hospital is 020 7188 8801. 
 
Will my taking part in the study be kept confidential? 
 
Yes. All the information about your participation in this study will be kept confidential.  Your 
name and address will not be recorded for the purposes of the study; a code number will be 
used instead and you will not be identifiable by any other way in the study records. We will keep 
copies of your signed consent form in your medical notes and in a research file. This is completely 
separate from the information collected during the clinic visit and from your medical notes for 






Even though you will not be identifiable from them, the study records will be stored securely in 
a locked cabinet within locked premises under the control of the Chief Investigator, Alastair 
Duncan. Access to the study records and your medical notes, may be granted to appropriate 
people from the Trust Research and Development department, so that they can check that the 
study was carried out correctly. These people will treat information about you as strictly 
confidential. When the information is entered into a database on a computer for studying, this 
will be protected by a special password, and only accessible to the research team. The study 
records will be kept securely in this way for 5 years, in case we need to refer to them to answer 
questions about the study. At the end of this time, the study records will be disposed of securely 
in accordance with Guy’s and St. Thomas NHS Foundation Trust policy. 
 
What will happen to the results of the research study? 
 
When the study is complete, the results will be written up by Alastair Duncan (the Chief 
Investigator for this study) and will be submitted for publication in medical journals and may be 
presented at medical conferences. You will not be identified in any report, publication or 
presentation. Your doctor will be able to tell you what the results of the study showed, if you 
are interested. Also your patient advocate will organise a patient forum to discuss the findings. 
If any abnormal or significant findings are found as part of your research visit, your GP and 
routine clinic doctor will be informed so they can review the information and action taken if 
necessary. 
 
Who is organising and funding the research? 
 
The study is sponsored by Guy’s & St. Thomas’ NHS Foundation Trust. It is funded by the 
Department of Health, through the National Institute for Health Research, and forms part of a 
PhD programme for the Investigator Alastair Duncan. Alastair has overall responsibility for this 
study, making sure that all procedures are followed correctly. His contact details are below. 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS on 12/11/2013 by the 
London-Bromley Research Ethics Committee. 
 
 
This Participant Information Sheet is for you to keep. 
Thank you for taking time to read the information. 
Contact for further information:  
Alastair Duncan (Research Dietitian) 
Department of Nutrition and Dietetics 
St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH 
Study Phone: 07907 849626 
Office Tel: 020 7188 2608 or 020 7188 2014 









CONSENT FORM 1 
 
Prevention of Type 2 Diabetes in HIV: RISK FACTORS 
(the “STOP Diabetes in HIV” study) 
 
Name of Researcher with overall responsibility for the study: Alastair Duncan 
 Please initial 
box 
1. I confirm that I have read and understand the information sheet 
dated............... (version ............) for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
   
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, and without my medical 
care or legal rights being affected. 
 
3. I understand that the study data will be stored securely for 5 years and 
disposed of securely at the end of this period. 
 
 
4. I agree to take part in the above study. 
 
 
5. I agree that relevant sections of my medical records will be looked at by 
a HIV research dietitian, nurse or doctor who will collect anonymised data 
where it is relevant to this study. I give permission for these researchers to 
have access to my records. 
 
6. I agree that any relevant material about me can be used in future 
research approved by an NHS Research Ethics Committee; I am aware this 
research may be in collaboration with a commercial company but that my 
identity will be kept anonymous. 
 








_________________________ _____________               _________________ 
Name of Participant Date Signature 
 
_________________________ _____________               _________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ _____________               _________________ 
Researcher Date  Signature 
 
When completed photocopy twice: first copy for participant; second copy for 






7.3 UK-SES Questionnaire 
 
UK NATIONAL STATISTICS SOCIOECONOMIC CLASSIFICATION 
QUESTIONNAIRE 
We are interested in finding out where you would be placed within a UK government method 
of measuring social standing. Please take your time to answer the following questions. 
QUESTION 1: Have you have been out of work, retired, or a student for more than 6 months 
now? If so please go straight to question 10 
Long-term unemployed   Retired  Student 
Questions 2-8 will ask about your job: 
if you have more than one job choose the main one 
if you have recently left work answer about your last job 
QUESTION 2: Industry description   
What does the firm/organisation you work for mainly make or do? 
 
 
Question 3: Occupation title, current or last main job   
What is your job? 
 
 
Question 4: Occupation description, current or last main job   
What did you mainly do in your job? 
 
 
Question 5: Employee or self-employed   
Were you working as an employee or were you self-employed? 
Employee... Go to question 6  











Question 6 (Employed only): Supervisory status   
In your job, did you have any formal responsibility for supervising the work of other 
employees? 
  Yes         No  
Question 7 (Employed only): Number of employees   
How many people worked for your employer at the place where you worked? Were there... 
1 to 24, 25 to 499, or 500 or more employees? 
    NOW GO TO QUESTION 10... 
Question 8 (Self-employed only): Self-employed working on own or with employees   
Were you working on your own or did you have employees? 
On own/with partner(s) but no employees  
    With employees Go to question 9 
Question 9 (Self-employed only): Number of employees (self-employed)   
How many people did you employ at the place where you worked? Were there… 
1 to 24, 25 to 499, or 500 or more employees? 
    NOW GO TO QUESTION 10... 
Question 10: Education   
Did you take part in further education after school?   
   Yes        No  
Question 11: Financial situation  
How does the cost of living affect you? 
    Quite comfortably off             Able to manage       
It’s a strain to get by week by week   













7.4 Macarthur Subjective Socioeconomic Scale 
 
Socioeconomic Status 
In this questionnaire we are trying to find out where you place yourself within society. There 
are two questions to answer. 
 
QUESTION 1: 
Think of this ladder as representing where people stand in their own communities. At the top 
of the ladder are the people who have the highest standing in their community. At the bottom 
are the people who have the lowest standing in their community. People define community in 
different ways: please define it in whatever way is most meaningful for you. 
 
Where would you place yourself on this ladder? Please place a large “X” on the rung where 




Think of this ladder as representing where people stand in the UK. At the top of the ladder are 
the people who are best off – those who have the most money, the most education, and the 
most respected jobs. At the bottom are the people who are the worst off – those who have 
the least money, least education, and the least respected jobs or no job. 
 
Where would you place yourself on this ladder? Please place a large “X” on the rung where 






7.5 Standard Operating Procedure: Frequently Sampled 
Liquid Meal Tolerance Test 
 
For the purpose of clinical research the Frequently Sampled Liquid Meal Tolerance Test may be 
used in place of the Oral Glucose Tolerance Test to measure the physiological response to a 
nutrient challenge in the fasting state. It is not standard practice to carry out such a procedure 
at Guy’s and St Thomas’ NHS Foundation Trust therefore this has been added.  
Document name The Frequently Sampled Liquid Meal Tolerance Test, Version 1.0 
Effective from  January 2016 until January 2016 
Author   Alastair Duncan, Lead Dietitian 
Approved by, date Professor Phil Chowienczyk 
Supporting references Maki et al (2010) DOI: 10.1089/dia.2010.0083 
 
1. This Standard Operating Procedure (SOP) applies to personnel who will perform the 
Frequently Sampled Liquid Meal Tolerance Test (FSLMTT), and subsequently obtain samples 
from a peripheral venous cannula within the Clinical Research Facilities (CRF). 
2. Personnel working in the CRF must use the same procedure when conducting a FSLMTT to 
ensure continuity and consistency of the procedure. As part of the FSLMTT peripheral venous 
cannulation is performed in order to provide access to the circulatory system. Multiple blood 
samples are obtained from this cannula to avoid repeated venepuncture. 
3. The Oral Glucose Tolerance Test (OGTT) is routinely used in clinical practice for assessing the 
physiological response in the fasting state. The FSLMTT provides rich data compared to the 
OGTT. A mixed-nutrient liquid meal elicits a release of gut hormones and stimulated insulin 
release, providing a more physiologically accurate simulation. Secondly, frequent sampling 
post-meal allows the researcher to observe the response more closely over time. 
4. The CRF Manager must ensure that relevant CRF personnel are trained in this SOP 
5.1 In advance of the procedure subjects will have been advised of the following: 
• For 48 hours in advance eat moderately portioned carbohydrate-containing meals three 
times per day and avoid strenuous exercise and smoking 
• Fast for 12 hours prior to attending for the procedure, although water is permitted. 
5.2 In advance of this procedure the Investigator or other delegated individual must check with 
the participant regarding any previous problems with phlebotomy or cannula insertion. 
5.3 The participant should be sitting comfortably in a chair 
5.4 The Investigator is responsible for inserting a peripheral venous cannula. This duty can be 
delegated to other appropriately qualified members of the research team who: 
• Have attended the Trust mandatory venepuncture training course. 
• Are deemed competent by an appropriately trained member of the CRF Management Team 






5.5 The delegated individual must perform the procedure in accordance with the Trust 
relevant Health and Safety Policy for Peripheral venous cannulation 
5.6 The delegated individual is responsible for ensuring that blood is obtained from a cannula 
according to the protocol. This duty can be delegated to other appropriately qualified staff. 
5.7 The delegated individual must ensure the correct participant is identified and cross 
referenced with appropriate blood request forms. 
5.8 The delegated individual will ensure all study/trial specific documentation is prepared, any 
local blood request forms are completed, and the correct blood bottles are labelled. 
5.9 The delegated individual will explain the procedure to the participant. 
5.10 The delegated individual must keep accurate records regarding: 
• The length, gauge of the cannula 
• Date and time of insertion, number and location of attempts 
• Identification of the site 
• Name and person placing the device 
• Type of dressing 
• Patients tolerance of the device 
 
5.11 Before and after each element of the procedure the delegated individual must wash their 
hands in accordance with Trust policy, and wear the appropriate protective clothing. 
5.12 The delegated individual will prepare all equipment required including sharps bin, 
Vacutainer Luer connector Blue, Vacutainer bottles / study/trial specific blood kits / Vacutainer 
Shield, Mediswab, non-sterile gloves and trolley, 10 ml Plastipak syringe x2 (1 for flush, 1 for 
4ml blood draw), 0.9% normal saline (check expiry date), Smartsite needle-free valve port  
 
5.13 The delegated individual must prepare the working environment to ensure comfort, light, 
room to manoeuvre, position and privacy of the patient. 
5.14 Following insertion of the cannula the delegated individual must check the cannula site 
for swelling or redness. Check that the appropriate dressing has been used. If redness or 
swelling is identified around the cannula site, the cannula should be removed and re-sited. 
5.15 The delegated individual must attach a smartsite needle-free valve port if the cannula 
does not already have one attached. This is achieved by screwing the clear section of the 
smartsite onto the end of the cannula. The smartsite needle-free port must be cleaned with an 
alcohol wipe. The smartsite connector should be allowed to dry for approximately one minute. 
5.16 The delegated individual must draw up 1-2 mls of 0.9% normal saline using a sterile 





5.17 The delegated individual must withdraw 4mls of blood from the cannula in a Plastipak 
10ml syringe and discard as clinical waste. Discarding this sample will ensure accurate analysis 
of the results and will also remove any residual saline from the previous flushing. 
5.18 Baseline blood samples should be drawn, with time accurately recorded, as follows: 
• The delegated individual must use a blue Vacutainer leur connector and attach it to the 
Vacutainer shield, remove the white cover of the tip to expose the grey sheath of the needle 
and screw mechanism, screw the tip onto the Vacutainer shield, remove the blue cover from 
the Vacutainer tip, and place the leur lock connector into the white section of the smartsite. 
• The delegated individual must then use the appropriate blood bottles as specified in the 
study/trial protocol. Order of draw instructions may be specified in the study/trial protocol. 
• For a standard frequently sampled liquid meal tolerance test a minimum of one tube each 
for glucose (fluoride oxalate) and insulin (clotted serum) should be drawn 
5.19 The delegated individual must place the blood bottle into the Vacutainer sheath. Slight 
force may be required. Once the connection is made the blood will begin to flow. 
5.20 The delegated individual must ensure that all sharps are disposed of immediately into a 
sharps container in accordance with the Trust Waste Policy, must wash their hands in 
accordance with the Trust Hand Hygiene Policy, and flush as outlined in 5.16 
5.21 The delegated individual must gently invert the specimens to mix if they contain an 
additive or as dictated by the study/trial protocol. 
5.22 The liquid meal should be given to the participant to drink and consumed within 2 
minutes. When the participant consumes the last of the 200g, the time should be recorded, 
and this time will dictate when samples should be drawn for the remainder of the test. 
5.23 Samples should be drawn at the following times post liquid meal: 5, 10, 15, 30, 60, 90, 
120, 150, 180 minutes 
5.24 At each time point the procedures outlined in 5.17 to 5.21 should be repeated, with 
flushing as in 5.16 completed at the end of each blood draw 
5.25 If any blood spillage occurs the delegated individual should clean up the spillage 
5.26 An appropriately trained individual must remove the cannula when no longer indicated. 
The time and date the cannula was removed must be documented in the source data. The 
state of the site should be recorded in source data.  
5.27 The delegated individual must dispose of the cannula as per the Waste Policy. 
5.28 The delegated individual will ensure all procedures for samples outlined in the study/trial 
protocol are followed. 
5.29 The delegated individual must ensure that samples shipped off site are prepared, stored 












7.7 Interview Topic Guides 
 
Interview Topic Guide 1: Decliners 
 
Introduce self, make sure participant is comfortable and have what they need, remind participant 
of consent process and confidentiality, remind participant that honest answers are important / 
they are the expert, they can decline answering individual / particular questions. 
Is there anything they want to ask before starting the recording? 
SWITCH ON RECORDERS 
Briefly explain the purpose of interview:  
We want to find out what people think about the STOP Diabetes in HIV study. 
Although this is about the diabetes in HIV study, we could start with a general chat.   
Can you tell me what’s happening in your life right now? Typical day? 
What’s easy and what’s hard in your life right now? 
How long have you been living with HIV?  
STOP DIABETES IN HIV 
Before hearing about the study: 
How long have you known you are borderline diabetic? How did you feel? 
How did you hear about the study? 
The study itself: 
How did you feel when we / you and Alastair first started talking about the study? 
Participant Information Sheet 
What sounded good / not so good? 
Anything that wasn’t explained properly? 
 
Can you tell me why you decided not to take part in the 6 month intervention study? 
 
Most people need to change what they eat, do more physical activity, and lose a few 
inches around their tummy to help bring down their blood sugar.  
How do you feel thinking about this? How do you feel about your body shape? 
 
Is there anything about living with HIV that made you think twice about taking part? 
If I was to start from scratch and redesign the study, what would make it better? 
Were the monthly visits enough or too frequent? 
Is there anything that would make it easier/harder to make changes to eating/activity? 
 
How do you feel now after deciding not to do the study? 
How do you feel about your body shape now? 
What are you going to do in the next few months? 
Is there anything else you’d like to tell me about the diabetes in HIV study? 
RESEARCH IN THE CLINIC 
Have you taken part in research here or elsewhere before? 
Can you tell me about what’s good / not good about research here? 
What are the Participant Information Sheets like for other studies? 
How do you feel about the support you get in research studies? 
Is there anything that would make research studies better for you? 






Ok that’s us getting towards the end now. Is there anything else you’d like to say? 
How was this interview for you? 
If you remember something later on that you wish you’d said you can always contact me 
THANK YOU VERY MUCH FOR YOUR TIME 




Interview Topic Guide 2: Withdrawers 
Face to face interview: participants who did not complete the intervention. 
 
Introduce self, make sure participant is comfortable and have what they need, remind participant 
of consent process and confidentiality, remind participant that honest answers are important / 
they are the expert, they can decline answering individual / particular questions. 
Is there anything they want to ask before starting the recording? 
SWITCH ON RECORDERS 
Briefly explain the purpose of interview:  
We want to find out what people think about the STOP Diabetes in HIV study. 
Although this is about the diabetes in HIV study, we could start with a general chat.   
Can you tell me what’s happening in your life right now? Typical day? 
What’s easy and what’s hard in your life right now? 
How long have you been living with HIV?  
STOP DIABETES IN HIV 
Before hearing about the study: 
How long have you known you are borderline diabetic? How did you feel? 
How did you hear about the study? 
The study itself: 
How did you feel when we / you and Alastair first started talking about the study? 
Participant Information Sheet 
What sounded good / not so good? 
Anything that wasn’t explained properly? 
 
Can you tell me why you decided to take part in the 6 month intervention study? 
 
Most people need to change what they eat, do more physical activity, and lose a few inches 
around their tummy to help bring down their blood sugar.  
How do you feel thinking about having to make these changes? 
How do you feel about your body shape at the moment? 
Is there anything about living with HIV that made you think twice about taking part in the study? 
If I was to start from scratch and redesign the study, what would make it more appealing for you? 
Were the monthly visits enough or too frequent? 
Is there anything that would make it easier / harder to make changes to eating / activity? 
 
OK now let’s talk about how you feel today. How do you feel after NOT completing the study? 
How do you feel about your body shape now? 
What are you going to do in the next few months? 
Is there anything else you’d like to tell me about the diabetes in HIV study? 
 
RESEARCH IN THE CLINIC 





Tell me about the research studies you have taken part in. 
Can you tell me about what’s good / not so good about research here? 
What are the Participant Information Sheets like for other studies? 
How do you feel about the support you get in research studies? 
Is there anything that would make research studies better for you? 
Is there anything else you’d like to say about research in general? 
 
Ok that’s us getting towards the end now. Is there anything else you’d like to say? 
How was this interview for you? 
If you remember something later on that you wish you’d said you can always contact me 
THANK YOU VERY MUCH FOR YOUR TIME 




Interview Topic Guide 3: Completers 
Face to face interview: participants who completed the intervention. 
 
Introduce self, make sure participant is comfortable and have what they need, remind participant 
of consent process and confidentiality, remind participant that honest answers are important / 
they are the expert, they can decline answering individual / particular questions. 
Is there anything they want to ask before starting the recording? 
SWITCH ON RECORDERS 
Briefly explain the purpose of interview:  
We want to find out what people think about the STOP Diabetes in HIV study. 
Although this is about the diabetes in HIV study, we could start with a general chat.   
Can you tell me what’s happening in your life right now? Typical day? 
What’s easy and what’s hard in your life right now? 
How long have you been living with HIV?  
STOP DIABETES IN HIV 
Before hearing about the study: 
How long have you known you are borderline diabetic? How did you feel? 
How did you hear about the study? 
How did you feel when we / you and Alastair first started talking about the study? 
Participant Information Sheet 
What sounded good / not so good? 
Anything that wasn’t explained properly? 
 
Can you tell me why you decided to take part in the 6 month intervention study? 
Most people need to change what they eat, do more physical activity, and lose a few inches 
around their tummy to help bring down their blood sugar.  
How do you feel thinking about having to make these changes? 
How do you feel about your body shape at the moment? 
Is there anything about living with HIV that made you think twice about taking part in the study? 
If I was to start from scratch and redesign the study, what would make it more appealing for you? 
Were the monthly visits enough or too frequent? 
Is there anything that would make it easier / harder to make changes to eating / activity? 
What happened during the six months… 
Can you tell me what it was like to take part? 





3-hour blood test? Questionnaires? 
Did you get enough information to go away with on that first day? 
 
How were the first few months? 
Level of support you received?  
Spacing of the visits? 
Reminder texts and calls? 
 
Changes you make to eating… 
What changes did you make in your diet? 
What foods did you enjoy changing?  
Anything in particular that made it easier or harder to make these changes to eating? 
Food samples at the end of the first month – useful or not so useful? 
Do you think changing what you were eating had any effect on your shopping? 
 
Changes you made to physical activity… 
Did you start doing more physical activity? 
How useful was the pedometer? 
Is there anything in particular that made it easier or harder to make these changes to activity? 
 
How do you feel now after completing the full 6 months of the study? 
 Probe: What impact has it had on you? 
 
How do you feel about your body shape now? 
What are you going to do in the next few months? 
Are there any challenges to keeping up the diet and activity changes? 
 Probe: Do you want to keep up these changes? 
 
If we were to redesign the study from scratch… 
Is there anything else you’d like to tell me about the diabetes in HIV study? 
 
RESEARCH IN THE CLINIC 
Have you taken part in research here or elsewhere before? 
Tell me about the research studies you have taken part in. 
Can you tell me about what’s good / not so good about research here? 
What are the Participant Information Sheets like for other studies? 
How do you feel about the support you get in research studies? 
Is there anything that would make research studies better for you? 
Is there anything else you’d like to say about research in general? 
 
Ok that’s us getting towards the end now. Is there anything else you’d like to say? 
How was this interview for you? 
If you remember something later on that you wish you’d said you can always contact me 
THANK YOU VERY MUCH FOR YOUR TIME 







7.8  Intervention Food Samples 
 
A range of foods was offered to participants at their visit on Day 30. The aim was to provide 
samples to try foods new to participants, or known but untested. The range included low salt, 
reduced sugar and reduced fat foods, oily fish, wholegrains, sweeteners and monounsaturated 



















Stock images of gay men who self-identify as bears. These are not photographs of study 
participants. They are presented to help the reader unfamiliar with the gay community 
visualise the identity of men who self-identify as bears. Source: Internet free licence. 
 
